Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk

ABSTRACT

The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

The present invention relates to azaindazole and diazaindazole fusedbicyclic derivatives for use in the treatment of cancer associated withthe overexpression of at least one Trk protein.

Protein kinases are enzymes that play a key role in cell signaltransduction. They are involved in physiological processes such as cellproliferation, mitosis, differentiation, cell invasion and mobility, andapoptosis, for example.

Deregulation of the physiological mechanisms controlled by proteinkinases is central to the appearance and development of manypathologies, notably including cancers. It is of particular note thatmany oncogenes and proto-oncogenes correspond to protein kinases.

Consequently, these enzymes are seen to play an important role duringthe various stages of tumor development and thus they constituteimportant pharmaceutical targets for cancer treatments.

Tyrosine kinase receptors (TKRs) form a particular class of proteinkinases among which, among others, mention may be made of ALK, EGFR,Her2, PDGFR, Kit, VEGFR, IGFR, FGFR, Trk, Axl, Mer, Met, Ron and Ret.

When a protein kinase is the result of a gene rearrangement, such as achromosomal translocation, or has been mutated, this can lead to theexpression of a modified kinase that is constitutively activated. Thisconstitutive activation of the kinase activity leads to tumor formation,and the survival and proliferation of these tumors became then dependenton this kinase activity. This type of kinase target is therefore calleda cancer driver. Inhibiting such kinase targets results in a markedantitumor efficacy against tumors resulting from the overexpression ofsuch a kinase. In that case, the tumor is dependent on theoverexpression of the target kinase for growth and maintenance. Thespecific inhibition of the target kinase results in the death of thetumoral cells.

In other words, overexpression of some members of protein kinases maycause various cancers irrespective of the nature and localization of thetumors. These tumors, in turn, are expected to be responsive to atreatment aiming to inhibit the overexpressed protein kinase. In a firstinstance, it is thus necessary to characterise the exact cause of thecancer in each patient to determine which treatment could be or noteffective.

Once a specific potentially responsible kinase is identified, a therapyinvolving specific inhibitors of this kinase can be proposed (Mc Dermottet al. (2007) PNAS 104(50):19936-19941, Jänne et al. (2009) NatureReviews 8:709-723). Today there are only a few driver kinases that havebeen validated in clinic for the treatment of cancer, such as ALK, Her2,Bcr-Abl or B-RAF^(V600E). Therefore, a need for novel cancer driverkinases and the corresponding inhibitors remains.

Tropomyo sin-related kinases (Trks) are receptor tyrosine kinasesinvolved in the development of nervous system. The Trk receptor familyis composed of three members A, B and C activated by specific ligandscalled neurotrophins. While Trks are not expressed or expressed at lowlevels in normal adult tissues, deregulation of Trk proteins and theirassociated ligands has been described in various types of cancers,including colon, prostate, pancreas, ovarian, lung, bladder, breast,melanoma, thyroid, head and neck cancers and neuroblastoma (Lee et al.,2012, PLoS one 7:1-10; Raeppel et al., 2012, Int J Med Chem 2012:1-6;Roesler et al., 2011, Exp Rev Anticancer Ther 11: 1473-1475; Thiele etal., 2009, Clin Cancer Res 15:5962-5967). More specifically, achromosomal translocation leading to the fusion protein TrkA-TPM3 hasbeen identified in colon cancer (Coulier et al., 1989, Mol Cell Biol9:15-23; Martin-Zanca et al., 1986, Nature 319:743-748). A role for BDNF(brain-derived neurotrophic factor-TrkB ligand)/TrkB signalling and/oroverexpression in breast, colon and bladder cancers have been reported(Akil et al., 2011, PLoS one 6:1-15; Roesler et al., 2011, previouslycited). TrkB mutations have also been described in lung and coloncancers (Roesler et al., 2011, previously cited). Results of Lee et al.(2012, previously cited) suggest that BDNF/TrkB system plays a criticalrole in cisplatin resistance of head and neck cancers.

The number of Trk inhibitors reported in the literature is limited anduntil yet none is used as a drug against cancer although Trk inhibitorshave already demonstrated antitumor efficacy in experimental preclinicalmodels, such as the colon cancer model KM-12 (Ardini et al., 2010, Eur JCancer Suppl. Poster 102, 2010).

There is thus a need for compounds capable of inhibiting Trk.

WO 2008/11269, describes compounds of type 5-azaindazole or5,7-diazaindazole substituted in position 6 as inhibitors of proteinkinases such as Trk. However, no biological result is present in thisapplication proving the inhibition of any protein kinases and inparticular of the protein kinase Trk.

WO 2004/113303 describes notably compounds of type 5-azaindazolesubstituted in position 6 as inhibitors of the protein kinase JNK. It isnever mentioned that such compounds could also inhibit the proteinkinase Trk.

WO 2007/023110 describes notably compounds of type azaindazole ordiazaindazole as inhibitors of the protein kinase p38. It is nevermentioned that such compounds could also inhibit the protein kinase Trk.

The compounds of the present invention, corresponding to azaindazole ordiazaindazole type compounds, more particularly substituted in position5, have the property of inhibiting or modulating the enzymatic activityof Trk proteins. Consequently, said compounds can be used as drug in thetreatment of cancers overexpressing at least one Trk protein.

More particularly, the present invention thus has as an object acompound of following general formula (I):

or a pharmaceutically acceptable salt or solvate of same, a tautomer ofsame, a stereoisomer or a mixture of stereoisomers of same in anyproportions, such as a mixture of enantiomers, notably a racemicmixture,wherein:

-   -   Y₁ and Y₄ each represent, independently of each other, a CH        group or a nitrogen atom,    -   Y₂ represents a nitrogen atom or a CH or C—X—Ar group,    -   Y₃ represents a nitrogen atom or a C—X—Ar or C—W group, on the        condition that:        -   at least one and at most two Y₁, Y₂, Y₃, and Y₄ groups            represent a nitrogen atom,        -   Y₂ and Y₄ cannot represent a nitrogen atom at the same time,        -   when Y₂═C—X—Ar, then Y₃ represents a nitrogen atom or a C—W            group, and        -   when Y₂═CH or N, then Y₃ represents a C—X—Ar group,    -   Ar represents an aryl or heteroaryl group optionally substituted        by one or more groups selected from a halogen atom,        (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, (C₁-C₆)haloalkoxy,        (C₁-C₆)halothioalkoxy, CN, NO₂, OR₁₁, SR₁₂, NR₁₃R₁₄, CO₂R₁₅,        CONR₁₆R₁₇, SO₂R₁₈, SO₂NR₁₉R₂₀, COR₂₁, NR₂₂COR₂₃, NR₂₄SO₂R₂₅, and        R₂₆NR₂₇R₂₈ and/or optionally fused to a heterocycle,    -   X represents a divalent group selected from O, S, S(O), S(O)₂,        NR₄, S(NR₄), S(O)(NR₄), S(O)₂(NR₄), NR₄S, NR₄S(O), NR₄S(O)₂,        CH₂, CH₂S, CH₂S(O), CH₂S(O)₂, SCH₂, S(O)CH₂, S(O)₂CH₂, CH₂CH₂,        CH═CH, C≡C, CH₂O, OCH₂, NR₄CH₂, and CH₂NR₄,    -   W represents an R₅, SR₅, OR₅ or NR₅R₆ group,    -   U represents a CH₂ or NH group, one or more hydrogen atoms which        may be replaced by a (C₁-C₆)alkyl group,    -   V represents C(O), C(S) or CH₂,    -   n represents 0 or 1,    -   R₁ represents a hydrogen atom, or an OR₇ or NR₇R₈ group,    -   R₂ represents a hydrogen atom, an optionally substituted        heterocycle, NO₂, OR₉ or NR₉R₁₀,    -   R₃, R₄, R₁₁ to R₂₅ and R₂₇ to R₂₈ each represent, independently        of each other, a hydrogen atom or a (C₁-C₆)alkyl group,    -   R₅ and R₆ each represent, independently of each other, a        hydrogen atom or a (C₁-C₆)alkyl, optionally substituted aryl or        optionally substituted benzyl group,    -   R₇, R₈, R₉ and R₁₀ each represent, independently of each other,        a hydrogen atom or an optionally substituted (C₁-C₆)alkyl or        (C₃-C₁₂)cycloalkyl group or an optionally substituted        heterocycle, and    -   R₂₆ represents (C₁-C₆)alkyl,        for use in the treatment of a cancer associated with the        overexpression of at least one Trk protein.

In the preceding definitions, all the combinations of substituents orvariables are possible insofar as they lead to stable compounds.

It should be noted moreover that at least one but only one of Y₂ and Y₃represents a C—X—Ar group.

In a preferred embodiment, the present invention has as an object acompound of following general formula (I):

or a pharmaceutically acceptable salt or solvate of same, a tautomer ofsame, or a stereoisomer or mixture of stereoisomers of same in anyproportions, such as a mixture of enantiomers, notably a racemicmixture, wherein:

-   -   Y₁ and Y₄ each represent, independently of each other, a CH        group or a nitrogen atom on the condition that at least one of        Y₁ and Y₄ represent a nitrogen atom,    -   Y₂ represents a C—X—Ar group,    -   Y₃ represents a C—W group,    -   Ar represents an aryl or heteroaryl group optionally substituted        by one or more groups selected from a halogen atom,        (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, (C₁-C₆)haloalkoxy,        (C₁-C₆)halothioalkoxy, CN, NO₂, OR₁₁, SR₁₂, NR₁₃R₁₄, CO₂R₁₅,        CONR₁₆R₁₇, SO₂R₁₈, SO₂NR₁₉R₂₀, COR₂₁, NR₂₂COR₂₃, NR₂₄SO₂R₂₅, and        R₂₆NR₂₇R₂₈ and/or optionally fused to a heterocycle,    -   X represents a divalent group selected from O, S, S(O), S(O)₂,        NR₄, S(NR₄), S(O)(NR₄), S(O)₂(NR₄), NR₄S, NR₄S(O), NR₄S(O)₂,        CH₂, CH₂S, CH₂S(O), CH₂S(O)₂, SCH₂, S(O)CH₂, S(O)₂CH₂, CH₂CH₂,        CH═CH, C≡C, CH₂O, OCH₂, NR₄CH₂, and CH₂NR₄,    -   W represents an R₅, SR₅, OR₅ or NR₅R₆ group,    -   U represents a CH₂ or NH group, one or more hydrogen atoms which        may be replaced by a (C₁-C₆)alkyl group,    -   V represents C(O), C(S) or CH₂,    -   n represents 0 or 1,    -   R₁ represents a hydrogen atom, or an OR₇ or NR₇R₈ group,    -   R₂ represents a hydrogen atom, an optionally substituted        heterocycle, NO₂, OR₉ or NR₉R₁₀,    -   R₃, R₄, R₁₁ to R₂₅ and R₂₇ to R₂₈ each represent, independently        of each other, a hydrogen atom or a (C₁-C₆)alkyl group,    -   R₅ and R₆ each represent, independently of each other, a        hydrogen atom or a (C₁-C₆)alkyl, optionally substituted aryl or        optionally substituted benzyl group,    -   R₇, R₈, R₉ and R₁₀ each represent, independently of each other,        a hydrogen atom or an optionally substituted (C₁-C₆)alkyl or        (C₃-C₁₂)cycloalkyl group or an optionally substituted        heterocycle, and    -   R₂₆ represents a (C₁-C₆)alkyl group,        for use in the treatment of a cancer associated with the        overexpression of at least one Trk protein.

The term “halogen” refers to fluorine, chlorine, bromine or iodine.

The term “(C₁-C₆) alkyl” refers to saturated linear or branchedhydrocarbon chains comprising 1 to 6 carbon atoms. It may be a methyl,ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentylor hexyl group.

The term “(C₁-C₆)alkoxy” refers to a (C₁-C₆) alkyl chain linked to therest of the molecule via an oxygen atom. As an example, mention may bemade of methoxy, ethoxy, propoxy, isopropoxy, butoxy or tert-butoxygroups.

The term “(C₁-C₆)thioalkoxy” refers to a (C₁-C₆) alkyl chain linked tothe rest of the molecule via a sulfur atom. As an example, mention maybe made of thiomethoxy, thioethoxy, thiopropoxy, thioisopropoxy,thiobutoxy or thio-tert-butoxy groups.

The term “(C₁-C₆)haloalkyl” refers to a (C₁-C₆) alkyl chain such asdefined above wherein one or more hydrogen atoms are replaced by ahalogen atom such as defined above. It may be in particular atrifluoromethyl group.

The term “(C₁-C₆)haloalkoxy” refers to a (C₁-C₆)alkoxy chain such asdefined above wherein one or more hydrogen atoms are replaced by ahalogen atom such as defined above. It may be in particular atrifluoromethoxy group.

The term “(C₁-C₆)halothioalkoxy” refers to a (C₁-C₆)thioalkoxy chainsuch as defined above wherein one or more hydrogen atoms are replaced bya halogen atom such as defined above. It may be in particular atrifluorothiomethoxy group.

The term “(C₃-C₁₂)cycloalkyl” refers to cyclic hydrocarbon systemscomprising from 3 to 12 carbon atoms and comprising one or more rings,in particular fused rings. As an example, mention may be made of anadamantyl or cyclohexyl group.

The term “aryl” refers to an aromatic hydrocarbon group preferablycomprising from 6 to 14 carbon atoms and comprising one or more fusedrings, such as, for example, a phenyl or naphthyl group. Advantageously,it is a phenyl group.

The term “heteroaryl” refers to a cyclic aromatic group comprising 5 to7 atoms included in the ring or a bicyclic aromatic group comprising 8to 11 atoms included in the rings, wherein 1 to 4 of the atoms includedin the rings are a heteroatom selected independently from sulfur,nitrogen and oxygen atoms, and wherein the other atoms included in therings are carbon atoms. Examples of heteroaryl groups include furyl,thienyl, pyridinyl, and benzothienyl groups.

The term “heterocycle” refers either to a stable monocycle containingfrom 4 to 7 cyclic atoms, or to a stable bicycle containing from 8 to 11cyclic atoms, which may be either saturated or unsaturated, wherein 1 to4 of the cyclic atoms are a heteroatom selected independently fromsulfur, nitrogen and oxygen atoms, and wherein the other cyclic atomsare carbon atoms. As an example, mention may be made of furan, pyrrole,thiophene, thiazole, isothiazole, oxadiazole, imidazole, oxazole,isoxazole, pyridine, piperidine, pyrazine, piperazine, tetrahydropyran,pyrimidine, quinazoline, quinoline, quinoxaline, benzofuran,benzothiophene, indoline, indolizine, benzothiazole, benzothienyl,benzopyran, benzoxazole, benzo[1,3]dioxole, benzisoxazole,benzimidazole, chromane, chromene, dihydrobenzofuran,dihydrobenzothienyl, dihydroisoxazole, isoquinoline,dihydrobenzo[1,4]dioxane, imidazo[1,2-a]pyridine, furo[2,3-c]pyridine,2.3-dihydro-1H-indene, [1,3]dioxolo[4,5-c]pyridine,pyrrolo[1,2-c]pyrimidine, pyrrolo[1,2-a]pyrimidine,tetrahydronaphthalene, benzo[b][1,4]oxazin.

In the context of the present invention, “optionally substituted” meansthat the group in question is optionally substituted by one or moresubstituents which may be selected in particular from a halogen atom,(C₁-C₆)alkyl, (C₁-C₆)haloalkyl, (C₁-C₆)haloalkoxy,(C₁-C₆)halothioalkoxy, CN, NO₂, OR₁₁, SR₁₂, NR₁₃R₁₄, CO₂R₁₅, CONR₁₆R₁₇,SO₂R₁₈, SO₂NR₁₉R₂₀, COR₂₁, NR₂₂COR₂₃, NR₂₄SO₂R₂₅, and R₂₆NR₂₇R₂₈,wherein R₁₁ to R₂₈ are such as defined above.

In the present invention, “pharmaceutically acceptable” refers to thatwhich is useful in the preparation of a pharmaceutical composition thatis generally safe, nontoxic and neither biologically nor otherwiseundesirable and that is acceptable for veterinary and humanpharmaceutical use.

“Pharmaceutically acceptable salt or solvate” of a compound refers tosalts and solvates which are pharmaceutically acceptable, as definedherein, and which has the desired pharmacological activity of the parentcompound.

Acceptable salts for the therapeutic use of the compounds of the presentinvention include the conventional nontoxic salts of the compounds ofthe invention such as those formed from pharmaceutically acceptableorganic or inorganic acids or from pharmaceutically acceptable organicor inorganic bases. As an example, mention may be made of salts derivedfrom inorganic acids such as hydrochloric acid, hydrobromic acid,phosphoric acid and sulfuric acid, and those derived from organic acidssuch as acetic acid, trifluoroacetic acid, propionic acid, succinicacid, fumaric acid, malic acid, tartaric acid, citric acid, ascorbicacid, maleic acid, glutamic acid, benzoic acid, salicylic acid,toluenesulfonic acid, methanesulfonic acid, stearic acid and lacticacid. As an example, mention may be made of salts derived from inorganicbases such as soda, potash or calcium hydroxide and salts derived fromorganic bases such as lysine or arginine.

These salts may be synthesized from the compounds of the inventioncontaining a basic or acidic part and the corresponding acids or basesaccording to conventional chemical methods well known to the personskilled in the art.

Acceptable solvates for the therapeutic use of the compounds of thepresent invention include conventional solvates such as those formedduring the last step of the preparation of the compounds of theinvention due to the presence of solvents. As an example, mention may bemade of solvates due to the presence of water or ethanol.

In the context of the present invention, “stereoisomer” refers to ageometric isomer or an optical isomer.

Geometric isomers result from the different position of substituents ona double bond which can then have a Z or E configuration.

Optical isomers result notably from the different position in space ofsubstituents on a carbon atom comprising four different substituents.This carbon atom thus constitutes a chiral or asymmetrical center.Optical isomers include diastereoisomers and enantiomers. Opticalisomers that are mirror images of each other but are non-superimposableare enantiomers. Optical isomers that are not mirror images of eachother are diastereoisomers.

In the context of the present invention, “tautomer” refers to aconstitutional isomer of the compound obtained by prototropy, i.e., bymigration of a hydrogen atom and a change in location of a double bond.The different tautomers of a compound are generally interconvertible andare in equilibrium in solution in proportions which may vary accordingto the solvent used, the temperature or the pH.

According to a first embodiment, Y₄═N.

Advantageously, Y₂═C—X—Ar and Y₃ preferably represents a C—W group.

In particular:

Y₁═CH or N, and advantageously CH,

Y₂═C—X—Ar,

Y₃═C—W, and

Y₄═N.

According to a second embodiment, Y₁ and/or Y₄ represent a nitrogenatom.

In this case, Y₂ and Y₃ preferably do not represent a nitrogen atom.

In particular:

Y₁ and/or Y₄═N,

Y₂═CH or C—X—Ar, and

Y₃═C—W or C—X—Ar.

In particular:

Y₁ represents a CH group,

Y₄ represents a nitrogen atom,

Y₂ represents a CH or a C—X—Ar group, and

Y₃ represents a C—X—Ar or a C—W group,

on the condition that:

-   -   when Y₂═C—X—Ar, then Y₃ represents a C—W group, and    -   when Y₂═CH, then Y₂ represents a C—X—Ar group.

Advantageously, X represents a divalent group selected from O, S, S(O),S(O)₂, NR₄, CH₂, CH₂S, CH₂S(O), CH₂S(O)₂, NHS(O)₂, SCH₂, S(O)CH₂,S(O)₂CH₂, S(O)₂NH, CH₂CH₂, CH═CH, CH₂O, OCH₂, NR₄CH₂, and CH₂NR₄.

In particular, X represents a divalent group selected from S, S(O),S(O)₂, NR₄, CH₂, CH₂S, CH₂S(O), CH₂S(O)₂, NHS(O)₂, SCH₂, S(O)CH₂,S(O)₂CH₂, S(O)₂NH, CH₂CH₂, C≡C, CH₂O, OCH₂, NR₄CH₂, and CH₂NR₄.

More particularly, X may be selected from S, S(O), S(O)₂, CH₂, CH₂S,CH₂S(O), CH₂S(O)₂, NHS(O)₂, SCH₂, S(O)CH₂, S(O)₂CH₂, S(O)₂NH, CH₂CH₂,CH═CH, and C≡C.

In particular, X may be selected from S, S(O)₂, CH₂, SCH₂, S(O)₂CH₂,S(O)₂NH, CH₂S, CH₂S(O)₂, NHS(O)₂, CH₂CH₂, and C≡C.

X may notably be selected from S, S(O), S(O)₂, NR₄, CH₂, SCH₂, S(O)CH₂,S(O)₂CH₂, S(O)₂NH, CH₂CH₂, OCH₂, and NR₄CH₂; notably from S, S(O)₂, CH₂,SCH₂, S(O)₂CH₂, S(O)₂NH, CH₂CH₂, and C≡C, wherein the first atom ofthese groups is bound to atom C of the C—X—Ar chain.

X may be in particular S, S(O)₂, SCH₂, S(O)₂CH₂, S(O)₂NH, CH₂S,CH₂S(O)₂, or NHS(O)₂; and notably S, S(O)₂, SCH₂, S(O)₂CH₂, or S(O)₂NH,wherein the first atom of these groups is bound to atom C of the C—X—Archain.

Advantageously, Ar represents a heteroaryl group, such as pyridine, oran aryl group, such as phenyl, optionally substituted by one or moregroups selected from a halogen atom, (C₁-C₆)alkyl, (C₁-C₆)haloalkyl,(C₁-C₆)haloalkoxy, (C₁-C₆)halothioalkoxy, CN, NO₂, OR₁₁, SR₁₂, NR₁₃R₁₄,CO₂R₁₅, CONR₁₆R₁₇, SO₂R₁₈, SO₂NR₁₉R₂₀, COR₂₁, NR₂₂COR₂₃, and NR₂₄SO₂R₂₅;and/or optionally fused to a heterocycle.

More particularly, Ar may represent an aryl group, such as phenyl,optionally substituted by one or more groups selected from a halogenatom, (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, (C₁-C₆)haloalkoxy,(C₁-C₆)halothioalkoxy, CN, NO₂, OR₁₁, SR₁₂, NR₁₃R₁₄, CO₂R₁₅, CONR₁₆R₁₇,SO₂R₁₈, SO₂NR₁₉R₂₀, COR₂₁, NR₂₂COR₂₃, and NR₂₄SO₂R₂₅.

Ar may notably represent an aryl group, such as phenyl, optionallysubstituted by one or more groups selected from a halogen atom,(C₁-C₆)alkyl, (C₁-C₆)haloalkyl, and CONR₁₆R₁₇, and in particular from ahalogen atom such as fluorine, (C₁-C₆)alkyl such as methyl, andCONR₁₆R₁₇ such as CONH₂.

Ar can also represent a pyridine group.

Ar may notably be selected from the following groups:

notably from the following groups:

in particular, from the following groups:

Ar may advantageously represent the group:

W may advantageously represent an R₅, SR₅, OR₅ or NR₅R₆ group, andpreferably R₅, OR₅ or NR₅R₆, with R₅ and R₆ representing, independentlyof each other, a hydrogen atom or a (C₁-C₆)alkyl group.

W may represent in particular H, OMe, Me, OH or NH₂, and notably H.

Advantageously, R₃ represents a hydrogen atom.

U may represent more particularly a CH₂ or NH group.

Advantageously, n may represent 0.

V may represent more particularly a C(O) or C(S) group, andadvantageously a C(O) group.

According to a particular embodiment of the invention:

-   -   R₃═H,    -   U═CH₂ or NH,    -   V═C(O) or C(S), and notably C(O), and    -   n=0 or 1, and notably 0.

According to another particular embodiment of the invention:

-   -   V═C(O) or C(S), and notably C(O), and    -   n=0.

According to still another particular embodiment of the invention:

-   -   R₃═H,    -   V═C(O) or C(S), and notably C(O), and    -   n=0.

R₁ may represent more particularly a hydrogen atom or an NR₇R₈ group,with R₇ notably representing a hydrogen atom and R₈ notably representingan optionally substituted (C₃-C₁₂)cycloalkyl group or an optionallysubstituted heterocycle.

The (C₃-C₁₂)cycloalkyl group may be in particular a cyclohexyl. It maybe substituted by one or more halogen atoms. It may be in particular thegroup:

The heterocyclic group may be in particular a tetrahydropyran, notablyunsubstituted. It may thus be the following group:

R₁ may thus represent more particularly one of the following groups:

and notably H and

and advantageously

R₂ may represent more particularly an optionally substituted heterocycle(notably substituted by (C₁-C₆)alkyl or NH₂), NO₂ or NR₉R₁₀, withnotably R₉═R₁₀═H or else R₉ and R₁₀ each represent H or an optionallysubstituted (C₁-C₆)alkyl.

R₂ may represent in particular an optionally substituted heterocycle,notably substituted by (C₁-C₆)alkyl or NH₂. The heterocycle may be inparticular a heterocycle with 5 or 6 members comprising at least onenitrogen atom, and in particular one or two. The heterocycle may thus beselected from piperazine, piperidine and pyrrolidine.

R₂ may notably represent one of the following groups: NH₂, NH(CH₂)₃NMe₂,NMe(CH₂)₃NMe₂, NO₂,

and notably NH₂, NO₂,

and in particular

and more particularly

The compounds of the present invention may be selected from thecompounds cited in the following table:

14-2

14-10

14-11

15

26-4

26-8

27

27-1

28

29

29-a

30

30-1

30-3

30-4

30-5

30-8

30-9

30-10

30-11

30-12

30-a

31

32

32-1

33

35

26-12

30-69

27-2

27-3

27-4

30-73

14bis

30-70

30-71

30-72

27-5

30-13

30-14

30-15

30-16

30-17

30-18

30-19

30-20

30-21

30-22

30-23

30-24

30-25

30-26

30-27

30-28

30-29

30-30

30-31

30-32

30-33

30-34

30-35

30-36

30-37

30-38

30-39

30-40

30-41

30-42

30-43

30-44

30-45

30-46

30-47

30-48

30-49

30-50

30-51

30-52

30-53

30-54

30-55

30-56

30-57

30-58

30-59

30-60

30-61

30-62

30-63

30-64

30-65

30-66

30-67

30-68

31-1

The present invention also relates to the use of a compound of formula(I) such as defined above, for the manufacture of a drug intended forthe treatment of a cancer associated with the overexpression of at leastone Trk protein.

The present invention also relates to a method for the treatment of acancer associated with the overexpression of at least one Trk proteincomprising the administration to a person in need thereof of aneffective dose of a compound of formula (I) such as defined above.

The present invention also relates to a pharmaceutical compositioncomprising at least one compound of formula (I) such as defined above,and at least one pharmaceutically acceptable excipient for use in thetreatment of a cancer associated with the overexpression of at least oneTrk protein.

The pharmaceutical compositions for use in the treatment of a cancerassociated with the overexpression of at least one Trk protein accordingto the invention may be formulated notably for oral administration orfor injection, wherein said compositions are intended for mammals,including humans.

The active ingredient may be administered in unit dosage forms ofadministration, in mixture with standard pharmaceutical carriers, toanimals or to humans. The compounds of the invention as activeingredients may be used in doses ranging between 0.01 mg and 1000 mg perday, given in a single dose once per day or administered in severaldoses throughout the day, for example twice a day in equal doses. Thedose administered per day advantageously is between 5 mg and 500 mg,even more advantageously between 10 mg and 200 mg. It may be necessaryto use doses outside these ranges as determined by the person skilled inthe art.

The pharmaceutical compositions for use in the treatment of a cancerassociated with the overexpression of at least one Trk protein accordingto the invention may further comprise at least one other activeingredient, such as an anticancer agent.

The present invention also has as an object a pharmaceuticalcomposition, for use in the treatment of a cancer associated with theoverexpression of at least one Trk protein, comprising:

(i) at least one compound of formula (I) such as defined above, and

(ii) at least one other active ingredient, such as an anticancer agent,as a combination product for simultaneous, separate or sequential use.

In the context of the invention, the term “treatment” means reversing,alleviating, or inhibiting the progress of cancer. In particular, thetreatment of cancer according to the invention may consist in reducingthe number of cancerous cells. Most preferably, such treatment leads tothe complete depletion of cancerous cells.

The term “cancer” refers to or describes the pathological condition inmammals, including humans, that is typically characterized byunregulated cell growth.

The cancer according to the invention is characterized by theoverexpression of at least one Trk protein.

According to the invention, “Trk protein” means any member of the Trkfamily, for example TrkA (in particular described in GenBank under thenumber AB019488), TrkB (in particular described in GenBank under thenumber AAB33109.1) and TrkC (in particular described in GenBank underthe number CAA12029.1), preferentially TrkA.

The Trk protein according to the invention may be overexpressed in itsnative form or in a modified form. By “modified form” is intended tomean a mutated form of the wild-type protein. The mutation may be apoint mutation, it may also be a deletion or an insertion of one or moreamino acids in the sequence of the Trk protein. Alternatively, themodified Trk protein according to the invention may be a fusion protein,for example obtained after a chromosomal re-arrangement. In oneembodiment, the mutated Trk protein according to the invention is afusion protein between TrkA and tropomyosine, like the TrkA/TPM3 fusion,for example the TrkA/TMP3 fusion protein described in Coulier et al.,1989 and Martin-Zanca et al., 1986 (previously cited). The modified Trkprotein can also result from an alternative splicing.

By <<overexpression>> is meant in the context of the invention that theexpression level of the Trk protein in a cancerous cell is higher thanthe reference expression level in a non cancerous cell. Preferentially,the reference expression level of the Trk protein is measured in a noncancerous cell of the same type as the cancerous cell. For example, whenthe cancerous cell is a colon cell, the non cancerous cell used for themeasurement of the reference expression level will also be a colon cell.In a preferred embodiment, the level of expression of the Trk protein ina cancerous cell and the reference expression level in a non cancerouscell are measured in cells isolated from the same patient. In anotherembodiment, the reference expression level is the average of expressionlevels measured in non cancerous cells of several individuals.

The isolation of cancerous and non cancerous cell from a patient can beachieved by any technique known by the person skilled in the art andmore specifically by biopsy. The culture of cancerous cells can also beachieved by any technique known by the skilled person and for example asdescribed in Akil et al. or Lee et al. (previously cited).

In a first embodiment, if the non cancerous cells do not express TrKprotein (reference expression level egal 0), a higher level ofexpression means any observed level of expression. In a secondembodiment, when the non cancerous cells express TrK protein (referenceexpression level superior to 0) a higher level of expression mean anysignificant increase in the expression of the Trk protein according tothe invention, for example an increase above or equal to 5%, notablyabove or equal to 10%, notably above or equal to 30%, notably above orequal to 50%, advantageously above or equal to 100%.

The level of expression of the Trk protein may be measured by any methodknown by the person skilled in the art for example by RT-PCR,immunofluorescence, or western blot.

In particular, it can be assessed by quantifying directly the Trkprotein or by quantifying the mRNAs encoding the Trk protein. Thus,expression can be determined at the protein level notably by methodsthat are well known in the art including, for example, immunoassaysbased on antibodies against the Trk proteins Numerous methods are alsoknown in the art for quantifying mRNAs, such as quantitativereverse-transcription-based polymerase chain reaction (RT-PCR) assaysusing primers specific for the mRNA sequences, or methods wherein mRNAs,or duplicates and/or replicates thereof, are hybridized under stringentconditions with probes. Adequate stringent conditions according to theinvention can be easily determined by one skilled in the art. Preferredstringent conditions according to the invention comprise a hybridizationstep of 10 to 20 hours, preferably about 16 hours, at about 40 to 55°C., preferably about 50° C., under an ionic strength equivalent to thatprovided by 500 mM to 2 M NaCl, preferably 1 M NaCl. Additionalcompounds well known to one skilled in the art can also be added such aspH buffers (e.g. Tris or MES), EDTA, Tween, Bovine Serum Albumin, andherring sperm DNA. Examples of RT-PCR, Western Blot, Immunofluorescenceand ELISA protocols are notably described in Alkil et al. and Lee et al.(previously cited).

According to the invention, the cancer associated with an overexpressionof a Trk protein may be more particularly a cancer of the colon,prostate, pancreas, ovarian, lung, bladder, breast, melanoma, thyroid,head or neck or neuroblastoma, as notably described in Lee et al., 2012;Raeppel et al., 2012; Roesler et al., 2011 and Thiele et al., 2009(previously cited). In an embodiment, the cancer associated with anoverexpression of a Trk protein according to the invention is a coloncancer.

In an embodiment of the present invention, the cancer associated with anoverexpression of a Trk protein according to the invention does notoverexpress the kinases ALK, Abl and c-Src.

The compounds of formula (I) according to the present invention can beprepared by various methods notably summarized in diagrams 1a and 1bbelow.

Method A:

According to method A, compounds of formula (I) are obtained by thepreliminary synthesis of compounds of general formula (V) characterizedby a halogenated heterobicyclic ring having an exocyclic primary amine.These compounds are obtained via the synthesis of intermediates ofgeneral formula (II) or (III).

Method A1:

Method A1, presented in diagram 2 (iodized compounds) or 3 (brominatedcompounds) below, describes the general process giving access tocompounds of general formula (V) with W defined as in the description ofgeneral formula (I), and notably H, (C₁-C₆)alkyl or aryl, and R_(j)═H orN-protecting group.

In the context of diagram 2, the optionally substituted2-chloro-5-iodonicotinonitrile (IIa) is obtained from the correspondinghydroxynicotinonitrile by the successive use of an iodination agent suchas N-iodosuccinimide (NIS), or molecular iodine with an inorganic basesuch as, for example, K₂CO₃ or Na₂CO₃, notably in a polar solvent suchas hot DMF, followed by treatment with phosphorus oxychloride, pure ordiluted in a high boiling-point non-polar solvent, or any otherequivalent chlorination agent well known to the person skilled in theart. Reaction temperatures are between −20° C. and 200° C. The compound(IIa) thus obtained is then transformed into optionally substituted5-iodo-pyrazolo[3,4-b]pyridine-3-amine (Va) by its reaction, preferablyunder heat, in the presence of a hydrazine optionally carrying anN-protecting group such as trityl, tert-butyl or BOC.

The brominated analogues of general formula (V) as described in diagram1a may be obtained by the use of the method described in the followingreferences: Witherington et al., Bioorg. Med. Chem. Lett., 2003, 13,1577-1580 and Lijuan Chen et al., Bioorg. Med. Chem. Lett., 2010, 20,4273-4278. For reasons of convenience, these molecules were obtained bythe use of the reaction sequence presented in following diagram 3.

The optionally functionalized 2-methoxy-nicotinotrile is obtained, forexample, by reaction of sodium methanolate in methanol at a temperaturebetween −20° C. and the boiling point of the mixture. Alternatively,this compound may be obtained by methylation of 2-hydroxynicotinonitrileor other methods described above. Bromination of2-methoxy-nicotinonitrile is typically carried out with dibromine inacetic acid at a temperature varying between 20° C. and 110° C.Formation of the pyrazole is typically carried out by reaction of anexcess of hydrazine, functionalized or not, at a temperature varyingbetween 20° C. and 100° C. in the presence of a polar solvent such aswater, ethanol, tetrahydrofuran (THF) or any other solvent withcomparable properties. Alternatively, the use of hydrazine in a salineor hydrated form, without solvent, is also possible.

Method A2:

Method A2 relates to the synthesis of the functionalizedpyrazolopyrazines presented in diagram 4 below with R_(j)═H orN-protecting group, Hal=halogen and in particular W═H, (C₁-C₆)alkyl oraryl.

The optionally functionalized 3-amino-6-iodopyrazine-2-carboxamides aretypically obtained in two steps from the corresponding methyl3-aminopyrazine-2-carboxylates by iodination in the presence ofN-iodosuccinimide or molecular iodine optionally in the presence of acofactor such as KIO₃, AgCO₂CF₃, Ag₂SO₄, AlCl₃, CuCl₂ or HgO, followedby a conversion reaction of the methyl ester function into carboxamide,notably by the use of ammonia in a polar solvent such as water, methanolor THF at temperatures varying between 0° C. and 100° C. The carboxamidefunction of the optionally functionalized3-amino-6-iodopyrazine-2-carboxamide is then converted into nitrile bythe use of dehydration agents such as, in particular, CCl₄/PPh₃, SOCl₂,PhSO₂Cl, P₂O₅, TsCl, COCl₂, DCC/py(N,N′-dicyclohexylcarbodiimide/pyridine) or (COCl)₂ used as the case maybe in the presence of an organic base such as pyridine. The preferredmethod involves the use of phosphorus oxychloride in dimethylformamide(DMF). Deprotection of the dimethylformimidamide function is carried outby treatment with acid such as aqueous hydrochloric acid or any otherreagent with equivalent properties. Formation of the pyrazole ring iscarried out by a Sandmeyer reaction, well known to the person skilled inthe art, followed by a reaction in the presence of a hydrazine,functionalized or not, under conditions as described in the methodsabove. Alternatively, the diazonium salt, an intermediate of theSandmeyer reaction, may be reduced by the use, for example, of tinchloride in an acid medium or any other equivalent agent, in order toform a hydrazine function that can undergo intramolecular cyclizationunder the effect of heat.

Method A3:

Method A3 aims at obtaining derivatives of general formula (V) featuringa variable function in position 6 of the pyrazolopyridine bicycle. It isdetailed in diagram 5 below.

Reaction of the cyanothioacetamide with ethyl 3-ethoxyacrilatesvariously substituted according to methods described notably byLitrivnor et al. in Russ. Chem. Bull., 1999, 48(1), 195-196 andTsann-Long Su et al. in J. Med. Chem., 1988, 31, 1209-1215 make itpossible to yield access, in two steps, to ethyl5-cyano-6-(methylthio)nicotinates carrying a variable functionality inposition 2. These syntheses are typically carried out, for the firststep, in an anhydrous polar solvent such as, for example, ethanol at atemperature ranging between 0° C. and 70° C. in the presence of anorganic base such as methylmorpholine, triethylamine, DIPEA(N,N-diisopropylethylamine) or DBU (1,8-diazabicyclo[5,4,0]undec-7-ene).The second step of intramolecular cyclization and of alkylation istypically carried out by the heating to a temperature ranging between20° C. and 100° C. of a solution of the intermediate thioamidate in apolar solvent, for example ethanol in the presence of a suitablealkylating agent such as alkyl halide or dialkyl sulfate.

The 5-cyano-6-(methylthio)nicotinic acids substituted in position 2 aretypically obtained by saponification of the corresponding ethyl estersaccording to methods well known to the person skilled in the art,notably by the use of hot lithium hydroxide. Decarboxylation of thesecompounds is carried out by heat treatment in a high boiling-pointsolvent such as diphenylether at a temperature ranging between 150° C.and 250° C.

Halogenation reactions principally aim at obtaining iodinated,brominated or chlorinated derivatives, more particularly iodinatedderivatives. The latter are typically obtained by a molecular iodinetreatment in the presence of a silver salt such as, for example, Ag₂SO₄in a polar solvent such as ethanol at a temperature ranging between 0°C. and 70° C. Alternative methods, notably those based on other saltssuch as KIO₃, AgCO₂CF₃, AlCl₃, CuCl₂ or HgO, or other iodination agentssuch as N-iodosuccinimide, are also considered. The conceivablebromination methods typically rely on agents such as N-bromosuccinimideor dibromine according to methods well known to the person skilled inthe art.

In the case in which W═OH (typically resulting from the use of diethyl2-(ethoxymethylene)malonate), the corresponding compounds are protectedby an alkylation reaction. This reaction is notably carried out by theuse of methyl iodide or bromomethane, and silver carbonate in dioxane,THF, acetonitrile or acetone, or any other equivalent agent such asdimethylsulfate. The 5-halo-2-(methylthio) nicotinonitriles obtained aresubjected to oxidation of their thiomethoxy function, typically by theuse of m-CPBA (m-chloroperbenzoic acid), oxone or any other equivalentagent, to lead to the formation of the corresponding sulfoxide. Thesecompounds, which may contain variable quantities of the correspondingsulfone, are engaged in a reaction in the presence of an optionallysubstituted hydrazine to form the corresponding5-halogeno-pyrazolo[3,4-b]pyridin-3-amine carrying a variablefunctionality in position 6.

Method A4:

Method A4 aims at obtaining derivatives of general formula (V) from thecompounds of general formula (III) via intermediate formation ofcompounds of formula (IV). These compounds are typically obtained by thepathway presented in diagram 6. The following references illustrate themethod used: Gueiffier et al. Heterocycles, 1999, 51(7), 1661-1667;Gui-Dong Zhu et al. Bioorg. Med. Chem., 2007, 15, 2441-2452.

The compounds of general formula (IIIa), acetylated beforehand by one oranother of the methods well known to the person skilled in the art, aresubjected to the action of isoamyl nitrite, sodium nitrite or any otherequivalent organic or inorganic nitrite, in water or acetic acid, forperiods typically varying from 1 to 3 days at temperatures varyingbetween 0° C. and 40° C. The compounds of general formula (IVa) thusobtained are deprotected in acidic conditions, for example by the use ofhydrochloric acid, before being subjected to the action of nitrationagents such as concentrated nitric acid or potassium nitrate in sulfuricacid at temperatures varying between 0° C. and 25° C.

It should be noted that the direct conversion of compounds of generalformula (IIIa) into deprotected compounds (IVb) is possible in general.

The nitropyrazoles thus obtained are typically reduced intoaminopyrazoles of general formula (Ve) by the use of SnCl₂ inhydrochloric acid. Alternative methods include the use of iron, zinc ortin in acidic conditions and methods of catalytic hydrogenation in thepresence of complexes of platinum, nickel or Pd/C under an atmosphere ofhydrogen or in the presence of equivalent agents such as cyclohexadiene,cyclohexene, sodium borohydride or hydrazine.

Method B:

According to method B, the compounds of formula (I) are obtained by thepreliminary synthesis of compounds of general formula (VI) characterizedby a functionalized heterobicyclic ring possessing an exocyclic amine.These compounds are obtained via the synthesis of intermediates ofgeneral formula (VI).

Method B1:

Method B1 is represented in diagram 7 below, with W notably representingH, (C₁-C₆)alkyl, aryl or benzyl.

The 3-nitro-6-thioxo-1,6-dihydropyridin-2-carbonitrile and3-nitro-6-thioxo-1,6-dihydropyrazine-2-carbonitrile derivatives,optionally functionalized in position 5, are typically obtained from thecorresponding 2,6-dichloro-3-nitropyridines or2,6-dichloro-3-nitropyrazines by the successive reactions of a cyanidesalt, such as copper cyanide, in a high boiling-point polar solvent suchas N-methylpyrrolidone at temperatures ranging between 100° C. and 200°C.; followed by the reaction of aqueous sodium hydrosulfite in a polarsolvent. These compounds are then alkylated, for example by the use of asubstituted benzyl bromide, in basic medium, according to methods wellknown to the person skilled in the art. The preferred protocol includesthe use of an aprotic and anhydrous polar solvent such as acetonecarried at its boiling point and an organic base such as pyridine,triethylamine or DIPEA, or an inorganic base such as sodium, potassiumor calcium carbonate. Reactions for reducing the nitro function in amineare preferentially carried out by the use of SnCl₂ in hydrochloric acid.Alternative methods include the use of iron, zinc or tin in acidicconditions and methods of catalytic hydrogenation in the presence ofcomplexes of platinum, nickel or Pd/C under an atmosphere of hydrogen orin the presence of equivalent agents such as cyclohexadiene,cyclohexene, sodium borohydride or hydrazine.

In certain cases, the product of the reduction reaction, in addition tohaving a primary amine, has a carboxamide function resulting fromhydrolysis of the nitrile function. In this case, isolation of thecorresponding 3-aminopicolinonitriles or 3-aminopyrazine-2-carbonitrilesmay be carried out by dehydration of the carboxamide into nitrile viathe use of phosphorus oxychloride in the presence of DMF or any othermethod well known to the person skilled in the art. Lastly, formation ofthe aminopyrazole ring is carried out preferentially by the formation ofa diazonium, obtained by the successive reaction at low temperature ofisoamyl nitrite, sodium nitrite or any other equivalent organic orinorganic nitrite, in water, hydrochloric acid, acetic acid or sulfuricacid, at temperatures varying between 0° C. and 20° C., followed by itsreduction into hydrazine and intramolecular cyclization activated byheating of the reaction medium. The reduction reaction is preferentiallycarried out with tin chloride in acidic conditions but may also becarried out by catalytic hydrogenation or any other method well known tothe person skilled in the art. In an alternative to this last step, itis conceivable that the intermediate diazonium undergoes a Sandmeyerreaction during which this functional group is substituted by a halogenatom, such as iodine, by the reaction of an adequate salt, such as NaI.If this option is preferred, formation of the aminopyrazole ring iscarried out by the use of a hydrazine, functionalized or not, in a polarsolvent such as ethanol at temperatures varying between 25° C. and 150°C.

Method B2:

Alternatively, it is possible to take advantage of an aromaticnucleophilic substitution reaction to functionalize the pyridine orpyrazine ring in position 6. In this case the nucleophiles used arephenols, thiophenols, benzyl alcohols or thiobenzyl alcohols as well asanilines or benzylamines, functionalized or not. The general reactiondiagram 8a is presented below, notably with W═H, (C₁-C₆)alkyl, aryl orbenzyl.

In the case in which X═O or S, the 6-chloro-3-nitropicolinonitriles and6-chloro-3-nitropyrazine-2-carbonitriles, optionally substituted inposition 5, are reacted in the presence of the suitable nucleophile,alcohol or thiol, in a polar solvent such as acetonitrile in thepresence of an inorganic base such as potassium or sodium carbonate.Solvents such as DMSO (dimethylsulfoxide), DMF (dimethylformamide),acetone, THF (tetrahydrofuran) or pyridine may also be considered. Ifnecessary, these reactions may be catalyzed by the action of copper andmay also be carried out without solvent. Typically, the preferredprotocol involves temperatures ranging between 20° C. and 150° C.

Alternatively, the use of bases such as pyridine, DIPEA,diisopropylamine, triethylamine, DBU, potassium tert-butylate, NEt₃ orNaH is also possible.

In the case in which X═N, toluene is a preferred solvent andtriethylamine (NEt3) the base of choice.

The following steps, up to the compounds of general formula (VIIb), areidentical to those documented in method B1 above.

Method B3:

Method B3, presented in diagram 8b below, is a variant of method B2characterized by a first step resulting from a catalytic couplingreaction between a benzyl boronate, in acid or ester form, and a6-chloro-3-nitropicolinonitrile or6-chloro-3-nitropyrazine-2-carbonitrile derivative. It is also wellknown to the person skilled in the art that catalytic coupling reactionsusing alternative catalysts and benzyl derivatives are also possible.Among these, the Stille reaction, based on tin complexes, or those basedon organozinc compounds may be considered.

An optionally substituted2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is obtained beforehand,for example from the corresponding benzyl chloride andoctamethyl-bi-dioxaborolane in dioxane in the presence of potassiumacetate and Pt(dppf)Cl₂ (dppf=1,1′-bis(diphenylphosphino)ferrocene).This compound is brought together with a6-chloro-3-nitropicolinonitrile, a6-chloro-3-nitropyrazine-2-carbonitrile optionally substituted inposition 5 or a 5-chloro-2-nitronicotinonitrile optionally substitutedin position 6 and a palladium catalyst such as Pd(dppf)Cl₂ or Pd(PPh₃)₄,an organic base such as triethylamine or an alcoholate, or an inorganicbase such as sodium, potassium or cesium carbonate in a solvent such astoluene, benzene, THF or dioxane. The preferred reaction temperaturesare between 20° C. and 100° C. The products of these reactionscorrespond to substituted 6-benzyl-3-nitropicolinonitrile,6-benzyl-3-nitropyrazine-2-carbonitrile or5-benzyl-2-nitronicotinonitrile derivatives for which the followingtransformation steps are reproduced from method B1 above.

Method B4:

Method B4, presented in diagram 9 below, gives access topyrazolopyridine and pyrazolopyrazines bicycles featuring optionallyfunctionalized aryl sulfonamide functions, with R₁═(C₁-C₆)alkyl andnotably W═H, (C₁-C₆)alkyl, aryl or benzyl.

The ethyl 2-chloro-5-(chlorosulfonyl)nicotinate derivatives required forthis reaction sequence may be obtained according to the methodsdescribed by Levett P. C. et al., Org. Proc. Res. Dev., 2002, 6(6),767-772; WO 01/98284 and WO 2008/010964.

The formation of sulfonamides is typically carried out by mixing the2-chloro-5-(chlorosulfonyl)nicotinate of interest with a primary orsecondary aniline, optionally functionalized, in an aprotic solvent suchas dichloromethane, THF, acetone or acetonitrile in the presence of anorganic base such as triethylamine (NEt₃), pyridine or DIPEA. The use ofan inorganic base such as sodium or potassium carbonate may also beconsidered. The optimal reaction temperatures are between 0° C. and 70°C.

The saponification reaction of the product thus obtained, notably by theuse of lithium hydroxide in a THF/water mixture, gives access to thecorresponding 2-chloro-5-(N-phenylsulfamoyl)nicotinic acids.

The corresponding acid chlorides are prepared by treatment with thionylchloride in toluene under reflux or by any other dehydrochlorinationmethod well known to the person skilled in the art. The reaction ofthese intermediates with aqueous ammonia makes it possible to formoptionally functionalized 2-chloro-5-(N-phenylsulfamoyl)nicotinamideswhich are then engaged in a dehydration reaction, notably by the use ofPOCl₃, at a temperature ranging between 75° C. and 150° C. Thealternative use of agents such as P₂O₅ or trifluoroacetic anhydride andpyridine may also be considered.

Lastly, these derivatives of general formula (VIh) are reacted in thepresence of a hydrazine, functionalized or not, in a polar solvent suchas ethanol at temperatures varying between 25° C. and 150° C. to formthe corresponding derivatives of general formula (VIId).

Method B5:

Method B5, presented in diagram 10 below, gives access topyrazolopyridine bicycles featuring optionally functionalized benzylether functions, notably with W═H, (C₁-C₆)alkyl, aryl or benzyl.

The method described below is inspired by the work of J. Baldwin et al.,J. Heterocyclic. Chem., 1980, 17(3), 445-448. The5-hydroxynicotinonitrile derivatives, optionally functionalized inposition 6, are alkylated, typically by the use of an optionallyfunctionalized benzyl halide in the presence of a base. The preferredmethod requires the use of an aprotic polar solvent such as DMF and abase such as NaH. The optimal reaction temperatures are between 20° C.and 100° C. Alternatively, the solvents which may be used include, forexample, THF, DMSO, dioxane, acetonitrile, dichloromethane or acetoneand bases such as ^(t)BuOK, DIPEA, pyridine, triethylamine, DBU orsodium, potassium or cesium carbonate.

Oxidation of the pyridine ring into pyridine-N-oxide is typicallycarried out by use of m-CPBA in dichloromethane at room temperature.Nevertheless, many alternative methods are conceivable, notably thosebased on the use of sodium percarbonate in the presence of a rheniumcatalyst, sodium perborate in the presence of acetic acid or theurea-hydrogen peroxide complex.

Treatment of these pyridine-N-oxide derivatives with phosphorusoxychloride leads to the formation of the corresponding2-chloronicotinonitriles (VI).

Their reaction under heat with a hydrazine, functionalized or not, in apolar solvent such as isopropanol or ethanol leads to the formation ofthe pyrazolopyridine bicycles (VIIe) sought.

Method B6:

Method B6, presented in diagram 10a below, gives access to optionallyfunctionalized pyrazolopyridine and pyrazolopyrazine bicycles featuringwith reversed sulfonamide functions, notably with W═H, (C₁-C₆)alkyl,aryl or benzyl.

Le method described below consists in forming a sulfonamide functionfrom an aromatic amine and an arylsulfonyl halide, or any otherequivalent reagent, in the presence of a base, which can optionally beintroduced as solvent or co-solvent. Alternatively, the arylsulfonylhalide or its equivalent can be generated in situ.

Their reaction under heat with a hydrazine, functionalized or not, in apolar solvent such as isopropanol or ethanol leads to the formation thedesired pyrazolopyridine and pyrazolopyrazine bicycles (VIIf).

Method C:

Method C aims at the preparation of compounds of general formula (XI) asdescribed in diagram 1.

Method C1:

Method C1, presented in diagram 11 below, is intended for thepreparation of pyrazolopyridines and pyrazolopyrazines functionalized atposition 6 with R_(n)=halogen, mesylate, tosylate or triflate, X═O, S,NH, N—(C₁-C_)alkyl, and optionally CH₂ for (Xc) and (Xd), and R_(j)═H orN-protecting group.

This method can also be used to carry out the synthesis of moleculescomprising a diatomic X group corresponding notably to an ArX grouprepresenting: —ArCH₂NH—, —ArCH₂N(R₄)—, —ArCH₂O—, —ArCH₂S—, —ArCH₂CH₂—,—ArCHCH—, or —ArCC—.

The 6-hydroxy-2-(methylthio)nicotinonitriles or 5-hydroxy-3-(methylthio)pyrazine-2-carbonitriles are subjected to a dehydrochlorinationreaction, typically in the presence of phosphorus oxychloride, with orwithout solvent, at temperatures varying between 70° C. and 180° C. If asolvent is used, a high boiling-point non-polar solvent such as tolueneor xylene will be preferred. Alternatively, it is possible to activatethe 6-hydroxy-2-(methylthio)nicotinonitriles and5-hydroxy-3-(methylthio)pyrazine-2-carbonitriles by their derivationinto sulfonic esters via the formation of the corresponding tosylates,mesylates or triflates. If this option is preferred, the use of tosyl,mesyl or triflyl chlorides in a solvent such as toluene,dichloromethane, THF, acetonitrile, acetone or dioxane in the presenceof an organic or inorganic base gives access to these derivatives.

The 6-chloro-2(methylthio)nicotinonitriles and5-chloro-3-(methylthio)pyrazine-2-carbonitriles respectively obtained,or their sulfonic ester analogues if this option is preferred, are thenreacted with a nucleophile such as a phenol, an aniline or a thiophenolin the context of aromatic nucleophilic substitution. In this case, thereaction is carried out in a polar solvent such as DMSO, DMF, acetone,THF or acetonitrile, in the presence of a base such as potassiumtert-butylate or NaH. If necessary, these reactions may be catalyzed bythe action of copper and may also be carried out without solvent.Typically, the preferred protocol involves temperatures ranging between20° C. and 150° C.

Alternatively, the use of organic bases such as pyridine,diisopropylamine, triethylamine or DBU, or inorganic bases such assodium or potassium carbonate is also possible.

Alternatively, the compounds of formula (IXb) may give rise to acatalytic coupling reaction such as a Suzuki reaction. In this case,these compounds are brought together with an optionally substituted2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane already described inpreceding method B3, a palladium catalyst such as Pd(dppf)Cl₂ orPd(PPh₃)₄, an organic base such as triethylamine or an alcoholate, or aninorganic base such as sodium, potassium or cesium carbonate in asolvent such as toluene, benzene, THF or dioxane. The preferred reactiontemperatures are between 20° C. and 100° C.

The derivatives obtained by one or another of these methods are thenoxidized, typically by the use of m-CPBA or oxone to form thecorresponding methyl sulfoxides or methyl sulfones. These compounds,sometimes obtained as mixtures, are used as-is in the aminopyrazole ringformation reaction by use of an optionally substituted hydrazine in apolar solvent such as ethanol at temperatures varying between 25° C. and150° C.

Alternatively, it is possible to modify the reaction sequence, notablyby reversing the synthesis steps.

Method C2:

Method C2, presented in diagram 12 below, is intended for thepreparation of pyrazolopyridines and pyrazolopyridazines functionalizedat position 6 with X═O, S, NH, N—(C₁-C_)alkyl, or CH₂ and R_(j)═H orN-protecting group.

The 6-hydroxy-4-(methylthio)nicotinonitrile or6-hydroxy-4-(methylthio)pyridazin-3-carbonitrile derivatives areoxidized, typically by the use of m-CPBA or oxone to form thecorresponding methyl sulfoxides or methyl sulfones. These compounds,sometimes obtained as mixtures, are used as-is in the aminopyrazole ringformation reaction by use of an optionally substituted hydrazine in apolar solvent such as ethanol at temperatures varying between 25° C. and150° C.

The pyrazolopyridines and pyrazolopyridazines thus obtained aresubjected to a dehydrochlorination reaction, typically in the presenceof phosphorus oxychloride, with or without solvent, at temperaturesvarying between 70° C. and 180° C. If a solvent is used, a highboiling-point non-polar solvent such as toluene or xylene will bepreferred. The optionally substituted6-chloro-pyrazolo[4,3-c]pyridin-3-amine and6-chloro-pyrazolo[4,3-c]pyridazin-3-amine respectively obtained are thenreacted with a nucleophile such as a phenol, an aniline or a thiophenolin the context of aromatic nucleophilic substitution. In this case, thereaction is carried out in a polar solvent such as DMSO, DMF, acetone,THF or acetonitrile, in the presence of a base such as potassiumtert-butylate or NaH. If necessary, these reactions may be catalyzed bythe action of copper and may also be carried out without solvent.Typically, the preferred protocol involves temperatures ranging between20° C. and 150° C.

Alternatively, the use of organic bases such as pyridine,diisopropylamine, triethylamine or DBU, or inorganic bases such assodium or potassium carbonate is also possible.

Alternatively, the compounds of formula (XIVa) may give rise to acatalytic coupling reaction such as a Suzuki reaction. In this case,these compounds are brought together with an optionally substituted2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane described above inpreceding method B3, a palladium catalyst such as Pd(dppf)Cl₂ orPd(PPh₃)₄, an organic base such as triethylamine or an alcoholate, or aninorganic base such as sodium, potassium or cesium carbonate in asolvent such as toluene, benzene, THF or dioxane. The preferred reactiontemperatures are between 20° C. and 100° C.

Method C3:

Method C3, presented in diagram 12a below, is a variant of method C1based on the regioselective functionalization of2,6-dichloronicotinonitrile either by an anionic nucleophile such as aphenate or a thiophenate, or by an organometallic such as a benzylzincchloride. In the latter case, the reaction is catalyzed for example witha palladium(II) complex. The transformation of the chloronicotinonitrilethus obtained in the corresponding pyrazolopyridine, in the case whereY₁═CH, is carried out as previously described in method A1.

Method D:

These methods have as an object the synthesis of compounds of generalformula (I) or (VII) by the use of various catalytic coupling methods.

Method D1:

Method D1, presented in diagram 13 below, makes use of the couplingreaction as described in J.A.C.S., 1984, 106, 158 between an organozinccompound prepared in situ and an aryl bromide catalyzed by palladiumcomplexes.

The optionally substituted 3-amino-diazaindazoles or3-amino-azaindazoles are brought together with a zinc benzyl chloride,optionally substituted, in an aprotic polar solvent such as THF ordioxane, in the presence of a catalytic quantity of a palladium complexsuch as (dppf)₂PdCl₂.CH₂Cl₂. The coupling reaction is carried out attemperatures ranging between 25° C. and 100° C.

Method D2:

Method D2, presented in diagram 14 below, makes use of the couplingreaction as described by Gueiffier A. et al., Tetrahedron, 2006, 62,6042-6049, between a thiol, in particular a thiophenol or a benzylthiol,and an aryl iodide catalyzed by copper complexes.

This reaction is typically carried out in a high boiling-point polarsolvent such as 2-propanol in the presence of a catalytic quantity ofpolyethylene glycol, a metal salt such as copper iodide (CuI) and anexcess of an inorganic base such as potassium carbonate, calciumcarbonate or sodium carbonate. The reaction temperatures typically varybetween 50° C. and 100° C.

Method D3:

Method D3, presented in diagram 15 below, makes use of the couplingreaction as described by Sonogashira, K. et al. in Tetrahedron Lett.,1975, 16, 4467-4470 between an acetylene derivative and an aryl halidecatalyzed by copper and palladium complexes.

Such a reaction is typically carried out by the reaction under an inertatmosphere of a heteroaryl halide with a stoichiometric quantity of anoptionally substituted ethynylbenzene in the presence of a catalyticquantity of a palladium complex, for example PdCl₂(PPh₃)₂ or Pd(PPh₃)₄,a catalytic quantity of a copper salt, for example CuI, and an organicbase such as triethylamine or DIPEA, or an inorganic base such aspotassium or cesium carbonate. The protocol generally involves reactiontemperatures ranging between 20° C. and 45° C. in solvents includingDMF, THF, dioxane or diethyl ether.

Method E:

The protocols of method E aim at functionalizing the exocyclic amine ofaminopyrazole rings by their reaction with an intermediate featuring anelectrophile function, optionally generated in situ, such as acidchloride, an isocyanate, a isothiocyanate or an aldehyde.

Method E1:

Method E1, presented in diagram 16 below, aims at the transformation ofthe primary exocyclic amine function of aminopyrazole compounds into anamide function.

These compounds are synthesized via the corresponding 3-aminopyrazole bythe addition of adequate acid chloride prepared beforehand by the use ofoxalyl chloride and a catalytic quantity of DMF in a solvent such astetrahydrofuran. These acid chlorides may be obtained by the use ofalternative methods, such as those based on the use of thionyl chlorideor phosphorus oxychloride, well known to the person skilled in the art.The condensation of acid chlorides on aminopyrazoles is typicallycarried out in an aprotic solvent such as tetrahydrofuran, toluene ordichloromethane in the presence of a base such as DIPEA, pyridine ortriethylamine.

Alternatively, the use of a base as a solvent, in particular pyridine,is a possibility.

Alternatively, this type of reaction may be conducted in a biphasicsystem according to the well-known Schotten-Baumann method.

Alternatively, formation of the amide bond may be carried out from thecorresponding 3-aminopyrazole and the acid of interest by the use ofpeptide coupling conditions using reagents such as HOBt(hydroxybenzotriazole), TBTU(O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate),HATU (2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate), EDCI(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) or carbonyldiimidazoleat a temperature ranging between −20° C. and 100° C. in an aproticsolvent such as tetrahydrofuran, dioxane, dichloromethane or any solventwith similar properties.

Method E2:

Derivatives characterized by the presence of a secondary amine inposition 3 of the aminopyrazole ring are synthesized by a reducingamination reaction according to diagram 17 below.

Reducing amination reactions are typically carried out by mixingadequate stoichiometric quantities of aminopyrazole and aldehyde in asolvent such as DCE (dichloroethane), THF or acetonitrile, optionally inthe presence of a quantity of water, TFA (trifluoroacetic acid) oracetic acid, by adding successive fractions of a reducing agent such asNaBH₄, NaBH(OAc)₃ or NaBH₃CN. These reactions are typically carried outat room temperature.

Method E3:

Derivatives carrying a 3-ureido or 3-thioureido function are obtained bythe reaction, presented in diagram 18 below, of an aminopyrazole with anisocyanate or isothiocyanate obtained according to methods well known tothe person skilled in the art.

In a typical reaction, the reaction mixture is prepared in a polar ornon-polar aprotic solvent such as dichloromethane, acetone, DMF, DMA,acetonitrile, THF or dioxane carried at temperatures varying between 20°C. and the boiling point of the chosen solvent. If necessary, recourseto a weakly nucleophilic organic or inorganic base may prove to benecessary. In this case, sodium hydride is a possible option.

Method F: Post-Synthetic Deprotections and Modifications

Method F1: Deprotections

The trifluoroacetate protecting groups are removed by the action of anorganic base such as triethylamine or pyridine in a polar solvent suchas methanol, ethanol or THF at the reflux temperatures of the solventsused.

The tert-butyl or trityl protecting groups carried by the pyrazole ringsare displaced by the action of a strong acid, typically TFA, in anon-polar solvent such as dichloromethane or DCE.

Method F2: Alkyne Reductions

Reactions for reducing diaryl alkynes into diaryl alkanes are typicallycarried out by catalytic hydrogenation, under hydrogen pressure, in thepresence of catalysts such as PtO₂, Pt, Pd/C, Ni or Rh. Alternatively,the use of DIBAL-H (diisobutylaluminum hydride) in the presence or theabsence of a catalyst such as Cp₂TiCl₂ is conceivable.

Method F3: Oxidation of Sulfides into Sulfones and Sulfoxides

Oxidation reactions of sulfides into sulfoxides are typically carriedout via the use of oxone in a mixture of polar solvents such as THF/MeOHor DMF/water. The optimal reaction temperatures are typically between25° C. and 50° C.

Many alternative methods are available, and some give the possibility ofproducing semi-oxidized derivatives, namely sulfoxides. Such alternativemethods include the use of m-CPBA, KMnO₄/MnO₂ in dichloromethane, H₂O₂(30%) in a biphasic medium and the presence of a phase transfer catalystor a catalyst in the form of a urea complex (UHP).

The combined use of H₂O₂ and metal complexes such as Sc(OTf)₃ promotespartial oxidation derivatives.

Other known methods include, for example, the use of CAN/NaBrO₃(CAN=ceric ammonium nitrate).

The examples which follow illustrate the invention without limiting itsscope in any way.

EXAMPLES

The following abbreviations are used:

DMSO Dimethylsulfoxide

E1 Electron impact

ES Electrospray

LCMS Liquid chromatography-mass spectrometry

mg milligram

mL milliliter

NMR Nuclear magnetic resonance

I. Synthesis of the Compounds According to the Invention Examples ofMethod A1 Example 1 5-iodo-1H-pyrazolo[3,4-b]pyridine-3-amine

Example 1a 2-hydroxy-5-iodonicotinonitrile

9 g (0.5 eq) of N-iodosuccinimide at room temperature is added to asolution of 10 g (83 mmol) of 2-hydroxynicotinonitrile in 150 ml ofanhydrous dimethylformamide. The reaction mixture is stirred at 60° C.After 30 minutes of stirring, 9 g (0.5 eq) of N-iodosuccinimide is addedand then the reaction mixture is stirred at 60° C. for 5 hours. Thesolvent is evaporated and the precipitate formed is filtered, rinsedwith water and with diethyl ether and then dried under vacuum to yield18.5 g (90%) of 2-hydroxy-5-iodonicotinonitrile in the form of a beigepowder.

LCMS (EI, m/z): (M+1) 246.93

¹H NMR: δH ppm (400 MHz, DMSO): 12.79 (1H, s, OH), 8.36 (1H, d,CH_(arom)), 8.04 (1H, d, CH_(arom)).

Example 1b 2-chloro-5-iodonicotinonitrile

30.7 ml (329 mmol) of phosphorus oxychloride at 0° C. and 6 drops ofsulfuric acid are added to 9 g (6.6 mmol) of2-hydroxy-5-iodonicotinonitrile. The reaction mixture is heated at 110°C. for 5 hours and then at room temperature overnight. The reactionmixture is poured in a beaker containing ice and a little water, and aprecipitate is formed. The mixture is allowed to gradually return toroom temperature and then is filtered and rinsed with water. The solidis dried to yield 6.8 g (70%) of 2-chloro-5-iodonicotinonitrile.

LCMS (EI, m/z): (M+1) 265.45

¹H NMR: δH ppm (400 MHz, DMSO): 9.61 (1H, d, CH_(arom)), 9.14 (1H, d,CH_(arom)).

Example 1 5-iodo-1H-pyrazolo[3,4-b]pyridine-3-amine

Hydrazine (3.86 ml, 79 mmol) is added at room temperature to 7 g (26.5mmol) of a solution of 2-chloro-5-iodonicotinonitrile in 25 ml ofpropan-2-ol. The reaction mixture is heated at 85° C. for 7 hours andthen at room temperature overnight. The suspended solid is filtered,rinsed with isopropanol and then with ether and dried in an oven at 50°C. to give 6 g (87%) of 5-iodo-1H-pyrazolo[3,4-b]pyridine-3-amine.

LCMS (EI, m/z): (M+1) 260.95

¹H NMR: δH ppm (400 MHz, DMSO): 12.12 (1H, bs, NH), 8.51 (1H, d,CH_(arom)), 8.45 (1H, d, CH_(arom)), 5.64 (2H, bs, NH₂).

The following compounds were obtained according to the same method.

Mass Ex.** W R_(j) Compound name Yield MH⁺ 1-2 H t-1-tert-butyl-5-iodo-1H-pyrazolo[3,4- 68% 317.05 butyl b]pyridin-3-amine1-3 Me H 5-iodo-6-methyl-1H-pyrazolo[3,4- 93% 275.02 b]pyridin-3-amine**¹H NMR, DMSO-d₆, Ex. 1-2: 8.55 (1H, bs, CH_(arom)), 8.42 (1H, bs,CH_(arom)), 6.33 (1H, bs, CH_(arom)), 1.57 (9H, s, CH); 1-3: 11.92 (1H,s, NH), 8.55 (1H, s, CH_(arom)), 5.59 (2H, bs, NH₂), 2.66 (3H, s, CH₃).

Example 2 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-amine

Example 2a 2-methoxy-nicotinonitrile

4.98 g (217 mmol) of sodium is added to 80 ml of anhydrous methanol. Thereaction medium is stirred at room temperature for 10 minutes and then10 g (72.2 mmol) of 2-chloronicotinonitrile is added at 0° C. Thereaction medium is stirred at 25° C. for 16 hours. The reaction ishydrolyzed by slowly adding water at 0° C. After returning to roomtemperature, the precipitate obtained is filtered, rinsed with water andthen dried at 50° C. to yield 7.85 g (81%) of 2-methoxy-nicotinonitrilein the form of a yellow solid.

LCMS (EI, m/z): (M+1) 135.04

¹H NMR: δH ppm (400 MHz, DMSO): 8.46-8.48 (1H, dd, CH_(arom)), 8.25-8.27(1H, dd, CH_(arom)), 7.17-7.20 (1H, dd, CH_(arom)), 3.99 (3H, s, CH₃).

Example 2b 5-bromo-2-methoxy-nicotinonitrile

12.23 g (149 mmol) of sodium acetate and then 7.66 ml (149 mmol) ofbromine at 0° C. are added to 10 g (74.6 mmol) of a solution of2-methoxy-nicotinonitrile in 29 ml of acetic acid. The reaction mixtureis heated at 70° C. overnight. After returning to room temperature, thereaction medium is added to an ice bath and the precipitate obtained isfiltered, rinsed with water and then dried at 50° C. to yield 11.6 g(73%) of 5-bromo-2-methoxy-nicotinonitrile in the form of a white solid.

LCMS (EI, m/z): (M+1) 214.95

¹H NMR: δH ppm (400 MHz, DMSO): 8.61 (1H, d, CH_(arom)), 8.60 (1H, d,CH_(arom)), 3.98 (3H, s, CH₃)

Example 2 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-amine

35 ml (23.47 mmol) of hydrazine is added at room temperature to 5 g(23.47 mmol) of 5-bromo-2-methoxynicotinonitrile. The reaction medium iscarried at 100° C. for 3 hours. After returning to room temperature, theprecipitate obtained is filtered, rinsed with water and then dried at50° C. to yield 3.6 g (72%) of5-bromo-1H-pyrazolo[3,4-b]pyridine-3-amine in the form of a yellowsolid.

LCMS (EI, m/z): (M+1) 214.05

¹H NMR: δH ppm (400 MHz, DMSO): 12.18 (1H, s, NH), 8.38 (1H, d,CH_(arom)), 8.37 (1H, d, CH_(arom)), 5.66 (2H, s, NH).

Examples of Method A2 Example 35-iodo-1H-pyrazolo[3,4-b]pyrazine-3-amine

Example 3a methyl 3-amino-6-iodopyrazine-2-carboxylate

1.5 equivalents of N-iodosuccinimide are added at room temperature to 5g (32.7 mmol) of a methyl 3-aminopyrazine-2-carboxylate solution in 25ml of dimethylformamide. The reaction medium is heated at 65° C. for 1hour, added together with 0.5 equivalents of N-iodosuccinimide andmaintained at 65° C. for 24 hours. After returning to room temperature,the solvent is evaporated and then the product is extracted severaltimes with dichloromethane. The organic phases are combined, washed with10% sodium bisulfite solution, dried on magnesium sulfate andconcentrated to yield 8 g (88%) of methyl3-amino-6-iodopyrazine-2-carboxylate in the form of a yellow solid.

LCMS (EI, m/z): (M+1) 280

¹H NMR: δH ppm (400 MHz, DMSO): 8.50 (1H, s, CH_(arom)), 7.50 (2H, bs,NH₂), 3.20 (3H, s, CH₃).

Example 3b 3-amino-6-iodopyrazine-2-carboxamide

30 ml of ammonia in water is added under magnetic stirring to 15 g (53.8mmol) of a solution of methyl 3-amino-6-iodopyrazine-2-carboxylate in150 ml of methanol. The reaction medium is stirred at 25° C. for 48hours. After evaporation of the solvents, the precipitate obtained isfiltered, rinsed with water and then dried at 50° C. to yield 12.50 g of3-amino-6-iodopyrazine-2-carboxamide (88%) in the form of a beige solid.

LCMS (EI, m/z): (M+1) 265.02

¹H NMR: δH ppm (400 MHz, DMSO): 8.35 (1H, s, CH_(arom)), 7.85 (1H, bs,NH), 7.60 (3H, bs, NH), 3.25 (3H, s, CH₃).

Example 3c N′-(3-cyano-5-iodopyrazine-2-yl)-N,N-dimethylformimidamide

13.59 ml (146 mmol) of phosphorus oxychloride is added drop by drop at0° C. to 11 g (41.7 mmol) of a solution of3-amino-6-iodopyrazine-2-carboxamide in 80 ml of dimethylformamide. Thereaction mixture is stirred at room temperature overnight and thenpoured in a beaker containing ice and a little water. The pH is adjustedto 8 with 1 N soda solution; a precipitate is formed. The mixture isallowed to gradually return to room temperature and then the solidformed is filtered, rinsed with water and dried at 50° C. to yield 10.50g of N′-(3-cyano-5-iodopyrazine-2-yl)-N,N-dimethyl formimidamide (84%)in the form of a beige solid.

LCMS (EI, m/z): (M+1) 302.07

¹H NMR: δH ppm (400 MHz, DMSO): 8.69 (1H, s, CH_(arom)), 8.67 (1H, s,CH_(ethyl)), 3.20 (3H, s, CH₃), 3.11 (3H, s, CH₃).

Example 3d 3-amino-6-iodopyrazine-2-carbonitrile

77 ml (77 mmol) of 1 M hydrochloric acid solution is added to 7.7 g(25.6 mmol) ofN′-(3-cyano-5-iodopyrazin-2-yl)-N,N-dimethylformimidamide. The reactionmedium is heated at 50° C. for 4 hours and then stirred at roomtemperature overnight. The precipitate formed is filtered, rinsed withwater and dried at 50° C. to yield 6 g (95%) of3-amino-6-iodopyrazine-2-carbonitrile in the form of a beige solid.

LCMS (EI, m/z): (M+1) 247.0

¹H NMR: δH ppm (400 MHz, DMSO): 8.49 (1H, s, CH_(arom)), 7.53 (2H, bs,NH₂).

Example 3e 3-chloro-6-iodopyrazine-2-carbonitrile

64.3 ml of hydrochloric acid is added at −5° C. to 7.7 g (31.3 mmol) of3-amino-6-iodopyrazine-2-carbonitrile. At this temperature, a sodiumnitrite solution (4.32 g, 62.6 mmol) dissolved in 9 ml of water is addedto the reaction mixture and is stirred for 4 hours at −50° C. and thenat room temperature overnight. Another equivalent of sodium nitrite isadded to the reaction mixture and the precipitate formed is filtered,rinsed with water and dried at 50° C. to yield 3.65 g (44%) of3-chloro-6-iodopyrazine-2-carbonitrile in the form of a beige solid.

LCMS (EI, m/z): (M+1) 266.49

¹H NMR: δH ppm (400 MHz, DMSO): 9.13 (1H, s, CH_(arom))

Example 3 5-iodo-1H-pyrazolo[3,4-b]pyrazine-3-amine

0.74 ml (9.8 mmol) of hydrazine is added to 2.6 g (9.80 mmol) of asolution of 3-chloro-6-iodopyrazine-2-carbonitrile in 15 ml of butanol.The reaction mixture is heated at 110° C. for 5 hours and then left atroom temperature overnight. The suspended solid is filtered, rinsed withbutanol and then dried in an oven at 50° C. to yield 2.2 g (86%) of5-iodo-1H-pyrazolo[3,4-b]pyrazine-3-amine in the form of a brown solid.

LCMS (EI, m/z): (M+1) 262.02

¹H NMR: δH ppm (400 MHz, DMSO): 12.59 (1H, bs, NH), 8.60 (1H, d,CH_(arom)), 5.83 (2H, bs, NH₂).

Examples of Method A3 Example 45-iodo-6-methoxy-1H-pyrazolo[3,4-b]pyridin-3-amine

Example 4a ethyl 5-cyano-2-hydroxy-6-(methylthio)nicotinate

Ethyl 5-cyano-2-hydroxy-6-(methylthio)nicotinate is obtained byfollowing the procedure of Ya. Yu. Yakunin et al., Russian ChemicalBulletin, 1999, 48(1), 195-6 with a total yield of 34%.

LCMS (EI, m/z): (M−1) 237.22

¹H NMR: δH ppm (400 MHz, DMSO): 12.72 (1H, bs, OH), 8.40 (1H, s,CH_(arom)), 4.29 (2H, q, CH₂), 2.64 (3H, s, CH₃), 1.30 (3H, t, CH₃).

Example 4b 5-cyano-2-hydroxy-6-(methylthio)nicotinic acid

4.16 g (2 eq) of lithium hydroxide monohydrate is added at roomtemperature to a solution of 11.8 g (49.5 mmol) of ethyl5-cyano-2-hydroxy-6-(methylthio)nicotinate in 100 ml of ethanol and 100ml of water. The reaction mixture is stirred at 60° C. for 2 hours. Theethanol is evaporated and 1 N aqueous soda is added. The aqueous phaseis washed with ethyl acetate and then re-acidified by adding 1 N aqueoushydrogen chloride (pH=1). The precipitate formed is filtered, rinsedwith water and with diethyl ether and then dried under vacuum to yield9.9 g (95%) of 5-cyano-2-hydroxy-6-(methylthio)nicotinic acid in theform of a brown powder.

LCMS (EI, m/z): (M−1) 209.09

¹H NMR: δH ppm (400 MHz, DMSO): 8.32 (1H, s, CH_(arom)), 2.61 (3H, s,CH₃).

Example 4c 6-hydroxy-2-(methylthio)nicotinonitrile

A solution of 6 g (28.5 mmol) of5-cyano-2-hydroxy-6-(methylthio)nicotinic acid in 35 ml of diphenylether is stirred at 250° C. for 4 hours. After returning to roomtemperature, 100 ml of cyclohexane is added and the reaction medium istriturated for 30 minutes. The solid formed is filtered, rinsedthoroughly with cyclohexane and then dried under vacuum to yield 2.87 g(60%) of 6-hydroxy-2-(methylthio)nicotinonitrile in the form of a brownpowder.

LCMS (EI, m/z): (M+1) 167.12

¹H NMR: δH ppm (400 MHz, DMSO): 12.16 (1H, bs, OH), 7.92 (1H, d,CH_(arom)), 6.46 (1H, d, CH_(arom)), 2.59 (3H, s, CH₃).

Example 4d 6-hydroxy-5-iodo-2-(methylthio)nicotinonitrile

6 g (1.6 eq) of silver sulfate and 4.58 g (1.5 eq) of iodine are addedsuccessively to a solution of 2 g (12 mmol) of6-hydroxy-2-(methylthio)nicotinonitrile in 200 ml of ethanol. Thereaction medium is stirred at room temperature for 2 hours. The solid isfiltered and the residue rinsed thoroughly with methanol. The filtrateis evaporated and then taken up in ethyl acetate. The organic phase iswashed with water three times, dried on magnesium sulfate and evaporatedto yield 3.18 g (90%) of 6-hydroxy-5-iodo-2-(methylthio)nicotinonitrilein the form of a yellow powder.

LCMS (EI, m/z): (M+1) 292.93

¹H NMR: δH ppm (400 MHz, DMSO): 12.96 (1H, bs, OH), 8.38 (1H, s,CH_(arom)), 2.62 (3H, s, CH₃).

Example 4e 5-iodo-6-methoxy-2-(methylthio)nicotinonitrile

905 μl (2 eq) of methyl iodide and 2.1 g (1.05 eq) of silver carbonateare added successively to a solution of 2.12 g (7.26 mmol) of6-hydroxy-5-iodo-2-(methylthio)nicotinonitrile in 20 ml of 1,4-dioxane.The reaction medium is stirred at 60° C. for 5 hours. The solid isfiltered and the residue rinsed thoroughly with methanol. The filtrateis evaporated and the residue purified by silica column chromatography(4:6 dichloromethane/cyclohexane as eluent) to yield 1.52 g (68%) of5-iodo-6-methoxy-2-(methylthio)nicotinonitrile in the form of a whitepowder.

LCMS (EI, m/z): (M+1) 306.95

¹H NMR: δH ppm (400 MHz, DMSO): 8.50 (1H, s, CH_(arom)), 4.04 (3H, s,CH₃), 2.63 (3H, s, CH₃).

Example 4f 5-iodo-6-methoxy-2-(methylsulfinyl)nicotinonitrile

1.42 g (1.1 eq) of 70% 3-chloroperbenzoic acid is added to a solution of1.6 g (5.23 mmol) of 5-iodo-6-methoxy-2-(methylthio)nicotinonitrile in20 ml of dichloromethane. The reaction medium is stirred at roomtemperature for 1 hour. Ethyl acetate is added and the organic phase iswashed with saturated sodium bicarbonate solution, dried on magnesiumsulfate, filtered and evaporated to yield 1.63 g (97%) of5-iodo-6-methoxy-2-(methylsulfinyl)nicotinonitrile in the form of awhite powder which may also contain5-iodo-6-methoxy-2-(methylsulfonyl)nicotinonitrile in small proportions(<20%). If necessary, the mixture is used as-is in the following steps.

LCMS (EI, m/z): (M+1) 322.95

¹H NMR: δH ppm (400 MHz, DMSO): 8.86 (1H, s, CH_(arom)), 4.05 (3H, s,CH₃), 2.95 (3H, s, CH₃).

Example 4 5-iodo-6-methoxy-1H-pyrazolo[3,4-b]pyridin-3-amine

294 μl (1.2 eq) of hydrazine monohydrate is added to a solution of 1.63g (5.05 mmol) of 5-iodo-6-methoxy-2-(methylsulfinyl)nicotinonitrile in30 ml of 2-propanol. The reaction medium is stirred at 80° C. for 9hours. After returning to room temperature, the solid formed is filteredand rinsed with 2-propanol to yield 1.14 g (78%) of5-iodo-6-methoxy-1H-pyrazolo[3,4-b]pyridin-3-amine in the form of awhite powder.

LCMS (EI, m/z): (M+1) 291.00

¹H NMR: δH ppm (400 MHz, DMSO): 11.87 (1H, s, NH), 8.49 (1H, s,CH_(arom)), 5.49 (2H, bs, NH₂), 3.90 (3H, s, CH₃).

Example 5 5-iodo-1H-pyrazolo[3,4-b]pyridine-3,6-diamine

Example 5a 4-methylmorpholinium(2,4)-ethyl-5-amino-2,4-dicyano-5-mercaptopenta-2,4-dienoate

4-methylmorpho linium(2,4)-ethyl-5-amino-2,4-dicyano-5-mercaptopenta-2,4-dienoate is preparedaccording to the procedure described by V. D. Dyachenko et al.,Chemistry of Heterocyclic Compounds, 2005, 41(4), 503-10 with a yield of50%.

¹H NMR: δH ppm (400 MHz, DMSO): 9.60 (1H, bs, NH), 8.66 (1H, s, CH),8.33 (1H, bs, NH), 7.43 (1H, bs, NH), 4.08 (2H, q, CH₂), 3.82-4.02 (2H,m, CH₂), 3.55-3.78 (2H, m, CH₂), 3.24-3.42 (2H, m, CH₂), 3.98-3.17 (2H,m, CH₂), 2.81 (3H, s, CH₃), 1.19 (3H, t, CH₃).

Example 5b ethyl 2-amino-5-cyano-6-(methylthio)nicotinate

2.73 ml (1 eq) of methyl iodide is added to a solution of 14.2 g (43.8mmol) of 4-methylmorpholinium(2,4)-ethyl-5-amino-2,4-dicyano-5-mercaptopenta-2,4-dienoate in 78 ml ofN,N-dimethylformamide. The reaction mixture is stirred at roomtemperature for 1 hour and then at 75° C. for 20 hours. After returningto room temperature, water is added and the solid formed is filtered anddried under vacuum to yield 10.31 g (100%) of ethyl2-amino-5-cyano-6-(methylthio)nicotinate in the form of a beige powder.

LCMS (EI, m/z): (M+1) 238.20

¹H NMR: δH ppm (400 MHz, DMSO): 8.25 (1H, s, CH_(arom)), 8.19 (1H, bs,NH), 7.99 (1H, bs, NH), 4.27 (2H, q, CH₂), 2.58 (3H, s, CH₃), 1.31 (3H,t, CH₃).

Example 5c 2-amino-5-cyano-6-(methylthio)nicotinic acid

3.08 g (2 eq) of lithium hydroxide monohydrate is added at roomtemperature to a solution of 8.7 g (36.7 mmol) of ethyl2-amino-5-cyano-6-(methylthio)nicotinate in 87 ml of ethanol and 87 mlof water. The reaction mixture is stirred at 60° C. for 2 hours. Theethanol is evaporated and 1 N aqueous soda is added. The aqueous phaseis washed with ethyl acetate and then re-acidified by adding 1 N aqueoushydrogen chloride (pH=1). The precipitate formed is filtered, rinsedwith water and with diethyl ether and then dried under vacuum to yield7.67 g (quantitative) of 2-amino-5-cyano-6-(methylthio)nicotinic acid inthe form of a brown powder.

LCMS (EI, m/z): (M+1) 210.16

¹H NMR: δH ppm (400 MHz, DMSO): 13.28 (1H, bs, CO₂H), 8.21 (1H, s,CH_(arom)), 8.13 (2H, bs, NH₂), 2.57 (3H, s, CH₃).

Example 5d 6-amino-2-(methylthio)nicotinonitrile

A solution of 3 g (14.3 mmol) of 2-amino-5-cyano-6-(methylthio)nicotinicacid in 30 ml of diphenyl ether is stirred at 255° C. for 60 hours.After returning to room temperature, 60 ml of cyclohexane is added andthe reaction medium is triturated for 30 minutes. The solid formed isfiltered and then rinsed thoroughly with cyclohexane. The solid isredissolved in ethyl acetate and then the organic phase is washed withwater, dried on magnesium sulfate, filtered and then evaporated to yield1.32 g (55%) of 6-amino-2-(methylthio)nicotinonitrile in the form of abrown powder.

LCMS (EI, m/z): (M+1) 166.13

¹H NMR: δH ppm (400 MHz, DMSO): 7.58 (1H, d, CH_(arom)), 7.12 (2H, bs,NH₂), 6.20 (1H, d, CH_(arom)), 2.51 (3H, s, CH₃).

Example 5e 6-amino-5-iodo-2-(methylthio)nicotinonitrile

3.75 g (1.5 eq) of silver sulfate and 2.85 g (1.4 eq) of iodine areadded successively to a solution of 1.32 g (8.02 mmol) of6-amino-2-(methylthio)nicotinonitrile in 65 ml of ethanol. The reactionmedium is stirred at room temperature for 3 hours. The solid is filteredand the residue rinsed thoroughly with methanol. The filtrate isevaporated and redissolved in ethyl acetate. The organic phase is washedwith water three times, dried on magnesium sulfate and evaporated toyield 1.89 g (81%) of 6-amino-5-iodo-2-(methylthio)nicotinonitrile inthe form of a brown powder.

LCMS (EI, m/z): (M+1) 291.99

¹H NMR: δH ppm (400 MHz, DMSO): 8.13 (1H, s, CH_(arom)), 7.19 (1H, broadflat singlet, NH₂), 2.51 (3H, s, CH₃).

Example 5f 6-amino-5-iodo-2-(methylsulfinyl)nicotinonitrile

1.77 g (1.1 eq) of 70% 3-chloroperbenzoic acid is added to a solution of1.89 g (6.51 mmol) of 6-amino-5-iodo-2-(methylthio)nicotinonitrile in 60ml of dichloromethane. The reaction medium is stirred at roomtemperature for 1 hour. Ethyl acetate is added and the organic phase iswashed with saturated sodium bicarbonate solution, dried on magnesiumsulfate, filtered and evaporated to yield 1.5 g (75%) of6-amino-5-iodo-2-(methylsulfinyl)nicotinonitrile in the form of a whitepowder which may also contain6-amino-5-iodo-2-(methylsulfonyl)nicotinonitrile in small proportions(<20%). If necessary, the mixture is used as-is in the following steps.

LCMS (EI, m/z): (M+1) 307.98

¹H NMR: δH ppm (400 MHz, DMSO): 8.45 (1H, s, CH_(arom)), 7.70 (2H, broadflat singlet, NH₂), 2.84 (3H, s, CH₃).

Example 5 5-iodo-1H-pyrazolo[3,4-b]pyridine-3,6-diamine

275 μl (2 eq) of hydrazine monohydrate is added to a solution of 872 mg(2.84 mmol) of 6-amino-5-iodo-2-(methylsulfinyl)nicotinonitrile in 11 mlof 2-propanol. The reaction medium is stirred at 80° C. for 3 hours.Water is added and the product is extracted with ethyl acetate. Theorganic phase is dried on magnesium sulfate, filtered and evaporated.The residue is triturated in a minimum of diisopropyl ether. The solidis filtered to yield 523 mg (67%) of5-iodo-1H-pyrazolo[3,4-b]pyridin-3,6-diamine in the form of a brownpowder.

LCMS (EI, m/z): (M+1) 276.00

¹H NMR: δH ppm (400 MHz, DMSO): 11.23 (1H, s, NH), 8.26 (1H, s,CH_(arom)), 6.11 (2H, bs, NH₂), 5.25 (2H, bs, NH₂).

Examples of Method B1 Example 65-(3,5-difluorobenzylthio)-1H-pyrazolo[4,3-b]pyridin-3-amine

Example 6a 6-chloro-3-nitropicolinonitrile

2,6-Dichloro-3-nitropyridine (5.18 mmol, 1 g) is mixed with 5 ml ofN-methyl-2-pyrrolidinone in a microwave reactor. The reaction mixture isheated at 180° C. for 15 minutes (6 bars). The crude reaction product isdissolved in ethyl acetate, filtered and washed several times using anaqueous phase. The organic phase is collected, dried on magnesiumsulfate and dry concentrated. The crude product thus obtained ispurified by silica gel chromatography (heptane/AcOEt) to yield, afterconcentration, 0.62 g (65%) of a brown oil.

¹H NMR: δH ppm (400 MHz, DMSO): 8.81 (1H, d, CH_(arom)), 8.18 (1H, d,CH_(arom)).

Example 6b 3-nitro-6-thioxo-1,6-dihydropyridine-2-carbonitrile

One equivalent of NaSH:H₂O is added to a solution of6-chloro-3-nitropicolinonitrile (5.45 mmol, 1 g) in 20 ml of EtOH. Thecolor turns orange. The reaction medium is stirred at room temperaturefor 30 minutes. The crude reaction product is then concentrated,redissolved in ethyl acetate and extracted several times using an acidicaqueous phase (1 N HCl) and then a neutral phase. The organic phase isconcentrated and the crude reaction product recrystallized in acetone toyield 0.64 g (79%) of yellow crystals.

¹H NMR: δH ppm (400 MHz, DMSO): 8.71 (1H, d, CH_(arom)), 8.27 (1H, d,CH_(arom)).

Example 6c 6-(3,5-difluorobenzylthio)-3-nitropicolinonitrile

A mixture of 3-nitro-6-thioxo-1,6-dihydropyridin-2-carbonitrile (4.42mmol, 1.34 g), 3,5-diflurobenzylbenzylbromide (8.83 mmol, 1.828 g), andK₂CO₃ (11.04 mmol, 1.525 g) in 5 ml of acetone is heated at 70° C. for10 hours and then evaporated under reduced pressure. The residue ispurified by silica gel chromatography (AcOEt/heptane) to yield 1.33 g(98%) of the expected product.

LCMS (ES−): m/z 306 (M−H+).

¹H NMR: δH ppm (400 MHz, DMSO): 8.53 (1H, d, CH_(arom)), 7.91 (1H, d,CH_(arom)), 7.21 (2H, m), 7.17 (1H, m), 4.55 (2H, CH₂).

Example 6d 3-amino-6-(3,5-difluorobenzylthio)picolinamide

A mixture of 6-(3,5-difluorobenzylthio)-3-nitropicolinonitrile (0.05 g,0.163 mmol) and PtO₂ (0.739 mg, 3.25 μmol) in 10 ml of MeOH is placedunder stirring at atmospheric pressure of hydrogen for 2 hours. Thecatalyst is filtered, the solution is concentrated and the residue thusobtained is purified by silica gel chromatography (AcOEt/heptane) toyield, after concentration, 0.04 g (83%) of white crystals.

LCMS (ES+) m/z: 296 (MH+).

¹H NMR: δH ppm (400 MHz, DMSO): 7.84 (1H, broad s, NH), 7.40 (1H, broads, NH), 7.14 (1H, d, CH_(arom)), 7.08 (4H, m, CH_(arom)), 6.80 (2H,broad s, NH₂), 4.43 (2H, s, CH₂).

Example 6e 3-amino-6-(3,5-difluorobenzylthio)picolinonitrile

A mixture of 3-amino-6-(3,5-difluorobenzylthio)picolinamide (2.37 mmol,0.7 g) and P₂Cl₅ (9.48 mmol, 1.346 g), 20 ml of toluene and 1 ml ofionic solvent (1-butyl-3-methylimidazolium tetrafluoroborate) are placedin a microwave reactor and then heated at 140° C. for 30 minutes. Thecrude reaction product is then concentrated under reduced pressure andthe orange crystals thus obtained are redissolved in ethyl acetate andwashed using saturated aqueous NaHCO₃ solution. The organic phase isdried on magnesium sulfate and then concentrated to yield 0.7 g of abrown oil. This crude reaction product is purified by silica gelchromatography (AcOEt/heptane+0.1% of NEt₃) to yield, afterconcentration, 0.15 g (23%) of orange crystals.

¹H NMR: δH ppm (400 MHz, DMSO): 7.73 (1H, d, CH_(arom)), 7.25 (2H, m,CH_(arom)), 7.18 (1H, m), 6.85 (1H, d), 5.43 (2H, CH₂).

Example 6 5-(3,5-difluorobenzylthio)-1H-pyrazolo[4,3-b]pyridin-3-amine

A solution cooled to 0° C. of NaNO₂ in 3 ml of water is added drop bydrop to a solution at 0° C. of3-amino-6-(3,5-difluorobenzylthio)picolinonitrile (1.587 mmol, 0.44 g)in 15 ml of 6 N HCl solution. After 15 minutes, a solution cooled to 0°C. of SnCl₂.2H₂O diluted in 4 ml of 12 N HCl is added drop by drop. Thereaction medium is then stirred at 25° C. for 1 hour. The solution isextracted with ethyl acetate and then washed using saturated NaHCO₃solution and then saturated NaCl solution. The organic phase iscollected, dried on magnesium sulfate and then concentrated underreduced pressure. The residue is purified by silica gel chromatography(AcOEt/heptane) to yield, after concentration of the organic phases,0.07 g (15%) of black crystals.

¹H NMR: δH ppm (400 MHz, DMSO): 11.64 (1H, s, NH), 7.63 (1H, d,CH_(arom)), 7.21 (2H, m, CH_(arom)), 7.13 (1H, d, CH_(arom)), 7.04 (1H,m, CH_(arom)), 5.38 (2H, s, NH₂), 4.51 (2H, s, CH₂).

The following compounds are obtained by a similar method:

Ex.** ArX W Y₄ R_(j) Compound names Yield Mass MH+ 6-2

H CH H 5-(2,5-difluorobenzylthio)-1H- pyrazolo[4,3-b]pyridin-3-amine 5%4 steps 293.0 6-3

H CH H 5-(2,5-dichlorobenzylthio)-1H- pyrazolo[4,3-b]pyridin-3-amine 3%4 steps 324.9 **¹H NMR: δH ppm (400 MHz, DMSO): 6-2: 11.65 (1H, s, NH),7.64 (1H, dd, CHarom, J = 8.8 Hz), 7.42-7.51 (1H, m, CHarom), 7.20-7.25(1H, m, CHarom), 7.14 (1H, dd, CHarom, J = 8.8 Hz), 7.01-7.11 (1H, m,CHarom), 5.37-5.41 (2H, m, NH2), 4.49 (2H, s). 6-3: 11.65 (1H, s, NH),7.83 (1H, m, CHarom), 7.61 (1H, dd, CHarom, J = 8.8 Hz), 7.50 (1H, m,CHarom), 7.28-7.32 (1H, m, CHarom), 7.10 (1H, dd, CHarom, J = 8.8 Hz),7.01-7.11 (1H, m, CHarom), 5.42 (2H, s, NH2), 4.47 (2H, s).

Examples of Method B2 Example 75-(3,5-dichlorophenylthio)-1H-pyrazolo[4,3-b]pyridin-3-amine

Example 7a 6-(3,5-dichlorophenylthio)-3-nitropicolinonitrile

A mixture of 6-chloro-3-nitropicolinonitrile (3.70 g, 0.02 mol),3,5-dichlorobenzenethiol (3.60 g, 0.02 mol) and K₂CO₃ (5.6 g, 0.04 mol)in 100 ml of acetonitrile is carried at 70° C. for 16 hours. The crudereaction product is diluted in an ethyl acetate fraction and washedusing an aqueous phase. The organic phase is dried with sodium sulfateand the residue is purified by silica gel chromatography(AcOEt/petroleum ether) to yield 5.4 g (80%) of a yellow solid.

Example 7b 3-amino-6-(3,5-dichlorophenylthio)picolinonitrile

10 ml of concentrated HCl is added to a solution of6-(3,5-dichlorophenylthio)-3-nitropicolinonitrile (3.4 g, 0.01 mol) in50 ml of methanol under stirring. The reaction medium is refluxed, addedtogether with 1.68 g (0.03 mol) of iron and stirred for 10 minutes.After returning to room temperature, the reaction mixture is addedtogether with 100 ml of ethyl acetate and 50 ml of water. The pH isadjusted to 10 using 30% soda solution and the organic phase isextracted and then dried on anhydrous sodium sulfate before beingconcentrated. The residue is purified by silica gel chromatography(ethyl acetate/petroleum ether) to yield, after concentration of thefractions, 2.82 g (91%) of a yellow solid.

LCMS (m/e): 296 (M+H+). %.

Example 7 5-(3,5-dichlorophenylthio)-1H-pyrazolo[4,3-b]pyridin-3-amine

A solution of 350 mg of NaNO₂ (5.07 mmol) in water (2 ml) is added to astirring solution of 1.5 g of3-amino-6-(3,5-dichlorophenylthio)picolinonitrile (5.07 mmol) in 100 mlof 50% sulfuric acid at 0° C. The mixture is stirred for 20 minutes at0-5° C. A solution of 2.9 g of SnCl₂.2H₂O (12.7 mmol, 2.5 eq) inhydrochloric acid (12 N solution, 10 ml) is then added and the solutionis stirred for 1 hour at room temperature. The solid formed is filteredand then washed twice with 20 ml of water. The solid is suspended in 100ml and the pH is adjusted to 10 by adding 30% soda solution. The organicphase is separated and then dried on anhydrous sodium sulfate beforebeing concentrated under vacuum. A light yellow solid is obtained afterrecrystallization in ethyl acetate (470 mg, 34%).

LCMS m/z 311 (M+H⁺).

¹H NMR: δH ppm (400 MHz, DMSO): 11.91 (1H, bs, NH), 7.79 (1H, d,CH_(arom)), 7.55 (1H, s, CH_(arom)), 7.36 (2H, s, CH_(arom)), 7.33 (1H,m, CH_(arom)), 5.42 (2H, s, NH₂).

The following compounds are obtained by a similar method:

Ex.** ArX Y₄ W R_(j) Compound names Yield Mass MH⁺ 7-1

CH H H 5-(3,5-difluorobenzyloxy)-1H- pyrazolo[4,3-b]pyridin-3-amine 28%277 7-2

CH H H 5-(3,5-difluorophenylthio)-1H- pyrazolo[4,3-b]pyridin-3-amine 33%3 steps 278.9 7-3

CH H H 5-(2,4-difluorophenylthio)-1H- pyrazolo[4,3-b]pyridin-3-amine 24%3 steps 279.0 7-4

CH H H 5-(2,4-dichlorophenylthio)-1H- pyrazolo[4,3-b]pyridin-3-amine 24%3 steps 311.0 7-5

CH H H 5-(2-(trifluoromethyl)phenylthio)-1H-pyrazolo[4,3-b]pyridin-3-amine 17% 3 steps 311.0 7-6

N H H 5-(3,5-difluorophenylthio)-1H- pyrazolo[3,4-b]pyrazin-3-amine 6% 7steps 279.9 7-7

N H H 5-(2,4-dichlorophenylthio)-1H- pyrazolo[3,4-b]pyrazin-3-amine 4% 7steps 311.9 7-8

N H H 5-(2-(trifluoromethyl)phenylthio)-1H-pyrazolo[3,4-b]pyrazin-3-amine 6% 7 steps 311.9 7-9

CH H H 5-(3,5-difluorobenzyloxy)-1H- pyrazolo[4,3-b]pyridin-3-amine 6% 3steps 277.0 7-10

CH H H 5-(2,5-difluorobenzyloxy)-1H- pyrazolo[4,3-b]pyridin-3-amine 3% 3steps 277.0 7-11

CH H H 5-(2,5-dichlorobenzyloxy)-1H- pyrazolo[4,3-b]pyridin-3-amine 32%3 steps 309.0 7-12

CH H H 5-(5-chloro-2- (trifluoromethyl)benzyloxy)-1H-pyrazolo[4,3-b]pyridin-3-amine 8% 3 steps 343.1 7-13

CH H H 5-(pyridin-3-ylmethoxy)-1H- pyrazolo[4,3-b]pyridin-3-amine 6% 3steps 342.1 **¹H NMR: δH ppm (400 MHz, DMSO): 7-1: 11.61 (1H, s large,NH), 7.73 (1H, d, CHarom), 7.24 (2H; m, CHarom), 7.18 (1H, m, CHarom),6.86 (1H, d, CHarom). 7-2: 11.95 (1H, sl, NH), 7.78 (1H, d, CHarom, J =11.6 Hz), 7.33 (1H, d, CHarom, J = 11.6 Hz), 7.19 (1H, t, CHarom), 7.04(2H, 2d, CHarom, J = 8.8 Hz), 5.51 (2H, s, NH₂). 7-3: 11.80 (1H, sl,NH), 7.70 (1H, d, CHarom, J = 8.8 Hz), 7.60 (1H, t, CHarom), 7.49 (1H,q, CHarom), 7.27-7.33 (1H, m, CHarom), 7.11 (1H, d, CHarom, J = 8.8 Hz),5.41 (2H, s, NH₂). 7-4: 11.93 (1H, sl, NH), 7.80 (1H, d, CHarom, J =11.6 Hz), 7.62 (1H, d, CHarom, J = 11.6 Hz), 7.40 (1H, dd, CHarom, J =11.2 Hz), 7.29 (1H, d, CHarom, J = 11.6 Hz), 7.1 (1H, s, CHarom), 5.51(2H, s, NH₂). 7-5: 11.86 (1H, sl, NH), 7.87 (1H, d, CHarom, J = 9.6 Hz),7.73 (1H, d, CHarom, J = 11.6), 7.50-7.68 (2H, m, CHarom), 7.44 (1H, d,CHarom, J = 10.4 Hz), 7.11 (1H, d, CHarom, J = 11.6 Hz), 5.46 (2H, s,NH₂). 7-6: 12.66 (1H, sl, NH), 8.52 (1H, s, CHarom), 7.12-7.20 (1H, m,CHarom), 7.02-7.10 (2H, m, CHarom), 5.90 (2H, s, NH₂). 7-7: 12.70 (1H,s, NH), 8.52 (1H, s, CHarom), 7.60 (1H, d, CHarom, J = 8.8 Hz), 7.38(1H, dd, CHarom, J = 8.4 Hz), 7.12 (1H, s, CHarom), 5.92 (2H, s, NH₂).7-8: 12.66 (1H, s, NH), 8.39 (1H, s, CHarom), 7.84 (1H, d, CHarom, J =7.6 Hz), 7.58 (1H, t, CHarom), 7.50 (1H, t, CHarom), 7.34 (1H, d,CHarom, J = 7.6 Hz), 5.87 (2H, s, NH₂). 7-9: 11.57 (1H, s, NH), 7.74(1H, d, Charom, J = 9 Hz), 7.25 (3H, m, CHarom), 6.88 (1H, d, Charom, J= 9 Hz), 5.44 (2H, s), 5.08 (2H, s). 7-10: 11.58 (1H, s, NH), 7.73 (1H,d, CHarom, J = 12.0 Hz), 7.48-7.58 (1H, m, CHarom), 7.21-7.37 (2H, m,CHarom), 6.85 (1H, d, CHarom, J = 12.0 Hz), 5.44 (2H, s, CH), 5.10 (2H,sl, NH₂). 7-11: 11.60 (1H, sl, NH), 7.70-7.77 (2H, m, CHarom), 7.57 (1H,d, CHarom, J = 11.2 Hz), 7.40-7.50 (1H, m, CHarom), 6.89 (1H, d, CHarom,J = 12.0 Hz), 5.48 (2H, s, CH), 5.06 (2H, sl, NH₂). 7-12: 11.60 (1H, sl,NH), 7.91 (1H, s, CHarom), 7.83 (1H, d, CHarom, J = 11.2 Hz), 7.75 (1H,d, CHarom, J = 12.0 Hz), 7.66 (1H, d, CHarom, J = 9.6 Hz), 6.88 (1H, d,CHarom, J = 12.0 Hz), 5.58 (2H, s, CH), 5.01 (2H, sl, NH₂). 7-13: 11.56(1H, sl, NH), 8.77 (1H, s, CHarom), 8.55 (1H, s, CHarom), 7.96 (1H, d,CHarom, J = 10.4 Hz), 7.72 (1H, d, CHarom, J = 12.0 Hz), 7.42 (1H, dd,CHarom, J = 10.0 Hz), 6.83 (1H, d, CHarom, J = 11.6 Hz), 5.45 (2H, s,CH), 5.15 (2H, sl, NH₂).

Example 8 N5-(3,5-difluorophenyl)-1H-pyrazolo[4,3-b]pyridine-3,5-diamine

Example 8a 6-(3,5-difluorophenylamino)-3-nitropicolinonitrile

A mixture of 6.5 g of 6-chloro-3-nitropicolinonitrile (0.065 mol) and6.2 g of 3,5-difluoroaniline (0.048 mol) in 100 ml of toluene is heatedat 70° C. for 5 hours. The crude reaction product is diluted in an ethylacetate fraction and washed using saturated NaCl solution. The organicphase is dried with sodium sulfate and the residue purified by silicagel chromatography (AcOEt/petroleum ether) to yield 3.9 g (33%) of ayellow solid.

Example 8b 3-amino-6-(3,5-difluorophenylamino)picolinonitrile

10 ml of concentrated HCl is added to a solution of6-(3,5-dichlorophenylthio)-3-nitropicolinonitrile (3.9 g, 0.0141 mol) in150 ml of ethanol under stirring. The reaction medium is refluxed, addedtogether with 2.4 g of iron (0.0423 mol) and stirred at 80° C. for 1hour. After returning to 0° C. the pH is adjusted to 8 using 1 N sodasolution and the reaction medium is filtered on Celite. The reactionmixture is added together with 100 ml of ethyl acetate and 50 ml ofmethanol. The organic phase is extracted and the aqueous phase isextracted several times by ethyl acetate fractions. The organic phasesare combined and then dried on anhydrous sodium sulfate before beingconcentrated to yield, after concentration, 2.3 g (66%) of a brownsolid.

Example 8 5-(3,5-difluorophenylamino)-1H-pyrazolo[4,3-b]pyridin-3-amine

A solution of 713 mg of NaNO₂ (10.3 mmol) in water (5 ml) is added, dropby drop, to a stirring solution of 2.3 g of3-amino-6-(3,5-difluorophenylamino)picolinonitrile (9.4 mmol) in 100 mlof 6 N hydrochloric acid at 0° C. The mixture is stirred for 20 minutesat 0-5° C. A solution of 5.3 g of SnCl₂.2H₂O (23.5 mmol, 2.5 eq) inhydrochloric acid (12 N solution, 30 ml) is then added drop by drop andthe solution is stirred for 1 hour at room temperature. The reactionmedium is then cooled at 0° C. and basified to pH 8 using 30% sodasolution. The mixture is extracted with ethyl acetate and washed usingsaturated NaCl solution and the organic phase is dried on anhydroussodium sulfate before being concentrated under vacuum. The residue ispurified by silica column chromatography (AcOEt). A light yellow solidis obtained (530 mg, 22%).

LCMS: m/z 262 (M+H⁺).

¹H NMR: δH ppm (400 MHz, DMSO): 11.47 (s, 1H), 9.45 (s, 1H), 7.65 (m,3H), 6.87 (d, 1H, J=7.8 Hz), 6.60 (m, 1H), 5.09 (s, 2H).

The following compounds are obtained by a similar method:

Ex.** ArX Y₄ W R_(j) Compound names Yield Mass MH⁺ 8-1

CH H H N-(2,5-difluorophenyl)-1H- pyrazolo[4,3-b]pyridine-3,5-diamine 4%4 steps 262.0 8-2

CH H H N-(2,5-dichlorophenyl)-1H- pyrazolo[4,3-b]pyridine-3,5-diamine 9%4 steps 294.0 ** ¹H NMR: δH ppm (400 MHz, DMSO): 8-1: 11.46 (1H, s, NH),8.75-8.82 (2H, m, CHarom), 7.65 (1H, dd, CHarom, J = 9.2 Hz), 7.19-7.31(2H, m, CHarom), 6.67-6.63 (1H, sl, CHarom), 5.06 (2H, s, NH₂). 8-2:11.58 (1H, sl, NH), 8.65 (1H, s, CHarom), 8.35 (1H, s, CHarom), 7.69(1H, d, CHarom, J = 12.0 Hz), 7.45 (1H, d, CHarom, J = 11.6 Hz), 7.24(1H, d, CHarom, J = 12.0 Hz), 6.96 (1H, dd, CHarom, J = 11.2 Hz), 5.03(2H, sl, NH₂).

Example of Method B3 Example 95-(3,5-difluorobenzyl)-1H-pyrazolo[4,3-b]pyridin-3-amine

This compound can be prepared from the following intermediates,according to method B3.

Example 9a2-(3,5-difluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Example9b 6-(3,5-difluorobenzyl)-3-nitropicolinonitrile Example 9c3-amino-6-(3,5-difluorobenzyl)picolinonitrile Example of Method B4Example 103-amino-N-(3,5-difluorophenyl)-1H-pyrazolo[3,4-b]pyridine-5-sulfonamide

Example 10a 5-(N-(3,5-difluorophenyl)sulfamoyl)nicotinic acid

2.74 g (9.64 mmol) of ethyl 2-chloro-5-(chlorosulfonyl)nicotinate insolution in 20 ml of anhydrous dichloromethane is added, drop by drop at0° C., to a mixture of 623 mg (4.82 mmol) of 3,5-difluoroaniline and1.68 ml (12.05 mmol) of triethylamine diluted in 10 ml of anhydrousdichloromethane. The solution is stirred at room temperature for 3hours. The solvent is evaporated to yield a light brown solid. The solidis triturated in 20 ml of methanol, filtered and then rinsed with 3 mlof methanol to yield 2.85 g of a white solid.

This solid is redissolved in 25 ml of tetrahydrofuran and is addedtogether with a solution of 0.421 g (10.04 mmol) of lithium monohydratehydroxide in 10 ml of water. The reaction mixture is left under stirringfor 3 hours at 35° C. and then diluted in water, acidified with 1 Nhydrochloric acid and extracted with ethyl acetate. The organic phase iscollected, dried on sodium sulfate, filtered and concentrated to yield1.12 g of 5-(N-(3,5-difluorophenyl)sulfamoyl)nicotinic acid in the formof an orange solid (yield=67%).

¹H NMR: δH ppm (400 MHz, DMSO): 8.91 (1H, s, CH_(arom)), 8.51 (1H, s,CH_(arom)), 7.02 (1H, dd, CH_(arom)), 6.83 (2H, d, CH_(arom)).

Example 10b 2-chloro-5-(N-(3,5-difluorophenyl)sulfamoyl)nicotinamide

0.288 ml (3.87 mmol) of thionyl chloride and a drop of DMF are addedsuccessively to 0.450 g (1.29 mmol) of2-chloro-5-(N-(3,5-difluorophenyl)sulfamoyl)nicotinic acid in 5 ml ofanhydrous toluene. The mixture is placed under stirring, at reflux oftoluene, for 2 hours. The acid chloride reaction mixture is then addeddrop by drop to an iced solution, under stirring, of 4.5 ml of 25%ammonium hydroxide. A release of gas is observed. The reaction medium isleft under stirring at room temperature for 30 minutes. The reactionmedium is extracted several times with ethyl acetate. The combinedorganic phases are dried on anhydrous sodium sulfate and thenconcentrated. 0.315 g of2-chloro-5-(N-(3,5-difluorophenyl)sulfamoyl)nicotinamide in the form ofa light brown solid is obtained (yield=72%).

¹H NMR: δH ppm (400 MHz, DMSO): 11.18 (1H, bs, NH), 8.86 (1H, s,CH_(arom)), 8.22 (1H, s, CH_(arom)), 8.21 (1H, bs, NH), 7.98 (1H, bs,NH), 6.96 (1H, dd, CH_(arom)), 6.79 (2H, d, CH_(arom)).

Example 10c6-chloro-5-cyano-N-(3,5-difluorophenyl)pyridine-3-sulfonamide

3.4 ml (36.2 mmol) of phosphoryl chloride and a drop of concentratedsulfuric acid are added to 0.315 g (0.906 mmol) of2-chloro-5-(N-(3,5-difluorophenyl) sulfamoyl)nicotinamide. The reactionmixture is stirred for 2 hours at 90° C. and then added drop by drop toice. The brown solid is filtered, rinsed with water and then dried undervacuum. 0.217 g of6-chloro-5-cyano-N-(3,5-difluorophenyl)pyridine-3-sulfonamide isobtained in the form of a light brown solid (yield=72%).

¹H NMR: δH ppm (400 MHz, DMSO): 11.34 (1H, bs, NH), 9.04 (1H, s,CH_(arom)), 8.92 (1H, s, CH_(arom)), 7.03 (1H, dd, CH_(arom)), 6.85 (2H,d, CH_(arom)).

Example 103-amino-N-(3,5-difluorophenyl)-1H-pyrazolo[3,4-b]pyridine-5-sulfonamide

0.377 ml (2.63 mmol) of 35% hydrazine is added to 0.217 g (0.658 mmol)of 6-chloro-5-cyano-N-(3,5-difluorophenyl)pyridine-3-sulfonamide dilutedin 6 ml of isopropanol. The solution is heated at 75° C. for 2 hours.The solvent is evaporated to yield 0.214 g of3-amino-N-(3,5-difluorophenyl)-1H-pyrazolo[3,4-b]pyridine-5-sulfonamidein the form of a yellow solid (yield=100%).

¹H NMR: δH ppm (400 MHz, DMSO): 8.74 (1H, d, CH_(arom)), 8.68 (1H, d,CH_(arom)), 6.88 (1H, dd, CH_(arom)), 6.80 (2H, d, CH_(arom)), 6.04 (2H,bs, NH).

Examples of Method B5 Example 115-(3,5-difluorobenzyloxy)-1H-pyrazolo[3,4-b]pyridin-3-amine

This compound can be prepared from the following intermediates,according to method B5.

Example 11a 5-hydroxynicotinonitrile

A mixture of 1 g of 5-methoxynicotinonitrile (7.46 mmol) and 8.62 g ofpyridine hydrochloride is heated at 200° C. for 2 hours. The crudereaction product is diluted in a water fraction several times withdiethyl ether. The aqueous phase is basified by adding sodiumbicarbonate and then extracted again with diethyl ether. The organicphase is dried and then concentrated to yield 850 mg of5-hydroxynicotinonitrile (95%) in the form of a beige solid.

LCMS: m/z 120.94 (M+H⁺).

¹H NMR: δH ppm (400 MHz, DMSO): 10.79 (s, 1H), 8.46 (s, 1H, CHarom.),8.42 (s, 1H, CHarom.), 7.60 (s, 1H, CHarom.).

Example 11b 5-(3,5-difluorobenzyloxy)nicotinonitrile

876 mg (2 eq) of sodium hydride is added gradually at 0° C. undernitrogen to a solution of 865 mg of 5-hydroxynicotinonitrile (7.2 mmol)in 15 mL of dimethylacetamide. The mixture is stirred 10 min at 0° C.before adding 2.24 g (1.5 aq) of 3,5-difluorobenzyl bromide. The mixtureis placed under stirring for 2.5 additional hours before being dilutedin an ethyl acetate fraction and being washed with aqueous fractions.The organic phases are isolated, dried and concentrated. The solidresidue obtained is recrystallized in methanol to yield 1.1 g (68% of5-(3,5-difluorobenzyloxy) nicotinonitrile in the form of a beige powder.

LCMS: m/z 247.11 (M+H⁺).

¹H NMR: δH ppm (400 MHz, DMSO): 8.69 (s, 1H, CH), 8.65 (s, 1H, CH), 8.08(s, 1H, CH), 7.26 (m, 3H, CH), 5.28 (d, 2H, CH₂).

Example 11c 3-cyano-5-(3,5-difluorobenzyloxyl)pyridine 1-oxide

224 mg of m-CPBA is added at 0° c. to a solution in acetonitrile of 250mg of 5-(3,5-difluorobenzyloxy)nicotinonitrile. The reaction medium isstirred for 20 hours while a precipitate is formed progressively. thissolid is then filtered and washed to yield 200 mg (75%) of3-cyano-5-(3,5-difluorobenzyloxyl)pyridine 1-oxide in the form of awhite powder.

LCMS: m/z 263.06 (M+H⁺).

Example 11d 2-chloro-5-(3,5-difluorobenzyloxy)nicotinonitrile

A mixture of 650 mg of 3-cyano-5-(3,5-difluorobenzyloxyl)pyridine1-oxide in 2.3 mL of POCl₃ added with few drops of H₂SO₄ is heated at110° C. for 1 h 30. The crude reaction medium is then poured in ice andthe precipitate thus formed is isolated by filtration and dried undervacuum to yield 600 mg of a beige solid in the form of a mixture ofregioisomers comprising mainly the desired2-chloro-5-(3,5-difluorobenzyloxy)nicotinonitrile which is used withoutfurther purification.

LCMS: m/z 281.02 (M+H⁺).

Example 11 5-(3,5-difluorobenzyloxy)-1H-pyrazolo[3,4-b]pyridin-3-amine

313 mg of hydrazine hydrate (5 eq) is added to a solution of 1.6 g of2-chloro-5-(3,5-difluorobenzyloxy)nicotinonitrile (450 μmol) in 10 mL ofpropan-2-ol. The reaction mixture is heated at 100° C. for 6 hours.After return to room temperature leading to a precipitation, the crudereaction medium is filtered, the solid is removed and the filtrate isdry evaporated. It is then purified by chromatography on a silica columneluted with a gradient of ethyl acetate and methanol, whereas the morepolar fraction is isolated, concentrated and suspended again in a smallfraction of methanol under stirring. The solid thus obtained is isolatedand dried to yield 221 mg of5-(3,5-difluorobenzyloxy)-1H-pyrazolo[3,4-b]pyridin-3-amine in the formof a beige solid which is used without further purification.

LCMS: m/z 277.07 (M+H⁺).

Example of Method B6 Example 11bisN-(3-amino-1H-pyrazolo[3,4-b]pyridin-5-yl)-3,5-difluorobenzenesulfonamide

Example 1 bis-aN-(6-chloro-5-cyanopyridin-3-yl)-3,5-difluorobenzene-sulfonamide

1.132 g (5.32 mmol) of 3,5-difluorobenzene-1-sulfonyle chloride is addedunder argon to a solution of 545 mg (3.55 mmol) of5-amino-2-chloronicotinotrile in 20 mL of an anhydrous 1:1 mixture ofTHF and pyridine. The reaction medium is heated to 70° C. for 3 hoursand let 12 additional hours under stirring at room temperature. Thesolvent is dry evaporated and the crude reaction product is redissolvedin ethyl acetate and washed with several aqueous fractions. The organicphase is dried on magnesium sulfate, filtered, concentrated and thenpurified by silica gel chromatography to yield 784 mg (67%) ofN-(6-chloro-5-cyanopyridin-3-yl)-3,5-difluorobenzene-sulfonamide.

¹H NMR: δH ppm (400 MHz, DMSO): 11.39 (1H, sl, NH), 8.34 (1H, m,CHarom), 8.10 (1H, m, CHarom), 7.67 (1H, m, CHarom), 7.59 (2H, m,CHarom).

Example 11bisN-(3-amino-1H-pyrazolo[3,4-b]pyridin-5-yl)-3,5-difluorobenzene-sulfonamide

1.786 g (35.7 mmol) of hydrazine hydrate is added under argon to asolution of 784 mg (2.38 mmol) ofN-(6-chloro-5-cyanopyridin-3-yl)-3,5-difluorobenzene-sulfonamide in 6 mLof ethanol. The solution is heated to 100° C. for 20 hours and thencooled to room temperature. The solvent is evaporated to yield 810 mg ofN-(3-amino-1H-pyrazolo[3,4-b]pyridin-5-yl)-3,5-difluorobenzene-sulfonamide(100%) which is used without further purification in the followingsteps.

LCMS: m/z 326.07 (M+H⁺).

Example of Method C1 Example 12N6-(2,4-difluorophenyl)-1H-pyrazolo[3,4-b]pyridine-3,6-diamine

This compound can be prepared from the following intermediates,according to method C1.

Example 12-a 5-cyano-6-(methylthio)pyridin-2-yltrifluoromethanesulfonate

15.26 mL (1.2 eq) of potassium 2-methylpropan-2-olate and then 9.03 g(1.2 eq) of1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamideare added dropwise to a solution of 3.5 g (21.06 mmol) of6-hydroxy-2-(methylthio)nicotinonitrile in 180 mL of tetrahydrofuraneunder nitrogen. The reaction mixture is stirred at room temperature for2 h 45. Water is added and the product is extracted with ethyl acetate.The organic phase is dried on anhydrous magnesium sulfate, filtered andevaporated to yield an orange solid. The product is purified on a silicagel column (eluent: cyclohexane/dichloromethane 5:5) to yield 5.31 g(85%) of 5-cyano-6-(methylthio)pyridin-2-yl trifluoromethanesulfonate inthe form of a yellow solid.

¹H NMR: δH ppm (400 MHz, DMSO): 8.57 (1H, d, CH), 7.52 (1H, d, CH), 2.59(3H, s, CH₃).

Example 12-b 6-(2,4-difluorophenylamino)-2-(methylthio)nicotinonitrile

0.81 mL (1.2 eq) of, 4-difluoroaniline and 1.53 g (1.4 eq) of cesium(I)carbonate are added under nitrogen to a solution of 2 g (6.71 mmol) of5-cyano-6-(methylthio)pyridin-2-yl trifluoromethanesulfonate in 30 mL of1,4-dioxane. The medium is degassed for 5 minutes under argon beforeadding 0.25 g (0.06 eq) of de2,2′-bis(diphenylphosphino)-1,1′-binaphthyl and 0.08 g (0.04 eq) of(1E,4E)-1,5-diphenylpenta-1,4-dien-3-one, palladium(II) complex. Thereaction medium is stirred at 100° C. for 2 hours. After return to roomtemperature, ethyl acetate and brine are added. The organic phase isdried on anhydrous magnesium sulfate, filtered and evaporated. Theresidue obtained is purified on silica gel chromatography (eluent:cyclohexane/ethyl acetate 8:2 then 7:3) to yield 1.52 g (82%) of6-(2,4-difluorophenylamino)-2-(methylthio)nicotinonitrile in the form ofa white solid.

LCMS (IE, m/z): (M+1) 278.06.

¹H NMR: δH ppm (400 MHz, DMSO): 9.57 (1H, s, NH), 7.73-7.86 (2H, m, CH),7.28-7.44 (1H, m, CH), 7.02-7.18 (1H, m, CH), 6.60 (1H, d, CH), 2.41(3H, s, CH₃).

Example 12N6-(2,4-difluorophenyl)-1H-pyrazolo[3,4-b]pyridine-3,6-diamine

769 mg (3.12 mmol) of m-chloroperbenzoic acid (mCPBA) is added underargon to a stirring solution of 786 mg (2.83 mmol) of6-(2,4-difluorophenylamino)-2-(methylthio)nicotinonitrile in 25 mL ofdichloromethane. The reaction medium is stirred 1 hour at roomtemperature before adding a fraction of ethyl acetate and washed thisorganic phase with a NaHCO₃ saturated solution. The combined organicphases are dried on magnesium sulfate and dry evaporated. The crudereaction product is dissolved again in 10 mL of propanol and 2equivalents of hydrazine hydrochloride in water are added. The mixtureis heated at 90° C. for 6 hours before being diluted in water andextracted with ethyl acetate. The organic phase is dried on magnesiumsulfate and dry evaporated before being purified by silica gelchromatography to yield 495 mg ofN6-(2,4-difluorophenyl)-1H-pyrazolo[3,4-b]pyridine-3,6-diamine in theform of a yellow-orange solid (67%).

LCMS (IE, m/z): (M+1) 262.14.

¹H NMR: δH ppm (400 MHz, DMSO): 11.40 (1H, s, NH), 8.76 (1H, s, NH),8.15 (1H, m, CH), 7.81 (1H, d, CH), 7.28 (1H, m, CH), 7.06 (1H, m, CH),6.55 (1H, d, CH), 5.24 (2H, s, NH₂).

The following compound is obtained by a similar method:

Ex.** ArX Y₁ Compound names Yield Mass MH⁺ 12-1

CH N6-(3,5-difluorobenzyl)-1H- pyrazolo[3,4-b]pyridine-3,6- diamine 70%276.15 **¹H NMR, dmso-d₆, Ex.: 12-1: 11.17 (1H, s, NH), 7.66 (1H, d,CH), 7.37 (1H, s, NH), 7.04 (3H, m, CH), 6.24 (1H, d, CH), 5.11 (2H, s,NH₂), 4.52 (2H, s, CH₂).

Example 12bisN6-(2,4-difluorophenyl)-N6-methyl-1H-pyrazolo[3,4-b]pyridine-3,6-diamine

Example 12bis-a 6-((3,5-difluorophenyl)(methyl)amino)-2-(methylthio)nicotinonitrile

3.05 mL (5.04 mmol) of potassium 2-methylpropan-2-olate and then 286 μL(1.8 eq) of iodomethane are added dropwise under nitrogen to a solutionof 700 mg (2.52 mmol) of6-(2,4-difluorophenylamino)-2-(methylthio)nicotinonitrile in 20 mL ofN,N-dimethyl formamide. The reaction medium is stirred at roomtemperature for 24 hours and then 126 μL (0.8 eq, 2.02 mmol) ofiodomethane is added. The reaction medium is stirred at room temperaturefor 2 additional hours. Water is added and the product is extracted withethyl acetate. The organic phase is dried on anhydrous magnesiumsulfate, filtered, and evaporated to yield 660 mg (90%) of6-((2,4-difluorophenyl)(methyl)amino)-2-(methylthio)nicotinonitrile inthe form of a brown solid.

LCMS (IE, m/z): (M+1) 292.09.

¹H NMR: δH ppm (400 MHz, DMSO): 7.74-7.80 (1H, m, CH), 7.55-7.63 (1H, m,CH), 7.43-7.52 (1H, m, CH), 7.18-7.27 (1H, m, CH), 6.16-6.30 (1H, m,CH), 3.43 (3H, s, CH₃), 2.42 (3H, s, CH₃).

Example 12bisN6-(2,4-difluorophenyl)-N6-methyl-1H-pyrazolo[3,4-b]pyridine-3,6-diamine

452 mg (1.84 mmol) of mCPBA is added under argon to a stirring solutionof 486 mg (1.67 mmol) of6-((2,4-difluorophenyl)(methyl)amino)-2-(methylthio)nicotinonitrile in15 mL of dichloromethane. The reaction medium is stirred 30 min at roomtemperature before adding an ethyl acetate fraction. The organic phaseis washed with a NaHCO₃ saturated solution, dried on magnesium sulfateand dry evaporated. The crude reaction product is dissolved again in 6mL of propanol and 164 μL (3.38 mmol) of hydrazine hydrochloride inwater is added. The mixture is heated at 90° C. for 6 hours before beingdiluted in water and extracted with ethyl acetate. the organic phase isdried on magnesium sulfate and dry evaporated before being purified bysilica gel chromatography to yield 328 mg ofN6-(2,4-difluorophenyl)-N6-methyl-1H-pyrazolo[3,4-b]pyridine-3,6-diaminein the form of a yellow-orange solid (70%).

LCMS (IE, m/z): (M+1) 276.15.

¹H NMR: δH ppm (400 MHz, DMSO): 11.41 (1H, s, NH), 7.75 (1H, d, CH),7.51-7.55 (1H, m, CH), 7.40-7.43 (1H, m, CH), 7.17-7.22 (1H, m, CH),6.03 (1H, d, CH), 5.23 (2H, s, NH₂), 3.28 (3H, s, CH₃).

Example of Method C3 Example 12ter6-(2,4-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-amine NH₂

Example 12ter-a 2-chloro-6-(2,4-difluorophenylthio)nicotinonitrile

A solution of 362 mg (1.05 eq) of potassium hydroxide in 10 mL ofethanol is added, under nitrogen, to a solution of 698 μL (6.16 mmol) of2,4-difluorobenzenethiol in 30 mL of ethanol. The reaction medium isstirred at room temperature for 15 minutes and then cooled in ice beforeadding a solution of 1.015 g (0.95 eq) of 2,6-dichloronicotinonitrile in30 mL of ethanol. The reaction medium is stirred for 2 hours at 0-5° C.63 mL of a 0.1N HCl solution is added to stop the reaction. Water isadded and the product is extracted with ethyl acetate. The organic phaseis dried on anhydrous magnesium sulfate, filtered and evaporated. Theresidue is purified by silica gel chromatography (eluent:cyclohexane/ethyl acetate 94:6) to yield 1.09 g (66%) of2-chloro-6-(2,4-difluorophenylthio)-nicotinonitrile in the form of awhite solid.

LCMS (IE, m/z): (M+1) 282,98.

¹H NMR: δH ppm (400 MHz, DMSO): 8.24 (1H, d, CH), 7.77-7.85 (1H, m, CH),7.52-7.63 (1H, m, CH), 7.25-7.35 (2H, m, CH), 2.41 (3H, s, CH₃).

Example 12ter6-(2,4-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-amine

0.561 mL (11.57 mmol) of hydrazine monohydrate is added under nitrogento a stirring solution of 1.09 g (3.86 mmol) of2-chloro-6-(2,4-difluorophenylthio)nicotinonitrile in 15 mL of propanol.The reaction medium is heated at 80° C. for 4 hours. A precipitate isobtained when the reaction medium is returned to room temperature. Thisprecipitate is filtered and rinsed with ethanol. The solid is dissolvedin an ethyl acetate fraction and washed with a 1N HCl solution. Theorganic phase is dried on magnesium sulfate and dry evaporated to yield420 mg (39%) of6-(2,4-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-amine in the formof a yellow solid.

¹H NMR: δH ppm (400 MHz, DMSO): 12.10 (1H, s, NH), 8.11 (1H, d, CH),7.82-7.89 (1H, m, CH), 7.58-7.63 (1H, m, CH), 7.32-7.36 (1H, m, CH),6.86 (1H, d, CH), 4.59 (2H, s, NH₂).

The following compound is obtained by a similar method:

Mass Ex.** ArX Y₁ R_(j) Compound names Yield MH⁺ 12ter- 1

CH H 6-(2,4- difluorophenoxy)- 1H-pyrazolo[3,4- b]pyridin-3-amine ND263.06

Example 12quater6-(3,5-difluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-amine

17.35 mL of a 0.5M solution in THF of (3,5-difluorobenzyl)zinc chloride(8.58 mmol) is added under argon to a solution of 416 mg ofpalladium(II) chloride (510 mmol) and 883 mg of2,6-dichloronicotinonitrile (5.1 mmol) in 2 mL of anhydrous THF. Thereaction is refluxed for 7 hours, then cooled to room temperature. A 1Nsoda aqueous solution is added and the product is extracted with severalsuccessive ethyl acetate fractions. The organic phases are dried onmagnesium sulfate and dry evaporated before being purified by silica gelchromatography to yield 680 mg of a mixture of2-chloro-6-(3,5-difluorobenzyl)-nicotinonitrile and by-products which isused without further purification in the following step.

The previous mixture is dissolved in 10 mL of isopropanol under stirringand 750 μL of 35% hydrazine hydrate is added. The solution is heated at80° C. for 4 hours. The solvent is dry evaporated and the product ispurified by silica gel chromatography (dichloromethane/methanol 9:1) toyield 290 mg of 6-(3,5-difluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-amine(64%).

LCMS (IE, m/z): (M+1) 261.16.

¹H NMR: δH ppm (400 MHz, DMSO): 11.82 (1H, s, NH), 8.01 (1H, d, CH),6.99-7.04 (3H, m, CH), 6.91 (1H, d, CH), 5.49 (2H, s, NH₂), 4.12 (2H, s,CH₂).

Example of Method D1 Example 135-(3,5-difluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-amine

0.575 g (0.704 mmol) of (dppf)₂PdCl₂.CH₂Cl₂ and 28 ml (14.08 mmol) of3,5-difluorobenzyl zinc (II) chloride are added to 1.5 g (7.04 mmol) ofa solution of 5-bromo-1H-pyrazolo[3,4-b]pyridin-3-amine in 10 ml oftetrahydrofuran. The reaction medium is heated at 90° C. for 18 hours.After returning to room temperature, the reaction is hydrolyzed byslowly adding water at 0° C. After filtration of the precipitate formed,the solid is rinsed with tetrahydrofuran and the aqueous filtrate isextracted several times with ethyl acetate. The organic phases arecombined, dried on magnesium sulfate and concentrated. The residue ispurified by silica chromatography (95:4.5:0.5 and then 95:4:1dichloromethane/methanol/ammonium as eluent) to yield 1.7 g (93%) of5-(3,5-difluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-amine in the form ofa beige solid.

LCMS (EI, m/z): (M+1) 261.41.

¹H NMR: δH ppm (400 MHz, DMSO): 11.87 (1H, s, NH), 8.31 (1H, d,CH_(arom)), 7.92 (1H, d, CH_(arom)), 6.98-7.08 (3H, m, CH_(arom)), 5.47(2H, s, NH), 4.04 (2H, s, CH₂).

The following compounds are obtained by a similar method:

Ex.** ArX Y₄ W R_(j) Compound names Yield Mass MH⁺ 13-1

CH H H 5-(3,5-difluorobenzyl)-1H- pyrazolo[4,3-b]pyridin-3-amine 8% 4steps 261.1 13-2

N H H 5-(3,5-difluorobenzyl)-1H- pyrazolo[3,4-b]pyrazin-3-amine 21% 3steps 262.1 **¹H NMR: δH ppm (400 MHz, DMSO): 13-1: 11.61 (1H, sl, NH),7.65 (1H, d, CHarom, J = 11.6 Hz), 7.20 (1H, d, CHarom, J = 11.2 Hz),6.95-7.10 (3H, m, CHarom), 5.32 (2H, sl, NH₂), 4.18 (2H, s, CH₂). 13-2:12.31 (1H, sl, NH), 8.44 (1H, s, CHarom), 7.03-7.08 (3H, m, CHarom),5.61 (2H, sl, NH₂), 4.25 (2H, s, CH₂).

Examples of Method D2 Example 145-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyrazin-3-amine

0.7 g (2.68 mmol) of 5-iodo-1H-pyrazolo[3,4-b]pyridine-3-amine, 0.74 g(5.36 mmol) of anhydrous potassium carbonate and 0.10 g of copper iodide(0.536 mmol) are mixed in a 50 ml round-bottom flask. 15 ml ofpropan-2-ol, 0.01 g (0.2 mmol) of polyethylene glycol and 0.43 g (2.95mmol) of 3,5-difluorothiophenol are then added. The reaction mixture isheated at 80° C. for 2 hours. The solvent is evaporated and the solidformed is filtered, rinsed with water and then with pentane and dried inan oven at 50° C. to yield 0.75 g (100%) of5-(3,5-diflurophenylthio)-1H-pyrazolo[3,4-b]pyrazin-3-amine in the formof a brown solid.

LCMS (EI, m/z): (M+1) 280.03.

¹H NMR: δH ppm (400 MHz, DMSO): 12.65 (1H, bs, NH), 8.52 (1H, s,CH_(arom)), 7.18 (1H, t, CH_(arom)), 7.05-7.18 (2H, m, CH_(arom)), 5.89(2H, s, NH).

The following derivatives were obtained according to the same method:

Ex.** Ar R_(k) n Y₁,Y₃,Y₄ R₃ R_(j) Compound name Yield Mass MH⁺ 14-1

H 0 CH, CH, N H H 2-(3-amino-1H- pyrazolo[3,4-b]pyridin-5-ylthio)benzamide ND ND 14-2

0 CH, CH, N H H N-(5-(3,5- dimethylphenylthio)- 1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4- methylpiperazin-1-yl)- 2-(tetrahydro-2H- pyran-4-ylamino)benzamide ND ND 14-3

H 0 CH, CH, N H H 5-(3,5- difluorophenylthio)- 1H-pyrazolo[3,4-b]pyridin-3-amine 45% (M + 1) 279.28 14-4

H 0 CH, C—OMe, N H H 5-(2.5- dichlorophenylthio)-6- methoxy-1H-pyrazolo[3,4-b]pyridin- 3-amine 80% ND 14-5

H 0 CH, C—NH₂, N H H 5-(2.5- dichlorophenylthio)- 1H-pyrazolo[3,4-b]pyridine-3,6-diamine 35% ND 14-6

H 0 CH, CH, N H ^(t)Bu 1-tert-butyl-5-(3,5- difluorobenzylthio)-1H-pyrazolo[3,4- b]pyridin-3-amine ND (M + 1) 293.08 14-7

H 0 CH, CMe, N H H 5-(3,5- difluorophenylthio)-6- methyl-1H-pyrazolo[3,4-b]pyridin- 3-amine ND (M + 1) 293.06 14-8

H 0 CH, C—OMe, N H H N-(5-(3,5- difluorophenylthio)-6- methoxy-1H-pyrazolo[3,4-b]pyridin- 3-amine 28% (M + 1) 610.30 14-9

H 0 CH, CH, N H ^(t)Bu 1-tert-butyl-5-(3,5- difluorophenylthio)-1H-pyrazolo[3,4- b]pyridin-3-amine 79% (M + 1) 335.26 14-10

0 CH, CH, N H H N-(5-(2.5- dichlorophenylthio)- 1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4- methylpiperazin-1-yl)- 2-(tetrahydro-2H- pyran-4-ylamino)benzamide 31% (M + 1) 612.37 14-11

0 CH, C—NH₂, N H H N-(6-amino-5-(3,5- difluorophenylthio)-1H-pyrazolo[3,4- b]pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4- ylamino)benzamide 68% ND **¹H NMR, DMSO-d₆,Ex.: 14-3: 12.65 (1H, bs, NH), 8.52 (1H, s, CH_(arom)), 7.18 (1H, t,CH_(arom)), 7.05-7.18 (2H, m, CH_(arom)), 5.89 (2H, s, NH). 14-6: 8.21(2H, bs, CH_(arom)), 7.07 (1H, m, CH_(arom)), 6.90 (2H, m, CH_(arom)),6.27 (2H, bs, NH), 4.03 (2H, s, CH), 1.63 (9H, s, CH). 14-7: 12.16 (1H,bs, NH), 8.39 (1H, s, CH_(arom)), 7.00-7.08 (1H, m, CH), 6.64-6.72 (2H,m, CH_(arom)), 5.73 (2H, bs, NH₂), 2.54 (3H, s, CH₃). 14-9: 8.51 (1H,bs, CH_(arom)), 8.35 (1H, bs, CH_(arom)), 7.02 (1H, m, CH_(arom)), 6.72(2H, bs, CH_(arom)), 6.52 (2H, bs, NH), 1.67 (9H, s, CH). (ND: notdetermined).

Example 14bisN-(5-(3,5-difluorophenylamino)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide

A solution of 225 mg ofN-(5-iodo-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide(0.25 mmol), 36 mg of difluoroaniline (0.275 mmol), 19 mg ofR-(+)-2,2′-bis(diphenylphosphino)-1,1′-binaphtyle (0.030 mmol), 11 mg(0.013 mmol) of tris(dibenzylideneacetone)dipalladium(0) and 75 mg (0.75mmol) of sodium tert-butoxide in 10 mL of THF is refluxed under argonovernight. The crude reaction medium is cooled, extracted with ethylacetate and washed with water. The organic phase is dried on magnesiumsulfate and purified by silica gel chromatography to yieldN-(5-(3,5-difluorophenylamino)-1-trityl-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamidewhich is used in the following step without further purification.

The product thus obtained is dissolved in 10 mL of dichloromethane at 0°C. and 56 mg (0.5 mmol) of TFA is added. The reaction medium is stirredfor 4 hours. Water is added and the pH of the reaction medium isadjusted to 7 with a NaHCO₃ solution. The aqueous phase is collected,basified (pH 9-10) with a concentrated K₂CO₃ solution and extracted withdichloromethane. The organic phase is collected, dried on magnesiumsulfate and dry concentrated to yield 40 mg ofN-(5-(3,5-difluorophenylamino)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide.

LCMS (IE, m/z): (M+1) 562.12.

¹H NMR: δH ppm (400 MHz, DMSO): 13.45 (1H, sl, NH), 10.47 (1H, sl, NH),8.65 (1H, s, CH_(arom)), 8.55 (1H, s, CH_(arom)), 8.14 (1H, d, NH), 7.77(1H, d, CH_(arom)), 7.26 (2H, m, CH_(arom)), 7.05 (1H, m, CH_(arom)),6.25 (1H, d, CH_(arom)), 6.14 (1H, s, NH), 6.77 (1H, s, NH), 3.82-3.84(2H, dt, CH), 3.72 (1H, m, CH), 3.47-3.52 (2H, m, CH), 3.28-3.34 (4H, m,CH), 2.43 (4H, m, CH), 2.23 (3H, s, CH₃), 1.94-1.97 (2H, m, CH),1.37-1.39 (2H, m, CH).

Examples of Method D3 Example 15N-(5-((3,5-difluorophenyl)ethynyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide

0.94 mg (0.926 mmol) of triethylamine is added to 400 mg (0.712 mmol) ofN-(5-iodo-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide,67.8 mg (0.356 mmol) of CuI, and 50 mg (0.071 mmol) of Pd(PPh₃)₂Cl₂under argon in 12 ml of anhydrous dioxane under stirring. The reactionis heated for 3.5 hours at 100° C. The reaction mixture is diluted with30 ml of water and extracted with ethyl acetate. The organic phase isdried on sodium sulfate, filtered and concentrated. The residue obtainedis purified by silica gel chromatography (dichloromethane/methanol) toyield 152 mg ofN-(5-((3,5-difluorophenyl)ethynyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamidein the form of a yellow solid (yield=37%).

LCMS (EI, m/z): (M+1) 572.17.

¹H NMR: δH ppm (400 MHz, DMSO): 13.57 (1H, bs, NH), 10.56 (1H, bs, NH),8.68 (1H, s, CH_(arom)), 8.43 (1H, s, CH_(arom)), 8.13 (1H, d, NH), 7.80(1H, d, CH_(arom)), 7.38 (2H, m, CH_(arom)), 6.27 (1H, d, CH_(arom)),6.15 (1H, d, CH_(arom)), 3.84-3.82 (2H, dt, CH), 3.70 (1H, m, CH),3.45-3.50 (2H, m, CH), 3.21-3.33 (4H, m, CH), 2.42-2.46 (4H, m, CH),2.28 (3H, s, CH₃), 1.94-1.97 (2H, m, CH), 1.37-1.39 (2H, m, CH).

The following derivative was obtained according to the same method:

Ex.** ArX Y₁, Y₃, Y₄ Compound names Yield Mass MH+ 15-1

N, CH, N 5-((3,5-difluorophenyl)ethynyl)-1H-pyrazolo[3,4-b]pyrazin-3-amine 6% 6 steps 272.1 **¹H NMR, dmso-d₆, Ex.:5-1: 12.71 (1H, sl, NH), 8.66 (1H, s, CHarom), 7.40-7.47 (3H, m,CHarom), 6.01 (2H, sl, NH₂).

Examples of Method E

The protocols comprising method E aim at functionalizing the exocyclicamine of the aminopyrazole rings by their reaction with an intermediatefeaturing an electrophilic function, optionally generated in situ, suchas acid chloride, isocyanate, isothiocyanate or aldehyde.

Preparation of the Reaction Intermediates Example 162-(N-(4,4-difluorocyclohexyl)-2,2,2-trifluoroacetamido)-4-(4-methylpiperazin-1-yl)benzoic acid

Example 16a tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate

This compound was previously described in WO 2008/74749.

5.28 ml (47.6 mmol) of 1-methylpiperazine is added to 4.1 g (17 mmol) oftert-butyl 4-fluoro-2-nitrobenzoate. The reaction mixture is stirredwithout solvent for 5 hours. 150 ml of water is added to the reactionmixture and it is stirred for 24 hours. The precipitate formed isfiltered, rinsed with water and dried under vacuum to yield 4.9 g (90%)of tert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate in the form ofa yellow solid.

LCMS (EI, m/z): (M+1) 322.37.

¹H NMR: δH ppm (400 MHz, DMSO): 7.69 (1H, d, CH_(arom)), 7.30 (1H, d,CH_(arom)), 7.20 (1H, dd, CH_(arom)), 3.38 (4H, m, CH), 2.40 (4H, m,CH), 2.22 (3H, s, CH₃), 1.45 (9H, s, CH₃).

Example 16b tert-butyl 2-amino-4-(4-methylpiperazin-1-yl)benzoate

This compound was previously described in WO 2008/74749.

0.160 g (1.500 mmol) of palladium on carbon (10%) and 15.19 ml (150mmol) of cyclohexene are added to a solution of 4.82 g (15 mmol) oftert-butyl 4-(4-methylpiperazin-1-yl)-2-nitrobenzoate in 100 ml ofethanol. The reaction mixture is heated at a temperature of 80° C. for 8hours. The reaction mixture is filtered and then rinsed with ethanol toyield 4.2 g (yield=96%) of tert-butyl2-amino-4-(4-methylpiperazin-1-yl)benzoate in the form of a yellowsolid.

LCMS (EI, m/z): (M+1) 292.39.

¹H NMR: δH ppm (400 MHz, DMSO): 7.44 (1H, d, CH_(arom)), 6.40 (2H, bs,NH₂), 6.19 (1H, dd, CH_(arom)), 6.12 (1H, d, CH_(arom)), 3.17 (4H, m,CH), 2.40 (4H, m, CH), 2.22 (3H, s, CH₃), 1.49 (9H, s, CH₃).

Example 16c tert-butyl2-(4,4-difluorocyclohexylamino)-4-(4-methylpiperazin-1-yl)benzoate

1.045 ml (13.57 mmol) of trifluoroacetic acid, 1 g (7.46 mmol) of4,4-difluorocyclohexanone and 2.158 g (8.20 mmol) of tetramethylammoniumtriacetoxyborohydride are added to 1.521 g (5.22 mmol) of tert-butyl2-amino-4-(4-methylpiperazin-1-yl)benzoate dissolved in 60 ml ofdichloromethane. The reaction is left under stirring at room temperaturefor 24 hours. The solvent is evaporated and then the crude reactionproduct is redissolved in 30 ml of ethyl acetate. The solution issuccessively washed with 0.5 M HCl solution, 0.5 M soda solution andfinally with saturated NaHCO₃ solution. The organic phase is dried onsodium sulfate, filtered and concentrated to obtain 2.2 g of tert-butyl2-(4,4-difluorocyclohexylamino)-4-(4-methylpiperazin-1-yl)benzoate inthe form of a light brown gum (yield=72%).

LCMS (EI, m/z): (M+1) 410.3.

¹H NMR: δH ppm (400 MHz, DMSO): 7.73 (1H, bs, NH), 7.58 (1H, m,CH_(arom)), 7.77 (1H, m, CH_(arom)), 6.09 (1H, bs, CH_(arom)), 3.37 (4H,m, CH), 3.27 (4H, m, CH), 2.47 (4H, m, CH), 2.25 (3H, s, CH), 1.99 (4H,s, CH), 1.40 (9H, s, CH).

Example 16d tert-butyl2-(N-(4,4-difluorocyclohexyl)-2,2,2-trifluoroacetamido)-4-(4-methylpiperazin-1-yl)benzoate

0.99 ml (6.98 mmol) of trifluoroacetic anhydride and 1.12 ml (8.06 mmol)of triethylamine are added to 2.2 g (5.3 mmol) of tert-butyl2-(4,4-difluorocyclohexylamino)-4-(4-methylpiperazin-1-yl)benzoatedissolved in 40 ml of dichloromethane. The reaction is left understirring at room temperature for 3 hours. The solvent is evaporated andthen the crude reaction product is taken up in 30 ml of ethyl acetate.The solution is washed with saturated NaHCO₃ solution. The organic phaseis dried on sodium sulfate, filtered and concentrated to obtain 2.5 g oftert-butyl2-(N-(4,4-difluorocyclohexyl)-2,2,2-trifluoroacetamido)-4-(4-methylpiperazin-1-yl)benzoatein the form of a light brown gum (yield=92%).

LCMS (EI, m/z): (M+1) 506.26.

¹H NMR: δH ppm (400 MHz, DMSO): 7.84 (1H, m, CH_(arom)), 7.09 (1H, m,CH_(arom)), 6.89 (1H, bs, CH_(arom)), 3.45-3.39 (8H, m, CH), 2.83 (4H,m, CH), 2.20 (4H, m, CH), 2.05 (3H, s, CH), 1.46 (9H, s, CH).

Example 162-(N-(4,4-difluorocyclohexyl)-2,2,2-trifluoroacetamido)-4-(4-methylpiperazin-1-yl)benzoic acid

7.62 ml (99 mmol) of trifluoroacetic acid is added to 2.5 g (4.95 mmol)of tert-butyl2-(N-(4,4-difluorocyclohexyl)-2,2,2-trifluoroacetamido)-4-(4-methylpiperazin-1-yl)benzoatedissolved in 30 ml of dichloromethane. The reaction is left understirring at room temperature overnight. The solvent is evaporated andthen the crude reaction product is redissolved in 30 ml of ethylacetate. The solvents are evaporated, the solid formed is redissolved inethyl ether and the solvent is evaporated again. This operation isrepeated three times until a light brown solid is obtained. 2.2 g of2-(N-(4,4-difluorocyclohexyl)-2,2,2-trifluoroacetamido)-4-(4-methylpiperazin-1-yl)benzoicacid in the form of a trifluoroacetic salt is obtained (yield=79%).

LCMS (EI, m/z): (M+1) 450.1.

¹H NMR: δH ppm (400 MHz, DMSO): 10.01 (1H, bs, OH), 7.92 (1H, m,CH_(arom)), 7.13 (1H, m, CH_(arom)), 7.01 (1H, bs, CH_(arom)), 4.39 (1H,m, CH), 3.12-3.52 (8H, m, CH), 2.86 (3H, s, CH), 1.75-2.0 (8H, m, CH).

The following compounds are also obtained by this method:

4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoic acid

This compound was previously described in WO 2008/74749, WO 2009/13126and WO 2010/69966.

LCMS (EI, m/z): (M+1) 416.40.

¹H NMR: δH ppm (400 MHz, DMSO): 12.60 (1H, bs, OH), 10.08 (1H, bs, OH),7.90 (1H, d, CH_(arom)), 7.13 (1H, dd, CH_(arom)), 6.90 (1H, d,CH_(arom)), 4.40 (1H, m, CH), 4.10 (2H, m, CH), 3.70-3.90 (2H, m, CH),3.59-3.62 (4H, m, CH), 3.30-3.32 (4H, m, CH), 2.87 (3H, s, CH₃),1.87-1.98 (1H, m, CH), 1.59-1.60 (1H, m, CH), 1.00-1.54 (2H, m, CH).

4-((3-(dimethylamino)propyl)(methyl)amino)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoicacid

This compound was previously described in WO 2009/13126 and WO2008/74749.

Example 17(S)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)-4-(3-(2,2,2-trifluoroacetamido)pyrrolidin-1-yl)benzoicacid

Example 17atert-butyl(S)-4-(3-(tert-butoxycarbonylamino)pyrrolidin-1-yl)-2-(tetrahydro-2H-pyran-4ylamino)benzoate

This compound was obtained by reproducing example 16d usingtert-butyl(S)-pyrrolidin-3-ylcarbamate.

Example 17b(S)-4-(3-aminopyrrolidin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoicacid

19.7 ml (25 eq) of trifluoroacetic acid is added to a solution of 4.72 g(10.23 mmol) oftert-butyl(S)-4-(3-(tert-butoxycarbonylamino)pyrrolidin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoatein 100 ml of dichloromethane. The reaction medium is stirred at roomtemperature for 30 hours. The solvents are evaporated and the residue isredissolved in diethyl ether and triturated until a solid is obtained.The solid formed is filtered and dried under vacuum to yield 4.3 g(100%) of a yellow powder of(S)-4-(3-aminopyrrolidin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoicacid in the form of a trifluoroacetic acid salt.

LCMS (EI, m/z): (M+1) 306.22.

Example 17(S)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)-4-(3-(2,2,2-trifluoroacetamido)pyrrolidin-1-yl)benzoicacid

1.74 ml (3.5 eq) of triethylamine and 1.6 ml (2.1 eq) of trifluoroaceticanhydride are added to a solution of 1.5 g (3.58 mmol) of(S)-4-(3-aminopyrrolidin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoicacid in the form of a trifluoroacetic acid salt in 40 ml ofdichloromethane at 0° C. The reaction medium is stirred at roomtemperature for 24 hours. Water (10 ml) is added drop by drop and thenthe organic phase is washed with saturated sodium chloride solution,dried on magnesium sulfate, filtered and evaporated. The residue ispurified by silica gel chromatography (96:4 dichloromethane/methanol aseluent) to yield 250 mg (14%) of(S)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)-4-(3-(2,2,2-trifluoroacetamido)pyrrolidin-1-yl)benzoicacid in the form of a yellow powder.

LCMS (EI, m/z): (M+1) 498.07.

Example 18 2-(2-fluoroethoxy)-4-(4-methylpiperazin-1-yl)benzoic acid

This compound can be prepared from the following intermediates.

Example 18a tert-butyl 4-fluoro-2-(2-fluoroethoxy)benzoate Example 18btert-butyl 2-(2-fluoroethoxy)-4-(4-methylpiperazin-1-yl)benzoate

The following compound was also obtained by this method:

2-(2-fluoroethoxy)-4-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)benzoicacid Example 194-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(2-fluoroethyl)-acetamido)-benzoicacid

This compound can be prepared from the following intermediates.

Example 19a tert-butyl 4-fluoro-2-(2-fluoroethylamino)benzoate Example19b tert-butyl4-fluoro-2-(2,2,2-trifluoro-N-(2-fluoroethyl)acetamido)benzoate Example19c tert-butyl4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(2-fluoroethyl)-acetamido)-benzoate

The following compound was also obtained by this method:

4-((3-(dimethylamino)propyl)(methyl)amino)-2-(2,2,2-trifluoro-N-(2-fluoroethyl)acetamido)benzoic acid Example 204-(1-methylpiperidin-4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoicacid hydrotrifloroacetate

This compound can be prepared from the following intermediates.

Example 20a tert-butyl 2-nitro-4-(pyridin-4-yl)benzoate

1.67 g of bis(triphenylphosphine)palladium(II)chloride (2.38 mmol) and15.8 g of sodium carbonate (149 mmol) are added to a solution of 18 g oftert-butyl 4-bromo-2-nitrobenzoate (59.6 mmol) and 10.98 g ofpyridine-4-ylboronic acid (89 mmol) in a mixture of 200 ml ofdimethoxyethane and 100 mL of water. The reaction medium is heated at100° C. for 24 hours and then concentrated under reduced pressure. Theresidue obtained is purified by flash chromatography (CH₂Cl₂/AcOEt:100:0 to 70:30, 30 min). The product is isolated in the form of an oilwhich crystallizes to yield 14.64 g (82%) of crystals.

MS (m/z): (M+1) 301.0.

¹H NMR: δH ppm (400 MHz, DMSO): 8.73 (2H, d, CHarom, J=6.0 Hz), 8.44(1H, s, CHarom), 8.24 (1H, dd, CHarom, J=8.0 Hz), 7.97 (1H, d, CHarom,J=8.0 Hz), 7.85 (2H, dd, CHarom, J=4.4 Hz), 1.54 (9H, s).

Example 20b 4-(4-(tert-butoxycarbonyl)-3-nitrophenyl)-1-methylpyridiniumiodide

7.55 mL of iodomethane (121 mmol) is added to a solution of 16.2 g oftert-butyl 2-nitro-4-(pyridin-4-yl)benzoate (60.6 mmol) in 20 mL ofacetone. The reaction medium is heated at 60° C. for 4 hours and then atroom temperature overnight. After dry concentration, 27 g of orangecrystals are isolated (100%).

MS (m/z): (M+1) 315.0.

¹H NMR: δH ppm (400 MHz, DMSO): 9.14 (2H, d, CHarom, J=6.4 Hz), 8.71(1H, s, CHarom), 8.63 (2H, d, CHarom, J=6.4 Hz), 8.47 (1H, dd, CHarom,J=8.0 Hz), 8.08 (1H, d, CHarom, J=8.0 Hz), 4.37 (3H, s, CH), 1.54 (9H,s).

Example 20c tert-butyl 2-amino-4-(1-methylpiperidin-4-yl)benzoate

0.48 g of platine (IV) oxide (2.12 mmol) is added to a solution of 26.8g of 4-(4-(tert-butoxycarbonyl)-3-nitrophenyl)-1-methylpyridinium iodide(60.6 mmol) in 200 mL of methanol placed in a reactor made in stainlesssteel. The reaction medium is brought under 5 bar of hydrogen for 24 h.The catalyst is filtered and the filtrate is concentrated under reducedpressure to yield 24.8 g (98%) of white crystals.

MS (m/z): (M+1) 291.1.

¹H NMR: δH ppm (400 MHz, DMSO): 9.18 (1H, s, HI), 7.60 (1H, d, CHarom,J=8.4 Hz), 6.54-6.40 (3H, m, CHarom), 6.39 (1H, d, CHarom, J=8.0 Hz),3.48-3.53 (2H, m, CH), 3.06 (2H, t, CH), 2.81 (3H, s, CH), 2.60-2.70(1H, m, CH), 1.89-1.97 (2H, m, CH), 1.70-1.80 (2H, m, CH), 1.52 (9H, s).

Example 20d tert-butyl4-(1-methylpiperidin-4-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoate

7.18 mL of 2,2,2-trifluoroacetic acid (93 mmol), 4.11 mg ofdihydro-2H-pyran-4(3H)-one (44.5 mmol) and then 14.5 g oftetramethylammonium triacetoxyborohydride (53.8 mmol) are successivelyadded to a solution of 15 g of tert-butyl2-amino-4-(1-methylpiperidin-4-yl)benzoate in 200 mL of dichloromethaneunder stirring. The reaction medium is stirred at room temperature for 2h and then taken up with a 1N soda solution. The organic phase isisolated, dried on magnesium sulfate and then dried concentrated. Theresidue contained always HI. It is thus taken up in dichloromethane andwashed with 100 mL of a 1H soda solution. The organic phase is decanted,dried on magnesium sulfate and dry concentrated to yield 14.6 g of ayellow solid (quantitative yield).

MS (m/z): (M+1) 375.2.

¹H NMR: δH ppm (400 MHz, DMSO): 7.69 (1H, d, CHarom, J=8.4 Hz), 7.63(1H, d, CHarom, J=7.6 Hz), 6.65 (1H, s, CHarom), 6.44 (1H, dd, CHarom,J=8.4 Hz), 3.74-3.86 (2H, m, CH), 3.66-3.71 (1H, m, CH), 3.51 (2H, t,CH), 3.05-3.12 (2H, m, CH), 2.6-2.5 (1H, m, CH), 2.42 (3H, s, CH),2.30-2.40 (2H, m, CH), 1.89-1.97 (2H, m, CH), 1.64-1.77 (4H, m, CH),1.52 (9H, s), 1.33-1.45 (2H, m, CH).

Example 20e tert-butyl4-(1-methylpiperidin-4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoate

6.35 mL of triethylamine and 5.50 mL of 2,2,2-trifluoroacetic anhydride(39.6 mmol) are added at 0° C. to a solution of 11.4 g of tert-butyl4-(1-methylpiperidin-4-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoate(30.4 mmol) in 240 mL of dichloromethane under stirring. The reactionmedium is stirred at room temperature for 1 h and then 100 mL of wateris added dropwise. The organic phase is decanted, dried on magnesiumsulfate and dry concentrated. The residue is taken up in a mixture ofethanol/diethyl ether to yield a solid which is filtered on a fritteddisc and 12.06 g of white crystals is isolated. The filtrate isconcentrated (4.5 g) and then purified by flash chromatography on silica(CH₂Cl₂/meOH: 95:5 to 90:10, 20 min). The product obtained isrecrystallized in diethyl ether to yield 1.04 g of additional whitecrystals (global yield=74%).

MS (m/z): (M+1) 471.1.

¹H NMR: δH ppm (400 MHz, DMSO): 9.45 (1H, sl, NH⁺), 7.96 (1H, d, CHarom,J=8 Hz), 7.51 (1H, d, CHarom, J=8 Hz), 7.31 (1H, s, CHarom), 4.6-4.5(1H, m, CH), 3.90-3.75 (2H, m, CH), 3.5-3.35 (4H, m, CH), 3.1-2.85 (3H,m, CH), 2.79 (3H, s, CH₃), 2.1-1.95 (3H, 3, CH), 1.9-1.75 (2H, m, CH),1.55-1.40 (11H, m), 1.0-0.85 (1H, m, CH).

Example 204-(1-methylpiperidin-4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoicacid hydrotrifluoroacetate

6.33 mL of 2,2,2-trifluoroacetic acid (82 mmol) is added under stirringto a solution of 3.2 g of tert-butyl4-(1-methylpiperidin-4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoate(5.47 mmol) (in the form of a salt of trifluoroacetic acid) in 30 mL ofdichloromethane. The reaction medium is stirred at room temperature for16 h, and then evaporated under reduced pressure. The residue is takenup in ethanol, and the white solid formed is filtered on a fritted discto yield 1.61 g (53%) of white crystals.

MS (m/z): (M+1) 415.1.

¹H NMR: δH ppm (400 MHz, DMSO): 13.39 (1H, sl, COOH), 9.46 (1H, sl, COOHdu TFA), 7.99 (1H, d, CHarom, J=8.4 Hz), 7.49 (1H, d, CHarom, J=8.4 Hz),7.30 (1H, s, CHarom), 4.53 (1H, m, CH), 3.74-3.86 (2H, m, CH), 3.35-3.45(5H, m, CH), 2.90-3.01 (3H, m, CH), 2.76 (3H, s, CH), 1.65-2.04 (5H, m,CH), 1.44-1.54 (2H, m, CH).

Example 21 1-(4-isothiocyanatophenyl)-4-methylpiperazine

This compound was prepared by adapting the method described in EP1215208.

The following compound was also obtained by this method:

tert-butyl 2-isothiocyanato-5-(4-methylpiperazin-1-yl)phenylcarbamateExample 22 tert-butyl2-isocyanato-5-(4-methylpiperazin-1-yl)phenylcarbamate

This compound can be prepared from the following intermediates.

Example 22a tert-butyl 5-(4-methylpiperazin-1-yl)-2-nitrophenylcarbamateExample 22b tert-butyl 2-amino-5-(4-methylpiperazin-1-yl)phenylcarbamateExample 22 tert-butyl2-isocyanato-5-(4-methylpiperazin-1-yl)phenylcarbamate Example 234-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzaldehyde

Example 23a(4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)phenyl)methanol

500 mg (1.060 mmol) of4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoicacid dissolved in 5 ml of tetrahydrofuran is added at 0° C. to asuspension of 201 mg (5.30 mmol) of LiAlH₄ in 9 ml of tetrahydrofuran.The reaction mixture is stirred at 0° C. for 1 hour and then at roomtemperature for 3 hours. The reaction mixture is cooled at 0° C. andthen, drop by drop, 200 μl water, then 200 μl of soda solution (15% byweight) and finally 1 ml of water are added. The reaction mixture isstirred at room temperature for 2 hours and then filtered and rinsedwith tetrahydrofuran. The filtrate is concentrated to yield 250 mg(yield=77%) of(4-(4-methylpiperazine-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)phenyl)methanolin the form of a white solid.

LCMS (EI, m/z): (M+1) 306.14.

¹H NMR: δ_(H ppm) (400 MHz, DMSO): 6.85 (1H, d, CH_(arom)), 6.20 (1H, d,CH_(arom)), 6.10 (1H, d, CH_(arom)), 4.95 (1H, bs, OH), 4.87 (1H, d,NH), 4.37 (2H, d, CH₂), 3.83-3.86 (2H, m, CH), 3.56 (1H, m, CH),3.46-3.56 (3H, m, CH), 3.45 (1H, m, CH), 3.05-3.07 (4H, m, CH),2.41-2.44 (4H, m, CH), 2.21 (3H, s, CH₃), 1.89-1.92 (2H, m, CH).

Example 234-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzaldehyde

85 mg (0.982 mmol) of manganese dioxide is added at room temperature toa solution of(4-(4-methylpiperazine-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)phenyl)methano1 (100 mg, 0.327 mmol) in a mixture of ethyl acetate (10 ml) anddichloromethane (9 ml). The reaction mixture is placed in an ultrasonicbath for 5 hours. The reaction mixture is filtered, the solvents areevaporated and the crude product is purified by chromatography to yield50.0 mg (yield=50.3%) of(4-(4-methylpiperazine-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzaldehydein the form of a white solid.

LCMS (EI, m/z): (M+1) 304.19.

¹H NMR: δ_(H ppm) (400 MHz, DMSO): 9.43 (1H, d, CH), 7.32 (1H, d,CH_(arom)), 6.36 (1H, d, CH_(arom)), 6.08 (1H, d, CH_(arom)), 3.94-3.99(2H, m, CH), 3.77 (1H, m, CH), 3.61-3.63 (2H, m, CH), 3.42-3.45 (4H, m,CH), 2.57-2.60 (4H, m, CH), 2.36 (3H, s, CH₃), 2.04-2.08 (2H, m, CH),1.51-1.60 (2H, m, CH).

Example 24 2-(4-(4-methylpiperazin-1-yl)phenyl)acetic acid

Example 24a 2,2,2-trichloro-1-(4-(4-methylpiperazin-1-yl)phenyl)ethanol

1.0 ml (10.00 mmol) of trichloroacetic acid and, in small portions,1.854 g (10 mmol) of sodium 2,2,2-trichloroacetate are added at roomtemperature to a solution of 1.362 g (6.67 mmol) of4-(4-methylpiperazine-1-yl)benzaldehyde in 13.5 ml of dimethylformamide.The reaction mixture is stirred for 3 hours at room temperature. Thesolvent is concentrated and the crude reaction product extracted withethyl acetate. The organic phase is washed using saturated sodiumbicarbonate solution. The organic phases are combined, dried onmagnesium sulfate and then concentrated to yield 1.760 g (yield=82%) of2,2,2-trichloro-1-(4-(4-methylpiperazine-1-yl)phenyl)ethanol in the formof a white solid.

LCMS (EI, m/z): (M+1) 324.04.

¹H NMR: δ_(H ppm) (400 MHz, DMSO): 7.41 (2H, d, CH_(arom)), 7.02 (1H,bs, OH), 6.90 (2H, d, CH_(arom)), 5.08 (1H, bs, CH), 3.14-3.16 (4H, m,CH), 2.42-2.47 (4H, m, CH), 2.21 (3H, s, CH₃).

Example 24 2-(4-(4-methylpiperazin-1-yl)phenyl)acetic acid

0.559 g (14.77 mmol) of sodium borohydride is added quickly to 2.294 g(7.35 mmol) of dibenzyl diselenide in 28 ml of ethanol. The reactionmixture is stirred at room temperature for 1 hour. 2.266 g (7 mmol) of2,2,2-trichloro-1-(4-(4-methylpiperazine-1-yl)phenyl)ethanol and 1.680 g(42.0 mmol) of sodium hydroxide are then added. The reaction mixture isstirred at 35° C. for 24 hours. The solvent is concentrated and thecrude product extracted with ethyl acetate after adding a pH 5 aqueousphase. The organic phases are combined, dried on magnesium sulfate andthen concentrated to yield 2-(4-(4-methylpiperazine-1-yl)phenyl)aceticacid which is used without additional purification.

LCMS (EI, m/z): (M+1) 235.294.

Example 25 2-(4-(4-methylpiperazin-1-yl)-2-nitrophenyl) acetic acid

This compound can be prepared from the following intermediates.

Example 25a diethyl 2-(4-fluoro-2-nitrophenyl)malonate Example 25bdiethyl 2-(4-(4-methylpiperazin-1-yl)-2-nitrophenyl)malonate Example ofMethod E1 Example 26N-(5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide

0.95 ml (11.21 mmol) of oxalyl chloride and 2 drops of anhydrousdimethylformamide are added to 2.97 g (5.61 mmol) of a solution of4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoicacid in 95 ml of dichloromethane. The reaction mixture is stirred for 2hours at room temperature. The solvents are evaporated, the solid formedis taken up in toluene and the solvent evaporated. This operation isrepeated three times until a white solid is obtained. The acid chlorideis dissolved in 35 ml of anhydrous tetrahydrofuran at −20° C. and thenthe solution formed is added to a solution containing 1.56 g (5.61 mmol)of 5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-amine and 3.71ml (21.30 mmol) of N-ethyl-N-isopropylpropan-2-amine in 30 ml ofanhydrous tetrahydrofuran. The reaction mixture is stirred for 3 hoursat −20° C. and then overnight at room temperature. The precipitateobtained is filtered and rinsed with tetrahydrofuran and water and thendried to yield 2 g (53%) ofN-(5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide.

LCMS (EI, m/z): (M+1) 676.20.

¹H NMR: δH ppm (400 MHz, DMSO): 13.66 (1H, bs, NH), 11.08 (1H, bs, NH),8.61 (1H, s, CH_(arom)), 8.46 (1H, s, CH_(arom)), 7.83 (1H, d,CH_(arom)), 7.05-7.10 (2H, m, CH_(arom)), 6.83-6.89 (3H, m, CH_(arom)),4.39-4.44 (1H, m, CH), 3.83-3.85 (1H, m, CH), 3.69-3.72 (1H, m, CH),3.59-3.62 (1H, m, CH), 3.30-3.32 (4H, m, CH₂), 2.30-2.44 (4H, m, CH₂),2.27 (3H, s, CH₃), 1.87-1.90 (1H, m, CH), 1.59-1.60 (1H, m, CH),1.49-1.50 (1H, m, CH), 1.20-1.40 (1H, m, CH).

The following derivatives were obtained according to the same method:

Y₁, Mass Ex.** Y R₁ R₂ n W R_(j) Y₄ Compound names Yield MH⁺ 26-1

0 H H CH, N N-(5- (2-carbamoylphenylthio)-1H- pyrazolo[3,4-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2- trifluoro-N-(tetrahydro-2H-pyran-4- yl)acetamido)benzamide ND ND 26-2

0 H H CH, N N-(5-(3,5- difluorophenylsulfonyl)- 1H-pyrazolo[3,4-b]pyridin-3-yl)-4- (4-methylpiperazin-1-yl)-2- (tetrahydro-2H-pyran-4-ylamino)benzamide ND ND 26-3 I

0 H H CH, N N-(5-iodo-1H- pyrazolo[3,4- b]pyridin-3-yl)-4-(4-methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N- (tetrahydro-2H-pyran-4-yl)acetamido)benzamide ND ND 26-4

H NO₂ 1 H H CH, N N-(5-(3,5- difluorophenylthio)-1H- pyrazolo[3,4-b]pyridin-3-yl)-2-(4- nitrophenyl)acetamide ND  442.21 26-5

0 H H CH, N N-(5-(3,5- difluorobenzylsulfonyl)- 1H-pyrazolo[3,4-b]pyridin-3-yl)-4- (4-methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-6

0 H H CH, N 2-(N-(4,4- difluorocyclohexyl)-2,2,2- trifluoroacetamido)-N-(5-(3,5- difluorophenylsulfonyl)-1H- pyrazolo[3,4-b]pyridin-3-yl)-4-(4- methylpiperazin-1- yl)benzamide ND ND 26-7

0 H H CH, N N-(5-(3,5- difluorobenzyl)-1H- pyrazolo[3,4-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2- trifluoro-N-(tetrahydro-2H-pyran-4- yl)acetamido)benzamide 22% 676.2 26-8

H

1 H H CH, N N-(5-(3,5- difluorophenylthio)-1H- pyrazolo[3,4-b]pyridin-3-yl)-2-(4-(4- methylpiperazin-1- yl)phenyl)acetamide ND  495.726-9 I

0 OMe H CH, N N-(5-iodo- 6-methoxy-1H- pyrazolo[3,4-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND  688.1826-10 I

0 NH₂ H CH, N N-(6-amino-5-iodo- 1H-pyrazolo[3,4- b]pyridin-3-yl)-4-(4-methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N- (tetrahydro-2H-pyran-4-yl)acetamido)benzamide ND  673.06 26-11

1 H H CH, N (S)-N-(5-(3,5- difluorophenylthio)- 1H-pyrazolo[3,4-b]pyridin-3-yl)-2- (2,2,2-trifluoro-N- (tetrahydro-2H-pyran-4-yl)acetamido)- 4-(3-(2,2,2- trifluoroacetamido) pyrrolidin-1-yl)benzamide ND ND 26-12

H

0 H H CH, N N-(5-(3,5- difluorophenylthio)-1H- pyrazolo[3,4-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)benzamide 46%  481.38 26-13

0 H H N, CH N-(5-(3,5- difluorobenzyl)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 35% 658.126-14

0 H H N, CH N-(5-(3,5- difluorobenzyloxy)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 63% 674.126-15

0 H H N, CH N-(5-(3,5- difluorobenzyloxy)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND 673.126-16

0 H H N, CH N-(5-(2,5- difluorobenzyloxy)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 62% 674.226-17

0 H H N, CH N-(5-(2,5- difluorobenzyloxy)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin-4- yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND 673.326-18

0 H H N, CH N-(5-(2,5- dichlorobenzyloxy)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-19

0 H H N, CH N-(5-(2,5- dichlorobenzyloxy)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-20

0 H H N, CH N-(5-(5-chloro-2- (trifluoromethyl) benzyloxy)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 55% 740.226-21

0 H H N, CH N-(5-(5-chloro-2- (trifluoromethyl) benzyloxy)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND 739.326-22

0 H H N, CH 4-(4-methylpiperazin- 1-yl)-N-(5- (pyridin-3- ylmethoxy)-1H-pyrazolo[4,3-b] pyridin-3-yl)-2- (2,2,2-trifluoro-N- (tetrahydro-2H-pyran-4-yl)acetamido) benzamide 90% 639.2 26-23

0 H H N, CH 4-(1-methylpiperidin- 4-yl)-N-(5- (pyridin-3- ylmethoxy)-1H-pyrazolo[4,3-b] pyridin-3-yl)-2- (2,2,2-trifluoro-N- (tetrahydro-2H-pyran-4-yl)acetamido) benzamide ND 638.2 26-24

0 H H N, CH N-(5-(3,5- difluorophenylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-25

0 H H N, CH N-(5-(3,5- difluorophenylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 50% ND 26-26

0 H H N, CH N-(5-(2,5- difluorophenylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-27

0 H H N, CH N-(5-(2,5- difluorophenylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-28

0 H H N, CH N-(5-(3,5- dichlorophenylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-29

0 H H N, CH N-(5-(3,5- dichlorophenylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-30

0 H H N, CH N-(5-(2,5- dichlorophenylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-31

0 H H N, CH N-(5-(2,5- dichlorophenylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-32

0 H H N, CH 4-(4-methylpiperazin- 1-yl)-2-(2,2,2- trifluoro-N-(tetrahydro-2H-pyran-4- yl)acetamido)- N-(5-(2- (trifluoromethyl)phenylthio)-1H- pyrazolo[4,3-b]pyridin-3- yl)benzamide ND ND 26-33

0 H H N, CH 4-(1-methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)-N-(5-(2-(trifluoromethyl) phenylthio)-1H- pyrazolo[4,3-b]pyridin-3- yl)benzamideND ND 26-34

0 H H N, CH N-(5-(3,5- difluorobenzylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-35

0 H H N, CH N-(5-(3,5- difluorobenzylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 73% ND 26-36

0 H H N, CH N-(5-(2,5- difluorobenzylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-37

0 H H N, CH N-(5-(2,5- difluorobenzylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-38

0 H H N, CH N-(5-(2,5- dichlorobenzylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-39

0 H H N, CH N-(5-(2,5- dichlorobenzylthio)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-40

0 H H N, CH N-(5-(3,5- difluorophenylamino)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 79% 659.226-41

0 H H N, CH N-(5-(3,5- difluorophenylamino)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin-4- yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND 658.226-42

0 H H N, CH N-(5-(2,5- difluorophenylamino)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND 659.226-43

0 H H N, CH N-(5-(3,5- difluorophenylamino)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND 658.226-44

0 H H N, CH N-(5-(2,5- dichlorophenylamino)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 26% 691.226-45

0 H H N, CH N-(5-(2,5- dichlorophenylamino)-1H- pyrazolo[4,3-b]pyridin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 98% 692.226-46

0 H H N, N N-(5-(3,5- difluorobenzyl)-1H- pyrazolo[3,4-b]pyrazin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-47

0 H H N, N N-(5-(3,5- difluorobenzyl)-1H- pyrazolo[3,4-b]pyrazin-3-yl)-4-(1- methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-48

0 H H N, N N-(5-((3,5- difluorophenyl)ethynyl)- 1H-pyrazolo[3,4-b]pyrazin-3-yl)-4- ((3- (dimethylamino) propyl)(methyl)amino)-2-(2,2,2-trifluoro-N- (tetrahydro- 2H-pyran-4-yl) acetamido)benzamide NDND 26-49

0 H H N, N N-(5-((3,5- difluorophenyl)ethynyl)- 1H-pyrazolo[3,4-b]pyrazin-3-yl)-4- (1-methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-50

0 H H N, N N-(5-(3,5- difiuorophenylthio)-1H- pyrazolo[3,4-b]pyrazin-3-yl)-4-((3- (dimethylamino) propyl)(methyl)amino)-2-(2,2,2-trifluoro- N-(tetrahydro- 2H-pyran-4-yl) acetamido)benzamide43% 693.2 26-51

0 H H N, N N-(5-(2,5- dichlorophenylthio)-1H- pyrazolo[3,4-b]pyrazin-3-yl)-4-(4- methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-52

0 H H N, CH 4-(4-methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)-N-(5-(2-(trifluoromethyl) phenylthio)-1H- pyrazolo[3,4-b]pyrazin-3- yl)benzamide66% 709.1 26-53

0 H H N, CH N-(5-(3,5- difluorophenylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (4-methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 28% 708.226-54

0 H H N, CH N-(5-(3,5- difluorophenylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (1-methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 74% 707.226-55

0 H H N, CH N-(5-(2,5- difluorophenylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (4-methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-56

0 H H N, CH N-(5-(2,5- difluorophenylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (1-methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-57

0 H H N, CH N-(5-(3,5- dichlorophenylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (4-methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-58

0 H H N, CH N-(5-(3,5- dichlorophenylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (1-methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-59

0 H H N, CH N-(5-(2,5- dichlorophenylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (4-methylpiperazin- 1-yl)-2-(2,2,2-trifiuoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-60

0 H H N, CH N-(5-(2,5- dichlorophenylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (1-methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-61

0 H H N, CH N-(5-(3,5- difluorobenzylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (4-methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 94% ND 26-62

0 H H N, CH N-(5-(3,5- difluorobenzylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (1-methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 99% ND 26-63

0 H H N, CH N-(5-(2,5- difluorobenzylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (4-methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 60% ND 26-64

0 H H N, CH N-(5-(2,5- difluorobenzylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (1-methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 36% ND 26-65

0 H H N, CH N-(5-(2,5- difluorobenzylsulfinyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (1-methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide ND ND 26-66

0 H H N, CH N-(5-(2,5- dichlorobenzylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (4-methylpiperazin- 1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 52% ND 26-67

0 H H N, CH N-(5-(2,5- dichlorobenzylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (1-methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 90% ND 26-68

0 H H N, CH N-(5-(2,5- dichlorobenzylsulfinyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4- (1-methylpiperidin- 4-yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acetamido)benzamide 50% ND 26-69I

0 H C(Ph)₃ CH, N N-(5-iodo-1-trityl- 1H-pyrazolo[3,4- b]pyridin-3-yl)-4-(4-methylpiperazin- 1-yl)-2-(tetrahydro- 2H-pyran-4- ylamino)benzamide67%  900.23 26-70

0 H H CH, N N-(5-(3,5- difluorophenylsulfonamido)- 1H-pyrazolo[3,4-b]pyridin- 3-yl)-4-(4- methylpiperazin-1- yl)-2-(2,2,2-trifluoro-N-(tetrahydro- 2H-pyran-4- yl)acelamido)benzamide 11% ND **¹HNMR, dmso-d₆, Ex.: 26-4: 13.64 (1H, sl, NH), 11.26 (1H, sl, NH), 8.68(1H, d, CH_(arom)) 8.58 (1H, d, CH_(arom)), 8.20 (2H, d, CH_(arom)),7.64 (2H, d, CH_(arom)), 7.03 (1H, m, CH_(arom)) 6.78 (2H, m,CH_(arom)), 3.95 (2H, m, CH₂). 26-8: 13.59 (1H, sl, NH), 11.05 (1H, sl,NH), 8.68 (1H, d, CH_(arom)), 8.57 (1H, d, CH_(arom)), 7.19 (2H, d,CH_(arom)), 6.99-7.08 (1H, m, CH_(arom)), 6.88 (2H, d, CH_(arom)),6.75-6.79 (2H, m, CH_(arom)), 3.61 (2H, m, CH₂), 3.07-3.09 (4H, m, CH),2.41-2.44 (4H, m, CH), 2.20 (3H, s, CH₃). 26-9: 13.17 (1H, sl, NH),10.90 (1H, sl, NH), 8.55 (1H, s, CHarom), 7.79 (1H, d, CHarom), 7.07(1H, dd, CHarom), 6.90 (1H, d, CHarom), 4.40-4.50 (1H, m, CH), 3.96 (3H,s, CH₃), 3.82-3.89 (1H, m, CH), 3.74-3.80 (1H, m, CH), 3.34-3.41 (2H, m,CH), 3.28-3.33 (4H, m, 2*CH₂), 2.43-2.47 (4H, m, 2*CH₂), 2.23 (3H, s,CH₃), 1.85-1.92 (1H, m, CH), 1.58-1.63 (1H, m, CH), 1.45-1.53 (1H, m,CH), 1.22-1.33 (1H, m, CH). 26-10: 12.48 (1H, sl, NH), 10.72 (1H, sl,NH), 8.30 (1H, s, CHarom), 7.77 (1H, d, CHarom), 7.06 (1H, dd, CHarom),6.88 (1H, d, CHarom), 6.40 (2H, sl, NH₂), 4.40-4.50 (1H, m, CH),3.82-3.89 (1H, m, CH), 3.74-3.80 (1H, m, CH), 3.34-3.41 (2H, m, CH),3.28-3.33 (4H, m, 2*CH₂), 2.43-2.47 (4H, m, 2*CH₂), 2.23 (3H, s, CH₃),1.85-1.92 (1H, m, CH), 1.58-1.65 (1H, m, CH), 1.45-1.55 (1H, m, CH),1.22-1.34 (1H, m, CH). (ND: not determined). 26-14: 12.99 (1H, sl, NH),10.25 (1H, s, NH), 7.96 (1H, d, CHarom, J = 9.2 Hz), 7.90-7.80 (1H, m,CHarom), 7.23-7.16 (3H, m, CHarom), 7.12-7.08 (1H, m, CHarom), 6.96 (1H,d, CHarom, J = 8.8 Hz), 6.87 (1H, s, CHarom), 5.31 (2H, s), 4.49-4.42(1H ,m), 3.86-3.75 (2H, m), 3.45 (1H, m), 3.37 (1H, m), 3.35 (4H, s),2.42 (4H, s), 2.22 (3H, s), 1.90-1.75 (2H, m), 1.53-1.49 (1H, m),1.31-1.25 (1H, m). 26-16: 13.00 (1H, s, NH), 10.27 (1H, s, NH), 7.95(1H, d, CHarom, J = 8.8 Hz), 7.89-7.84 (1H, m, CHarom), 7.50-7.40 (1H,m, CHarom), 7.35-7.20 (2H, m, CHarom), 7.12-7.09 (1H, m, CHarom), 6.94(1H, d, CHarom, J = 8.8 Hz), 6.87 (1H, s, CHarom), 5.30 (2H, s),4.52-4.43 (1H, m), 3.85-3.75 (2H, m), 3.46-3.43 (1H, m), 3.36 (5H, s),2.45 (4H, s), 2.22 (3H, s), 1.92-1.82 (2H, m), 1.60-1.52 (1H, m),1.33-1.26 (1H, m). 26-20: 13.01 (1H, s, NH), 10.22 (1H, s, NH), 7.97(1H, d, CHarom, J = 8.8 Hz), 7.90-7.78 (3H, m, CHarom), 7.68-7.64 (1H,m, CHarom), 7.12-7.08 (1H, m, CHarom), 6.97 (1H, d, CHarom, J = 8.8 Hz),6.85 (1H, s, CHarom), 5.43 (2H, s), 4.45-4.40 (1H, m), 3.86-3.70 (2H,m), 3.46-3.42 (1H, m), 3.30-3.28 (5H, m), 2.46 (4H, s), 2.23 (3H, s),1.90 (1H, d, J = 11.2 Hz), 1.77 (1H, d, J = 11.2 Hz), 1.58-1.50 (1H, m),1.30-1.20 (1H, m).

In certain cases, the major product of these reactions corresponds tothe disubstituted product characterized by the additionalfunctionalization of the pyrazole ring. In these cases, this product isisolated and transformed into a monosubstituted product by treatmentwith a base as described below.

Example 27N-(5-(3,5-difluorophenylthio)-1-H-pyrazolo[3,4-b]pyrazine-3-yl)-4-(4-methylpiperazine-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide

Example 27aN-(5-(3,5-difluorophenylthio)-1-(4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoyl)-1H-pyrazolo[3,4-b]pyrazine-3-yl)-4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide

1.51 ml (17.90 mmol) of oxalyl chloride and 2 drops of anhydrousdimethylformamide are added to 4.74 g (8.95 mmol) of a solution of4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoicacid in 60 ml of dichloromethane. The reaction mixture is stirred for 2hours at room temperature. The solvents are evaporated, the solid formedis taken up in toluene and the solvent is evaporated; this operation isrepeated three times until a white solid is obtained.

The acid chloride is added at 0° C. in small fractions to 1 g (3.58mmol) of 5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyrazine-3-aminedissolved in 15 ml of pyridine. The reaction mixture is stirred at 25°C. overnight at room temperature. After evaporation of the solvent, theresidue is purified by silica gel chromatography (90:10dichloromethane/methanol and then 90:9:1 and then 90:5:5dichloromethane/methanol/ammonium as eluent) to yieldN-(5-(3,5-difluorophenylthio)-1-(4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoyl)-1H-pyrazolo[3,4-b]pyrazine-3-yl)-4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide.

LCMS (EI, m/z): (M+1) 1074.64.

Example 27N-(5-(3,5-difluorophenylthio)-1-H-pyrazolo[3,4-b]pyrazine-3-yl)-4-(4-methylpiperazine-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide

0.27 ml (1.95 mmol) of triethylamine is added to 0.21 g (0.19 mmol) of asolution ofN-(5-(3,5-difluorophenylthio)-1-(4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoyl)-1H-pyrazolo[3,4-b]pyrazine-3-yl)-4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamidein 5 ml of methanol. The reaction medium is heated at 65° C. for 4hours, and then overnight at room temperature. After evaporation of thesolvent, the product is extracted several times with ethyl acetate. Theorganic phases are combined, washed with saturated sodium bicarbonatesolution, dried on magnesium sulfate and concentrated. The residue ispurified by silica gel chromatography (95:4:1dichloromethane/methanol/ammonium as eluent) to yield 0.065 g (57%) ofN-(5-(3,5-difluorophenylthio)-1-H-pyrazolo[3,4-b]pyrazine-3-yl)-4-(4-methylpiperazine-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamidein the form of a yellow solid.

LCMS (EI, m/z): (M−1) 579.21.

¹H NMR: δH ppm (400 MHz, DMSO): 13.95 (1H, bs, NH), 10.25 (1H, bs, NH),8.62 (1H, s, CH_(arom)), 8.27 (1H, d, NH), 7.80 (1H, d, CH_(arom)),7.17-7.27 (3H, m, CH_(arom)), 6.27 (1H, d, CH_(arom)), 6.12 (1H, d,CH_(arom)), 3.79-3.82 (2H, m, CH), 3.67 (1H, m, CH), 3.45-3.50 (2H, m,CH), 3.26-3.29 (4H, m, CH), 2.42-2.44 (4H, m, CH), 2.22 (3H, s, CH₃),1.90-1.93 (2H, m, CH), 1.31-1.36 (2H, m, CH).

The following compounds were obtained by the same method:

Ex.** Y R₁ R₂ Y₁ n W R_(j) Compound names Yield Mass 27-1

CH 0 H H N-(5-(3,5- difluorophenylsulfonyl)-1H pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1- yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide 18.6% (M + H)  612.13 27-2

N 0 H H N-(5-(3,5- difluorophenylsulfinyl)-1H- pyrazolo[3,4-b]pyrazin-3-yl)-4-(4-methylpiperazin-1- yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide ND (M + Na) 619.6 27-3

N 0 H H N-(5-(3,5- difluorophenylsulfonyl)-1H- pyrazolo[3,4-b]pyrazin-3-yl)-4-(4-methylpiperazin-1- yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide ND (M + H) 613.5 27-4 H

CH 0

H N-(6-(3,5-difluorobenzyl)- 1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin- 1-yl)-2-(telrahydro-2H-pyran-4-ylamino)benzamide   24% (M + H)  562.00 27-5 H

CH 0

H N-(6-(3,5- difluorobenzylamino)-1H- pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1 - yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide ND (M − H) 275.1Reactions carried out in pyridine often make it possible to modify theregioisomer distribution of the products. The following example ischaracteristic of a reaction of this type.

Example 27-bisN-(5-(N-(3,5-difluorophenyl)sulfamoyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide

0.224 ml (2.63 mmol) of oxalyl chloride and 2 drops of anhydrousdimethylformamide are added to 0.697 g (1.316 mmol) of a solution of4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzoicacid in 20 ml of dichloromethane. The reaction mixture is stirred for 2hours at room temperature. The solvents are evaporated, the solid formedis redissolved in toluene and the solvent is evaporated. This operationis repeated three times until a white solid is obtained.

The acid chloride is dissolved in 5 ml of anhydrous pyridine and thenthe solution formed is added to a solution of 0.214 g (0.658 mmol) of3-amino-N-(3,5-difluorophenyl)-1H-pyrazolo[3,4-b]pyridine-5-sulfonamidein 5 ml of pyridine at 0° C. The reaction mixture is stirred for 3 hoursat 0° C., and then overnight at room temperature. The pyridine isevaporated and the crude reaction product is redissolved in toluene andthen dry concentrated. The reaction mixture is diluted with saturatedNaHCO₃ solution and extracted with ethyl acetate. The organic phase isdried on MgSO₄, filtered and concentrated and the crude product is useddirectly in the deprotection reaction with no purification orcharacterization.

The following compounds were obtained by the same method:

Ex.** Y R₁ R₂ Y₁ n W R_(j) Compound names Yield Mass 27bis-1 H

CH 0

H N-(6-(2,4-difluorophenylthio)-1H- pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(2,2,2- trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide ND 676.18 (M + H) 27bis-2 H

CH 0

H N-(6-(2,4-difluorophenylamino)- 1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2- (2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide 28% 657.13 (M − H) 27bis-3 H

CH 0

H N-(6-((2,4- difluorophcnyl)(methyl)amino)-1H-pyrazolo[3,4-b]pyridin-3-yl)- 4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H- pyran-4-yl)acetamido)benzamide ND671.05 (M − H)

Example of Method E2 Example 285-(3,5-difluorophenylthio)-N-(4-(4-methylpiperazin-1-yl)benzyl)-1H-pyrazolo[3,4-b]pyridin-3-amine

41.5 μl of trifluoroacetic acid (0.539 mmol) and, in small fractions,129 mg (0.611 mmol) of sodium triacetoxyborohydride are added to asolution of 100 mg (0.35 mmol) of5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-amine and 81 mg(0.395 mmol) of 4-(4-methylpiperazin-1-yl)benzaldehyde in 20 ml of a 1:1mixture of dichloromethane and tetrahydrofuran. The reaction medium isstirred for 16 hours at room temperature. An additional fraction of 125μl of trifluoroacetic acid and 388 mg of sodium triacetoxyborohydrideare added and the reaction medium is stirred for an additional 24 hours.The solvent is then concentrated and the reaction medium extracted withethyl acetate and washed using saturated sodium bicarbonate solution.The organic phases are combined, dried on magnesium sulfate and thenconcentrated to yield a yellow oil. A trituration of this oil inmethanol leads to the isolation of 135 mg of a yellow solid.

LCMS (EI, m/z): (M+1) 467.57.

¹H NMR: δH ppm (400 MHz, DMSO): 12.43 (1H, bs, NH), 8.49 (1H, d,CH_(arom)), 8.47 (1H, d, CH_(arom)), 7.25 (2H, d, CH_(arom)), 7.03-7.08(1H, m, CH_(arom)), 6.89 (2H, d, CH_(arom)), 6.76-6.77 (3H, m, NH andCH_(arom)), 4.34 (2H, d, CH), 3.08 (4H, m, CH), 2.44 (4H, m, CH), 2.21(3H, s, CH₃).

The following derivative was obtained according to the same method:

Ex.** ArX R₁ R₂ n W R_(j) Compound name Yield Mass MH⁺ 28-1

NO₂

0 H H 5-(3,5-difluorophenylthio)-N-(4-(4- methylpiperazin-1-yl)-2-nitrobenzyl)-1H-pyrazolo[3,4- b]pyridin-3-amine 91% 512.16 **¹H NMR,DMSO-d₆, Ex.: 28-1: 12.43 (1H, bs, NH), 8.49 (1H, d, CH_(arom)), 8.47(1H, d, CH_(arom)) 7.51 (1H, d, CH_(arom)), 7.45 (1H, m, CH_(arom)),7.27 (1H, m, CH_(arom)), 7.03-7.08 (1H, m, CH_(arom)), 7.00 (1H, t, NH),6.77-6.80 (2H, m, CH_(arom)), 4.63 (2H, d, CH), 3.19-3.21 (4H, m, CH),2.42-2.45 (4H, m, CH), 2.21 (3H, s, CH₃).

Example of Method E3 Example 291-(5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)thiourea

0.507 g (2.17 mmol) of 1-(4-isothiocyanatophenyl)-4-methylpiperazine isadded at 25° C. to 0.540 g (2.17 mmol) of3,5-difluorophenylthio-1H-pyrazolo[3,4-b]pyridin-3-amine dissolved in 12ml of anhydrous dimethylacetamide. The mixture is left under stirringfor 15 hours at 85° C. The reaction is treated by adding 20 ml of waterand then is extracted with ethyl acetate. The organic phase is dried onsodium sulfate, filtered and concentrated. The product is purified bysilica chromatography (15:1 dichloromethane/methanol as eluent) to yield0.156 g (yield=15%) of1-(1-tert-butyl-5-(3,5-difluorophenylthio)-1H-pyrazlo[3,4-b]pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)thioureain the form of a light brown solid.

LCMS (EI, m/z): (M+1) 512.08.

¹H NMR: δH ppm (400 MHz, DMSO): 13.69 (1H, bs, NH), 11.50 (1H, bs, NH),11.19 (1H, bs, NH), 8.96 (1H, d, CH_(arom)), 8.66 (1H, d, CH_(arom)),7.41 (2H, d, CH_(arom)), 7.10 (1H, ddd, CH_(arom)), 6.95 (2H, d,CH_(arom)), 6.89 (2H, bd, CH_(arom)), 3.13-3.16 (4H, m, CH), 2.45-2.47(4H, m, CH), 2.23 (3H, s, CH).

Example 29-bis1-(5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)urea

0.048 g (1.19 mmol) of sodium hydride is added at 0° C. to 0.200 g(0.598 mmol) of1-tert-butyl-5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-aminedissolved in 10 ml of anhydrous dimethylacetamide. The reaction is leftunder stirring for 10 minutes. 0.130 g (0.598 mmol) of1-(4-isocyanatophenyl)-4-methylpiperazine is then added at 0° C. Themixture is left under stirring for 3 hours at room temperature. Thereaction is treated by adding 20 ml of water drop by drop at 0° C. andthen is extracted with ethyl acetate. The organic phase is dried onsodium sulfate, filtered and concentrated. The product is purified bysilica chromatography to yield 0.150 g (yield=45%) of1-(1-tert-butyl-5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)ureain the form of a light brown solid.

LCMS (EI, m/z): (M+1) 552.21.

¹H NMR: δH ppm (400 MHz, DMSO): 8.92 (1H, bs, NH), 8.58 (1H, bs, NH),8.51 (1H, bs, CH_(arom)), 8.30 (1H, bs, CH_(arom)), 7.31 (2H, d,CH_(arom)), 7.05 (1H, m, CH_(arom)), 6.83-6.85 (2H, m, CH_(arom)),3.03-3.08 (4H, m, CH), 2.45-2.48 (4H, m, CH), 2.21 (3H, s, CH), 1.76(9H, s, CH).

A solution of 0.150 g (0.272 mmol) of1-(1-tert-butyl-5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)ureadissolved in 20 ml of TFA (trifluoroacetic acid) is refluxed for 3hours. The solvent is evaporated and the crude reaction product isdiluted with saturated NaHCO₃ solution and extracted with ethyl acetate.The organic phase is dried on MgSO₄, filtered and concentrated. Thesolid obtained is triturated in methanol, filtered and dried. 110 mg(82%) of1-(5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)ureain the form of a beige solid is obtained.

LCMS (EI, m/z): (M+1): 496.06.

¹H NMR: δH ppm (400 MHz, DMSO): 10.85 (1H, bs, NH), 9.57 (1H, bs, NH),8.57 (1H, bs, CH_(arom)), 8.30 (1H, bs, CH_(arom)), 7.39 (2H, d,CH_(arom)), 6.99 (1H, m, CH_(arom)), 6.89 (2H, d, CH_(arom)), 6.70 (2H,bd, CH_(arom)), 3.03-3.08 (4H, m, CH), 2.45-2.48 (4H, m, CH), 2.21 (3H,s, CH).

Examples of Method F Examples of Method F1 Deprotection Example 30N-(5-(3,5-difluorophenylthio)-1-H-pyrazolo[3,4-b]pyridine-3-yl)-4-(4-methylpiperazine-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide

9.08 ml (65.1 mmol) of triethylamine is added to 2 g (2.96 mmol) of asolution ofN-(5-(3,5-difluorophenylthio)-1H-pyrazlo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamidein 65 ml of methanol. The reaction medium is heated at 65° C. for 2hours, and then overnight at room temperature. The precipitate formed isfiltered, rinsed with pentane, with water and then with diethyl ether,and then is dried under vacuum to yield 0.73 g (43%) of(N-(5-(3,5-difluorophenylthio)-1-H-pyrazolo[3,4-b]pyridine-3-yl)-4-(4-methylpiperazine-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamidein the form of a white solid.

LCMS (EI, m/z): (M+1) 580.23.

¹H NMR: δH ppm (400 MHz, DMSO): 13.59 (1H, bs, NH), 10.56 (1H, bs, NH),8.61 (1H, s, CH_(arom)), 8.50 (1H, s, CH_(arom)), 8.17 (1H, d, NH), 7.80(1H, d, CH_(arom)), 7.07 (1H, m, CH_(arom)), 6.86 (2H, m, CH_(arom)),6.23 (1H, d, CH_(arom)), 6.13 (1H, d, CH_(arom)), 3.79-3.82 (2H, dt,CH), 3.60 (1H, m, CH), 3.45-3.50 (2H, m, CH), 3.21-3.33 (4H, m, CH),2.42-2.46 (4H, m, CH), 2.22 (3H, s, CH₃), 1.91-1.94 (2H, m, CH),1.35-1.38 (2H, m, CH).

The following derivatives were obtained according to the same method:

Y₁, Y₂, Y₃, Ex.** ArX R₁ R₂ (U)_(n) V Y₄ R₃ Compound name Yield Mass30-1

n = 0 CO CH, CXAr, CH, N H N-(5-(2- carbamoylphenylthio)-1H-pyrazolo[3,4-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino) benzamide ND ND 30-2 I

n = 0 CO CH, CXAr, CH, N H N-(5-iodo-1H-pyrazolo [3,4-b]pyridin-3-yl)-4-(4-methylpiperazin- 1-yl)-2-(tetrahydro- 2H-pyran-4- ylamino)benzamideND ND 30-3

n = 0 CO CH, CXAr, CH, N H N-(5-(3,5- difluorobenzylsulfonyl)-1H-pyrazolo[3,4-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino) benzamide ND (M + 1) 626.14 30-4

n = 0 CO CH, CXAr, CH, N H 2-(4,4- difluorocyclohexylamino)- N-(5-(3,5-difluorophenylthio)- 1H-pyrazolo[3,4- b]pyridin-3-yl)-4-(4-methylpiperazin-1- yl)benzamide ND ND 30-5

n = 0 CO CH, CXAr, CoMe, N H N-(5-(3,5- difluorophenylthio)- 6-methoxy-1H-pyrazolo[3,4-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide ND 610.20 30-6 I

n = 0 CO CH, CXAr, CoMe, N H N-(5-iodo-6-methoxy- 1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4- methylpiperazin-1-yl)- 2-(tetrahydro-2H-pyran-4-ylamino)benzamide ND 592.12 30-7 I

n = 0 CO CH, CXAr, CNH₂, N H N-(6-amino-5-iodo- 1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4- methylpiperazin-1-yl)- 2-(tetrahydro-2H-pyran-4-ylamino)benzamide ND (M − 1) 574.87 30-8

n = 0 CO CH, CXAr, CH, N H N-(5-(N-(3,5-difluorophenyl) sulfamoyl)-1H-pyrazolo[3,4-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   30% (2 steps) (M + 1)627.20 30-9

n = 0 CO CH, CXAr, CH, N H N-(5-(3,5-difluorobenzyl)- 1H-pyrazolo[3,4-b]pyridin-3-yl)-4- (4-methylpiperazin-1-yl)- 2-(tetrahydro-2H-pyran-4-ylamino)benzamidc   20% (M + 1) 562.42 30-10

n = 0 CO CH, CXAr, CH, N H N-(5-(3,5- difluorobenzylthio)-1H-pyrazolo[3,4-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide 20.6% (M + 1) 594.11 30-11

n = 0 CO CH, CXAr, CH, N H N-(5-(3,5- difluorophenylthio)-1H-pyrazolo[3,4-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide 59.4% (2 steps (M + 1)579.11 30-12

n = 0 CO CH, CXAr, CCH₃, N H N-(5-(3,5- difluorophenylthio)-6-methyl-1H- pyrazolo[3,4-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   45% (M + 1) 579.11 30-13

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5-difluorobenzyl)- 1H-pyrazolo[4,3-b]pyridin-3-yl)-4-(4- methylpiperazin-1-yl)- 2-(tetrahydro-2H-pyran-4-ylamino)benzamide   70% 562.27 30-14

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- difluorobenzyloxy)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- ethylpiperazin-1-yl)-2-(telrahydro-2H- pyran-4-ylamino)benzamide   55% 578.27 30-15

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- difluorobenzyloxy)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   49% 2 steps 577.2730-16

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluorabenzyloxy)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide 61% 578.27 30-17

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluorobenzyloxy)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino) benzamide   54% 2 steps 577.2730-18

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorobenzyloxy)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   10% 2 steps 610.01 30-19

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorobenzyloxy)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   40% 2 steps 609.03 30-20

n = 0 CO N, ArXC, CH, CH H N-(5-(5-chloro-2- (trifluoromethyl)benzyloxy)-1H- pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H pyran-4-ylamino)benzamide   64% 644.24 30-21

n = 0 CO N, ArXC, CH, CH H N-(5-(5-chloro-2- (trifluoromethyl)benzyloxy)-1H- pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   39% 2 steps 643.2430-22

n = 0 CO N, ArXC, CH, CH H 4-(4-methylpiperazin- 1-yl)-N-(5-(pyridin-3-ylmethoxy)-1H-pyrazolo [4,3-b]pyridin-3- yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide   30% 543.28 30-23

n = 0 CO N, ArXC, CH, CH H 4-(1-methylpiperidin- 4-yl)-N-(5-(pyridin-3-ylmethoxy)-1H-pyrazolo [4,3-b]pyridin-3- yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide   67% 2 steps 542.29 30-24

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- difluorophenylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   65% 2 steps 580.23 30-25

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- difluorophenylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   56% 2 steps 579.23 30-26

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluoraphenylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   27% 2 steps 580.2330-27

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluorophenylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   54% 2 steps 579.2330-28

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- dichlorophenylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H pyran-4-ylamino)benzamide   31% 2 steps 612.1730-29

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- dichlorophenylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   43% 2 steps 611.17 30-30

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorophenylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   31% 2 steps 612.2030-31

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorophenylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   57% 2 steps 611.18 30-32

n = 0 CO N, ArXC, CH, CH H 4-(4-methylpiperazin- 1-yl)-2-(tetrahydro-2H-pyran-4- ylamino)-N-(5-(2- (trilluoromethyl) phenytihio)-1H-pyrazolo[4,3-b]pyridin- 3-yl)benzamide   38% 2 steps 612.24 30-33

n = 0 CO N, ArXC, CH, CH H 4-(1-methylpiperidin- 4-yl)-2-(tetrahydro-2H-pyran-4- ylamino)-N-(5-(2- (trifluoromethyl) phenylthio)-1H-pyrazolo[4,3-b]pyridin- 3-yl)benzamide   57% 2 steps 611.24 30-34

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- difluorobenzylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   21% 2 steps 594.25 30-35

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- difluorobenzylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   91% 593.25 30-36

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluorobenzylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino) benzamide 2,2,2- trifluoroacetate  86% 2 steps 594.25 30-37

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluorobenzylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   55% 2 steps 593.25 30-38

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorobenzylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   24% 2 steps 626.1930-39

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorobenzylthio)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   50% 2 steps 625.19 30-40

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- difluorophenylamino)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   70% 563.27 30-41

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- difluorophenylamino)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   27% 2 steps 562.27 30-42

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluorophenylamino)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   37% 2 steps 563.27 30-43

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluorophenylamino)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   41% 2 steps 562.27 30-44

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorophenylamino)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   74% 595.21 30-45

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorophenylamino)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   33% 594.21 30-46

n = 0 CO N, ArXC, CH, N H N-(5-(3,5-difluorobenzyl)- 1H-pyrazolo[3,4-b]pyrazin-3-yl)-4- (4-methylpiperazin-1-yl)- 2-(tetrahydro-2H-pyran-4-ylamino)benzamide   12% 2 steps 563.07 30-47

n = 0 CO N, ArXC, CH, N H N-(5-(3,5-difluorobenzyl)- 1H-pyrazolo[3,4-b]pyrazin-3-yl)-4- (1-methylpiperidin-4-yl)- 2-(tetrahydro-2H-pyran-4-ylamino)benzamide   15% 2 steps 562.04 30-48

n = 0 CO N, ArXC, CH, N H N-(5-((3,5- difluorophenyl)ethynyl)-1H-pyrazolo[3,4-b] pyrazin-3-yl)-4-((3- (dimethylamino)propyl)(methyl)amino)-2- (tetrahydro-2H-pyran-4- ylamino)benzamde   12% 2 steps589.24 30-49

n = 0 CO N, ArXC, CH, N H N-(5-((3,5- difluorophenyl)ethynyl)-1H-pyrazolo[3,4-b] pyrazin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   16% 2 steps 572.07 30-50

n = 0 CO N, ArXC, CH, N H N-(5-(3,5- difluorophenylthio)-1H-pyrazolo[3,4-b] pyrazin-3-yl)-4-((3- (dimethylamino)propyl)(methyl)amino)-2- (tetrahydro-2H-pyran-4- ylamino)benzamide   27% 597.2630-51

n = 0 CO N, ArXC, CH, N H N-(5-(2,5- dichlorophenylthio)-1H-pyrazolo[3,4-b] pyrazin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   23% 2 steps 613.1630-52

n = 0 CO N, ArXC, CH, N H 4-(4-metlhylpiperazin- 1-yl)-2-(tetrahydro-2H-pyran-4- ylamino)-N-(5-(2- (trifluoromethyl) phenylthio)-1H-pyrazolo[3,4-b]pyrdzin- 3-yl)benzamide   64% 613.23 30-53

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- difluorophenylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   64% 612.22 30-54

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- difluorophenylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   48% 611.22 30-55

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluorophenylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   50% 2 steps 612.22 30-56

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluorophenylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   28% 2 steps 611.2230-57

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- dichlorophenylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   29% 2 steps 644.1630-58

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- dichlorophenylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   28% 2 steps 643.1730-59

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorophenylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   21% 2 steps 644.1630-60

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorophenylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   36% 2 steps 643.1730-61

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- difluorobenzylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   66% 626.24 30-62

n = 0 CO N, ArXC, CH, CH H N-(5-(3,5- difluorobenzylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   67% 625.24 30-63

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluorobenzylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   74% 626.24 30-64

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluorobenzylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   58% 625.24 30-65

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- difluorobenzylsulfiny])-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino) benzamide 2,2,2- trifluoroacetate  31% 2 steps 629.24 30-66

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorobenzylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   55% 658.18 30-67

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorobenzylsulfonyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   57% 657.18 30-68

n = 0 CO N, ArXC, CH, CH H N-(5-(2,5- dichlorobenzylsulfinyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-4-(1- methylpiperidin-4-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   20% 641.19 30-69

n = 0 CO CH, ArXC, CH, N H N-(5-(3,5- difluorophenylthio)-1H-pyrazolo[3,4-b] pyridin-3-yl)-4-((3- (dimethylamino)propyl)(methyl)amino)-2- (tetrahydro-2H-pyran-4- ylamino)benzamide   57% 596.2630-70

n = 0 CO CH, CH, ArXC, N H N-(6-(2,4- difluorophenylamino)-1H-pyrazolo[3,4-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   33% 561.19 (M − 1)30-71

n = 0 CO CH, CH, ArXC, N H N-(6-((2,4-difluorophenyl) (methyl)amino)-1H-pyrazolo[3,4-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide ND 577.26 (M + 1) 30-72

n = 0 CO CH, ArXC, CH, N H N-(5-(3,5- difluorophenylsulfonamido)- 1H-pyrazolo[3,4-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   74% 627.19 (M + 1)30-73

n = 0 CO CH, CH, ArXC, N H N-(6-(2,4- difluorophenylthio)- 1H-pyrazolo[3,4-b] pyridin-3-yl)-4-(4- methylpiperazin-1-yl)-2-(tetrahydro-2H- pyran-4-ylamino)benzamide   42% (2 steps (M + 1)580.23 **¹H NMR, DMSO-d₆, Ex.: 30-3: 13.86 (1H, bs, NH), 10.70 (1H, bs,NH), 8.67 (2H, bs, CH_(arom)) 8.10 (1H, d, NH), 7.77 (1H, d, CH_(arom)),7.22 (1H, m, CH_(arom)), 6.95 (2H, d, CH_(arom)) 6.26 (1H, d, CH_(arom))6.16 (1H, bs, CH_(arom)), 4.85 (2H, bs, CH), 3.82-3.86 (2H, dt, CH),3.70 (1H, m, CH), 3.47-3.53 (2H, m, CH), 3.28-3.32 (4H, m, CH),2.42-2.46 (4H, m, CH), 2.20 (3H, s, CH₃), 1.94-1.98 (2H, m, CH),1.34-1.41 (2H, m, CH).; 30-5: 13.25 (1H, bs, NH), 10.48 (1H, bs, NH),8.42 (1H, s, CH_(arom)), 8.11 (1H, d, NH), 7.76 (1H, d, CH_(arom))7.00-7.10 (1H, m, CH_(arom)), 6.79-6.87 (2H, m, CH_(arom)), 6.23 (1H,dd, CH_(arom)) 6.12 (1H, d, CH_(arom)) 3.94 (3H, s, CH₃), 3.75-3.83 (2H,m, CH), 3.63-3.71 (1H, m, CH), 3.42-3.52 (2H, m, CH), 3.22-3.32 (4H, m,2*CH₂), 2.36-2.48 (4H, m, 2*CH₂), 2.22 (3H, s, CH₃), 1.88-1.97 (2H, m,CH), 1.32-1.42 (2H, m, CH). 30-6: 13.10 (1H, bs, NH), 10.38 (1H, bs,NH), 8.56 (1H, s, CH_(arom)), 8.12 (1H, d, NH), 7.75 (1H, d, CH_(arom)),6.23 (1H, dd, CH_(arom)), 6.14 (1H, d, CH_(arom)), 3.97 (3H, s, CH₃),3.80-3.86 (2H, m, CH), 3.62-3.74 (1H, m, CH), 3.40-3.55 (2H, m, CH),3.22-3.32 (4H, m, 2*CH₂), 2.36-2.48 (4H, m, 2*CH₂), 2.23 (3H, s, CH₃),1.90-1.99 (2H, m, CH), 1.32-1.45 (2H, m, CH). 30-7: 12.43 (1H, bs, NH),10.22 (1H, bs, NH), 8.32(1H, s, CH_(arom)), 8.13(1H, d, NH), 7.73 (1H,d, CH_(arom)), 6.37 (2H, bs, NH₂), 6.22 (1H, dd, CH_(arom)), 6.13 (1H,d, CH_(arom)), 3.78-3.86 (2H, m, CH), 3.65-3.74 (1H, m, CH), 3.44-3.54(2H, m, CH), 3.22-3.32 (4H, m, 2*CH₂), 2.36-2.48 (4H, m, 2*CH₂), 2.23(3H, s, CH₃), 1.90-1.99 (2H, m, CH), 1.32- 1.45 (2H, m, CH). 30-8: 13.79(1H, bs, NH), 10.91 (1H, bs, NH), 10.69 (1H, bs, NH), 8.83 (1H, s,CH_(arom)), 8.76 (1H, s, CH_(arom)), 8.18 (1H, d, NH), 7.80 (1H, d,CH_(arom)), 6.82-6.75 (3H, m, CH_(arom)), 6.26 (1H, d, CH_(arom)) 6.15(1H, d, CH_(arom)), 3.87-3.82 (2H, dt, CH), 3.72 (1H, m, CH), 3.54-3.47(2H, m, CH), 3.32-3.29 (4H, m, CH), 2.42-2.46 (4H, m, CH), 2.28 (3H, s,CH₃), 1.97-1.95 (2H, m, CH), 1.43-1.36 (2H, m, CH). 30-13: 12.99 (1H, s,NH), 9.92 (1H, s, NH), 8.38 (1H, d, NH, J = 7.6 Hz), 7.92 (1H, d,CHarom, J = 8.4 Hz), 7.84 (1H, d, CHarom, J = 9.2 Hz), 7.32 (1H, d,CHarom, J = 8.4 Hz), 7.07-7.00 (3H, m, CHarom), 6.26 (1H, d, CHarom, J =8.8 Hz), 6.14 (1H, s, CHarom), 4.21 (2H, s), 3.82-3.76 (2H, m),3.69-3.63 (1H, m), 3.48 (2H, t), 3.28 (4H, s), 2.46 (4H, s), 2.25 (3H,s), 2.00-1.90 (2H, m), 1.37-1.26 (2H, m). 30-14: 12.96 (1H, sl, NH),9.84 (1H, s, NH), 8.34 (1H, d, NH, J = 7.6 Hz), 7.96 (1H, d, CHarom, J =9.2 Hz), 7.81 (1H, d, CHarom, J = 8.8 Hz), 7.25 (1H, s, CHarom), 7.23(1H, s, CHarom), 7.17 (1H, t, CHarom), 6.96 (1H, d, CHarom, J = 9.2 Hz),6.25 (1H, d, CHarom, J = 7.6 Hz), 6.14 (1H, s, CHarom), 5.35 (2H, s),3.82-3.77 (2H, m), 3.67 (1H, sl), 3.46 (2H, t), 3.29 (4H, s), 2.50 (4H,s), 2.29 (3H, s), 1.93-1.88 (2H, m), 1.35-1.25 (2H, m). 30-15: 13.01(1H, sl, NH), 10.11 (1H, sl, NH), 7.99 (1H, sl, NH), 7.97 (1H, d,CHarom, J = 9.2 Hz), 7.84 (1H, d, CHarom, J = 8.4 Hz), 7.25-7.14 (3H, m,CHarom), 6.97 (1H, d, CHarom, J = 8.8 Hz), 6.67 (1H, sl, CHarom), 6.51(1H, d, CHarom, J = 8.0 Hz), 5.35 (2H, s, CHarom), 3.83-3.78 (2H, m),3.68-3.63 (1H, m), 3.47 (2H, t), 2.87 (2H, d, J = 11.2 Hz), 2.45-2.40(1H, m), 2.19 (3H, s), 2.00-1.87 (4H, m), 1.75-1.65 (4H, m), 1.34-1.28(2H, m). 30-16: 12.95 (1H, sl, NH), 9.85 (1H, s, NH), 8.33 (1H, d, NH, J= 7.6 Hz), 7.95 (1H, d, CHarom, J = 8.8 Hz), 7.81 (1H, d, CHarom, J =8.8 Hz), 7.48 (1H, q, CHarom), 7.31-7.20 (2H, m, CHarom), 6.93 (1H, d,CHarom, J = 9.2 Hz), 6.25 (1H, d, CHarom, J = 9.2 Hz), 6.14 (1H, s,CHarom), 5.35 (2H, s), 3.81-3.76 (2H, m), 3.68 (1H, sl), 3.47 (2H, t),3.26 (4H, s), 2.44 (4H, s), 2.29 (3H, s), 1.94-1.88 (2H, m), 1.36-1.27(2H, m). 30-17: 13.06 (1H, sl, NH), 10.12 (1H, sl, NH), 7.93 (1H, sl,NH), 7.86 (2H, d, CHarom, J = 8.4 Hz), 7.51-7.44 (1H, m, CHarom),7.30-7.20 (2H, m, CHarom), 6.90 (1H, sl, CHarom), 6.64 (1H, sl, CHarom),6.49 (1H, sl, CHarom), 5.37 (2H, s, CHarom), 3.83-3.76 (2H, m),3.68-3.63 (1H, m), 3.46 (2H, t), 2.86 (2H, d, J = 10.4 Hz), 2.44-2.38(1H, m), 2.19 (3H, s), 1.99-1.90 (4H, m), 1.75-1.65 (4H, m), 1.40-1.30(2H, m). 30-18: 12.94 (1H, sl, NH), 9.81 (1H, s, NH), 8.32 (1H, d,CHarom, J = 7.7 Hz), 7.96 (1H, d, CHarom, J = 9 Hz), 7.81 (1H,d, CHarom,J = 9 Hz), 7.71 (1H, d, NH), 7.51 (1H, d, CHarom, J = 8.6 Hz), 7.43 (1H,dd, CHarom, J = 8.6 Hz), 6.97 (1H, d, CHarom, J = 8.6 Hz), 6.24 (1H, d,CHarom, J = 8.9 Hz), 6.13 (1H, s, CHarom), 5.39 (2H, s), 3.82-3.74 (2H,m), 3.72-3.62 (1H, m), 3.46 (2H, t), 3.28-3.22 (4H, m), 2.46-2.40 (4H,m), 2.22 (3H, s), 1.95-1.87 (2H, m), 1.37-1.26 (2H, m). 30-19: 13.01(1H, sl, NH), 10.09 (1H, s, NH), 7.97 (2H, d, CHarom, J = 9 Hz), 7.83(1H,d, CHarom, J = 8.2 Hz), 7.71 (1H, dd, NH), 7.50 (1H, d, CHarom, J =7.4 Hz), 7.43 (1H, dd, CHarom, J = 8.6 Hz), 6.98 (1H, d, CHarom, J = 9Hz), 6.67 (1H, s, CHarom), 6.51 (1H, d, CHarom, J = 8.2 Hz), 5.38 ( 2H,s), 3.84-3.75 (2H, m), 3.72-3.62 (1H, m), 3.46 (2H, t), 2.86 (2H, d),2.43 (1H, m), 2.19 (3H, s), 1.99-1.88 (4H, m), 1.74-1.64 (4H, m),1.38-1.26 (2H, m). 30-20: 12.97 (1H, sl, NH), 9.82 (1H, s, NH), 8.32(1H, d, NH, J = 8.0 Hz), 7.97 (1H, d, CHarom, J = 8.8 Hz), 7.87 (1H, s,CHarom), 7.80-7.76 (2H, m, CHarom), 7.64 (1H, d, CHarom, J = 8.4 Hz),6.96 (1H, d, CHarom, J = 8.8 Hz), 6.24 (1H, d, CHarom, J = 8.8 Hz), 6.13(1H, s, CHarom), 5.47 (2H, s), 3.81-3.76 (2H, m), 3.66 (1H, sl), 3.46(2H, t), 3.26 (4H, s), 2.43 (4H, s), 2.29 (3H, s), 1.93-1.88 (2H, m),1.35-1.25 (2H, m). 30-21: 13.03 (1H, s, NH), 10.08 (1H, s, NH),8.00-7.95 (2H, m, CHarom), 7.87-7.75 (3H, m, CHarom), 7.63 (1H, d,CHarom, J = 8.4 Hz), 6.97 (1H, d, CHarom, J = 8.8 Hz), 6.67 (1H, s,CHarom), 6.51 (1H, d, CHarom, J = 8.0 Hz), 5.47 (2H, s, CHarom),3.83-3.76 (2H, m), 3.68-3.64 (1H, m), 3.47 (2H, t), 2.87 ( 2H, d, J =10.4 Hz), 2.45-2.40 (1H, m), 2.20 (3H, s), 2.00-1.87 (4H, m), 1.74-1.65(4H, m), 1.36-1.25 (2H, m). 30-22: 12.93 (1H, s, NH), 9.86 (1H, s, NH),8.70 (1H, s, CHarom), 8.51 (1H, dd, CHarom, J = 5.2 Hz), 8.38 (1H, d,NH, J = 8.0 Hz), 7.96-7.90 (2H, m, CHarom), 7.84 (1H, d, CHarom, J = 8.8Hz), 7.73-7.33 (1H, m, CHarom), 6.91 (1H, d, CHarom, J = 8.8 Hz), 6.27(1H, d, CHarom, J = 8.8 Hz), 6.15 (1H, s, CHarom), 5.35 (2H, s),3.83-3.77 (2H, m), 3.70-3.64 (1H, m), 3.47 (2H, t), 3.59 (4H, s), 2.59(4H, s), 2.34 (3H, s), 1.95-1.88 (2H, m), 1.40-1.28 (2H, m). 30-23:13.03 (1H, s, NH), 10.17 (1H, s, NH), 8.70 (1H, s, CHarom), 8.52 (1H,dd, CHarom, J = 4.8 Hz), 8.06 (1H, d, NH, J = 7.6 Hz), 7.96 (1H, d,CHarom, J = 8.8 Hz), 7.94-7.88 (2H, m, CHarom), 7.37-7.34 (1H, m,CHarom), 6.93 (1H, d, CHarom, J = 9.2 Hz), 6.69 (1H, s, CHarom), 6.52(1H, d, CHarom, J = 8.0 Hz), 5.36 (2H, s, CHarom), 3.83-3.79 (2H, m),3.68-3.64 (1H, m), 3.46 (2H, t), 3.25-3.15 (2H, m), 2.65-2.55 (3H, m),2.54 (3H, s), 2.00-1.85 (6H, m), 1.41-1.28 (2H, m). 30-24: 13.21 (1H, s,NH), 10.00 (1H, s, NH), 8.30 (1H, d, NH, J = 7.6 Hz), 8.00 (1H, d,CHarom, J = 8.8 Hz), 7.79 (1H, d, CHarom, J = 9.2 Hz), 7.33 (1H, d,CHarom, J = 8.8 Hz), 7.26-7.16 (3H, m, CHarom), 6.24 (1H, d, CHarom, J =8.8 Hz), 6.13 (1H, s, CHarom), 4.06-3.99 (2H, m), 3.67 (1H, sl), 3.47(2H, t), 3.28 (4H, s), 2.47 (4H, s), 2.25 (3H, s), 1.94-1.88 (2H, m),1.37-1.26 (2H, m). 30-25: 13.26 (1H, s, NH), 10.28 (1H, s, NH), 8.02(1H, d, CHarom, J = 8.8 Hz), 7.97 (1H, d, NH, J = 7.6 Hz), 7.83 (1H, d,CHarom, J = 8.0 Hz), 7.34 (1H, d, CHarom, J = 8.8 Hz), 7.27-7.17 (3H, m,CHarom), 6.68 (1H, s, CHarom), 6.51 (1H, d, CHarom, J = 8.0 Hz),3.85-3.78 (2H, m), 3.71-3.65 (1H, m), 3.47 (2H, t), 2.87 (2H, d, J =11.2 Hz), 2.48-2.40 (1H, m), 2.19 (3H, s), 1.98-1.88 (4H, m), 1.74-1.66(4H, m), 1.36-1.27 (2H, m). 30-26: 13.12 (1H, s, NH), 9.95 (1H, s, NH),8.32 (1H, d, NH, J = 7.6 Hz), 7.93 (1H, d, CHarom, J = 8.8 Hz), 7.79(1H, d, CHarom, J = 8.8 Hz), 7.73 (1H, t, CHarom), 7.52-7.40 (2H, m,CHarom), 7.12 (1H, d, CHarom, J = 8.8 Hz), 6.25 (1H, d, CHarom, J = 8.8Hz), 6.13 (1H, s, CHarom), 3.83-3.77 (2H, m), 3.69 (1H, sl), 3.48 (2H,t), 3.28 (4H, s), 2.44 (4H, s), 2.27 (3H, s), 1.96-1.89 (2H, m),1.37-1.27 (2H, m). 30-27: 13.17 (1H, s, NH), 10.21 (1H, s, NH),7.99-7.92 (2H, m, CHarom et NH), 7.81 (1H, d, CHarom, J = 8.4 Hz),7.77-7.70 (1H, m, CHarom), 7.51-7.40 (2H, m, CHarom), 7.13 (1H, dd,CHarom, J = 8.8 Hz), 6.69 (1H, s, CHarom), 6.51 (1H, d, CHarom, J = 8.4Hz) 3.85-3.78 (2H, m), 2.72-3.67 (1H, m), 3.48 (2H, t), 2.87 (2H, d, J =11.2 Hz), 2.47-2.40 (1H, m), 2.20 (3H, s), 1.96-1.87 (4H, m), 1.75-1.65(4H, m), 1.38-1.28 (2H, m). 30-28: 13.31 (1H, sl, NH), 9.95 (1H, sl,NH), 8.31 (1H, d, NH, J = 7.6 Hz), 7.99 (1H, d, CHarom, J = 7.6 Hz),7.78 (1H, d, CHarom, J = 9.2 Hz), 7.58-7.49 (3H, m, CHarom), 7.31 (1H,d, CHarom, J = 8.8 Hz), 6.24 (1H, d, CHarom, J = 8.8 Hz), 6.10 (1H, s,CHarom), 3.83-3.76 (2H, m), 3.70-3.60 (1H, m), 3.45 (2H, t), 3.21 (4H,s), 2.43 (4H, s), 2.22 (3H, s), 1.94-1.86 (2H, m), 1.38-1.28 (2H, m).30-29: 13.26 (1H, s, NH), 10.25 (1H, s, NH), 8.01 (1H, d, CHarom, J =8.8Hz), 7.94 (1H, d, NH, J = 7.6 Hz), 7.82 (1H, d, CHarom, J = 8.4 Hz),7.59-7.54 (3H, m, CHarom), 7.32 (1H, d, CHarom, J = 8.8 Hz), 6.67 (1H,s, CHarom), 6.54 (1H, d, CHarom, J = 7.6 Hz), 3.84-3.78 (2H, m),3.71-3.62 (1H, m), 3.47 (2H, t), 2.87 (2H, d, J = 11.2 Hz), 2.45-2.41(1H, m), 2.19 (3H, s), 1.96-1.90 (4H, m), 1.74-1.68 (4H, m), 1.34-1.27(2H, m). 30-30: 13.23 (1H, s, NH), 9.98 (1H, s, NH), 8.29 (1H, d, NH, J= 7.6 Hz), 8.01 (1H, d, CHarom, J = 8.8 Hz), 7.79 (1H, d, CHarom, J =8.8 Hz), 7.62 (1H, d, CHarom, J = 8.4 Hz), 7.52 (1H, s, CHarom), 7.44(1H, d, CHarom, J = 7.6 Hz), 7.24 (1H, d, CHarom, J = 8.4 Hz), 6.25 (1H,d, CHarom, J = 8.0 Hz), 6.12 (1H, s, CHarom), 3.82-3.75 (2H, m),3.73-3.67 (1H, m), 3.47 (2H, t), 3.27 (4H, s), 2.43 (4H, s), 2.22 (3H,s), 1.95-1.87 (2H, m), 1.35-1.28 (2H, m). 30-31: 13.28 (1H, s, NH),10.25 (1H, s, NH), 8.02 (1H, d, CHarom, J = 8.8 Hz), 7.95 (1H, d, NH, J= 7.6 Hz), 7.81 (1H, d, CHarom, J = 8.0 Hz), 7.61 (1H, d, CHarom, J =8.4 Hz), 7.56 (1H, s, CHarom), 7.43 (1H, dd, CHarom, J = 8.4 Hz), 7.25(1H, d, CHarom, J = 8.8 Hz), 6.68 (1H, s, CHarom), 6.51 (1H, d, CHarom,J = 7.2 Hz), 3.84-3.78 (2H, m), 3.69-3.61 (1H, m), 3.47 (2H, t), 2.87(2H, d, J = 11.2 Hz), 2.47-2.41 (1H, m), 2.20 (3H, s), 2.00-1.90 (4H,m), 1.76-1.69 (4H, m), 1.40-1.30 (2H, m). 30-32: 13.16 (1H, s, NH), 9.95(1H, s, NH), 8.33 (1H, d, NH, J = 8.0 Hz), 7.93 (1H, d, CHarom, J = 8.8Hz), 7.89 (1H, d, CHarom, J = 9.2 Hz), 7.79 (1H, d, CHarom, J = 9.2 Hz),7.70-7.63 (2H, m, CHarom), 7.60 (1H, t, CHarom), 6.97 (1H, d, CHarom, J= 8.8 Hz), 6.25 (1H, d, CHarom, J = 9.2 Hz), 6.14 (1H, s, CHarom),3.83-3.78 (2H, m), 3.68 (1H, sl), 3.48 (2H, t), 3.28 (4H, s), 2.44 (4H,s), 2.23 (3H, s), 1.95-1.90 (2H, m), 1.38-1.28 (2H, m). 30-33: 13.21(1H, s, NH), 10.22 (1H, s, NH), 7.99 (1H, d, NH, J = 7.6 Hz), 7.94 (1H,d, CHarom, J = 9.2 Hz), 7.89 (1H, d, CHarom, J = 7.2 Hz), 7.82 (1H, d,CHarom, J = 8.4 Hz), 7.71-7.57 (3H, m, CHarom), 6.98 (1H, d, CHarom, J =8.8 Hz), 6.69 (1H, s, CHarom), 6.52 (1H, d, CHarom, J = 8.0 Hz),3.85-3.79 (2H, m), 3.72-3.62 (1H, m), 3.48 (2H, t), 2.87 (2H, d, J =11.2 Hz), 2.47-2.41 (1H, m), 2.19 (3H, s), 2.00-1.90 (4H, m), 1.76-1.69(4H, m), 1.40- 1.30 (2H, m). 30-34: 13.07 (1H, s, NH), 10.11 (1H, s,NH), 8.32 (1H, d, NH, J = 7.6 Hz), 7.90-7.85 (2H, m, CHarom), 7.22 (1H,d, CHarom, J = 8.8 Hz), 7.19 (1H, s, CHarom), 7.17 (1H, s, CHarom), 7.03(1H, t, CHarom), 6.30 (1H, d, CHarom, J = 8.4 Hz), 6.19 (1H, s, CHarom),4.43 (2H, s), 4.02 (2H, sl), 3.80-3.74 (2H, m), 3.67 (1H, sl), 3.44 (2H,t), 3.10 (4H, s), 2.84 (3H, s), 1.89-1.84 (2H, m), 1.30-1.14 (4H, m).30-35: 13.08 (1H, s, NH), 10.28 (1H, s, NH), 7.96 (1H, d, NH, J = 7.6Hz), 7.88 (1H, d, CHarom, J = 8.8 Hz), 7.86 (1H, d, CHarom, J = 6.8 Hz),7.22 (1H, d, CHarom, J = 8.8 Hz), 7.18 (1H, s, CHarom), 7.17 (1H, s,CHarom), 7.02 (1H, t, CHarom), 6.66 (1H, s, CHarom), 6.51 (1H, d,CHarom, J = 8.4 Hz), 4.43 (2H, s), 3.80-3.74 (2H, m), 3.64 (1H, sl),3.44 (2H, t), 2.89-2.84 (2H, m), 2.43 (1H, sl), 2.20 (3H, s), 1.98-1.95(2H, m), 1.89-1.84 (2H, m), 1.72-1.69 (4H, m), 1.29-1.20 (2H, m). 30-36:13.10 (1H, sl, NH), 10.11 (1H, s, NH), 9.73 (1H, sl, COOH), 8.34 (1H,sl, NH), 7.92-7.86 (2H, m, CHarom), 7.47-7.40 (1H, m, CHarom), 7.23 (1H,d, CHarom, J = 8.8Hz), 7.20-7.13 ( 1H, m, CHarom), 7.11-7.05 (1H, m,CHarom), 6.31 (1H, dd, CHarom, J = 9.2 Hz), 6.20 (1H, s, CHarom), 4.41(2H, s), 4.04 (2H, d, J = 8.8 Hz), 3.81-3.75 (2H, m), 3.70-3.66 (1H, m),3.51 (2H, d, J = 11.2 Hz), 3.44 (2H, t), 3.16-2.97 ( 4H, m), 2.87 (3H,s), 1.91-1.84 (2H, m), 1.34-1.22 (2H, m). 30-37: 13.09 (1H, s, NH),10.29 (1H, s, NH), 7.97 (1H, d, NH, J = 7.6 Hz), 7.90-7.86 (2H, m,CHarom), 7.47-7.41 (1H, m, CHarom), 7.23 (1H, d, CHarom, J = 8.8Hz),7.19-7.13 (1H, m, CHarom), 7.11-7.05 (1H, m, CHarom), 6.67 (1H, s,CHarom), 6.52 (1H, d, CHarom, J = 8.0 Hz), 4.41 (2H, s), 3.79-3.74 (2H,m), 3.66-3.62 (1H, m), 3.44 (2H, t), 2.86 ( 2H, d, J = 11.2 Hz),2.45-2.40 (1H, m), 2.19 (3H, s), 2.00-1.85 (4H, m), 1.74-1.65 (4H, m),1.33-1.23 (2H, m). 30-38: 13.02 (1H, s, NH), 10.04 (1H, s, NH), 8.28(1H, d, NH, J = 8.0 Hz), 7.88-7.84 (2H, m, CHarom), 7.74 (1H, s,CHarom), 7.43 (1H, d, CHarom, J = 8.8 Hz), 7.29 (1H, dd, CHarom, J = 8.4Hz), 7.22 (1H, d, CHarom, J = 8.8 Hz), 6.25 (1H, dd, CHarom, J = 9.2Hz), 6.12 (1H, s, CHarom), 4.50 (2H, s), 3.78-3.74 (2H, m), 3.66-3.62(1H, m), 3.44 (2H, t), 3.26 (4H, s), 2.43 ( 4H, s), 2.22 (3H, s),1.91-1.84 (2H, m), 1.35-1.23 (2H, m). 30-39: 13.09 (1H, s, NH), 10.32(1H, s, NH), 8.28 (1H, d, NH, J = 8.0 Hz), 7.90 (2H, D, CHarom), 7.74(1H, s, CHarom), 7.43 (1H, d, CHarom, J = 8.4 Hz), 7.29 (1H, dd, CHarom,J = 8.4 Hz), 7.25 (1H, d, CHarom, J = 8.8 Hz), 6.67 (1H, s, CHarom),6.54 (1H, dd, CHarom, J = 8.4 Hz), 4.51 (2H, s), 3.79-3.76 (2H, m),3.70- 3.64 (1H, m), 3.44 (2H, t), 2.95-2.92 (2H, m), 2.52-2.51 (1H, m),2.27 (3H, s), 2.13-2.01 (2H, m), 1.90-1.87 (2H , m) 1.77-1.69 (4H, m),1.32-1.24 (2H, m). 30-40: 12.77 (1H, s, NH), 9.86 (1H, s, NH), 9.60 (1H,s, NH), 8.40 (1H, d, NH, J = 7.6 Hz), 7.86 (1H, d, CHarom, J = 8.8 Hz),7.83 (1H, d, CHarom, J = 9.2 Hz), 7.56 (2H, d, CHarom, J = 8.8 Hz), 6.93(1H, d, CHarom, J = 9.2 Hz), 6.55 (1H, t, CHarom), 6.23 (1H, dd, CHarom,J = 9.2 Hz), 6.13 (1H, s, CHarom), 3.82-3.75 (2H, m), 3.69-3.61 (1H, m),3.46 (2H, t), 3.27 (4H, s), 2.44 (4H, s), 2.29 (3H, s), 1.96-1.88 (2H,m), 1.38-1.26 (2H, m). 30-41: 12.85 (1H, sl, NH), 10.13 (1H, s, NH),9.62 (1H, s, NH), 8.03 (1H, d, NH, J = 7.2 Hz), 7.90-7.84 (2H, m,CHarom), 7.57 (2H, dd, CHarom, J = 10.4 Hz), 6.95 (1H, d, CHarom, J =8.8 Hz), 6.68 (1H, s, CHarom), 6.60-6.50 (2H, m, CHarom), 3.83-3.78 (2H,m), 3.68-3.63 (1H, m), 3.46 (2H, t), 2.87 (2H, d, J = 11.2 Hz),2.45-2.40 (1H, m), 2.20 (3H, s), 2.00-1.92 (4H, m), 1.75-1.65 (4H, m),1.37-1.27 (2H, m). 30-42: 12.77 (1H, s, NH), 9.87 (1H, s, NH), 9.02 (1H,s, NH), 8.80-8.72 (1H, m, CHarom), 8.41(1H, d, NH, J = 7.6 Hz), 7.86(1H, d, CHarom, J = 8.8 Hz), 7.83 (1H, d, CHarom, J = 9.2 Hz), 7.28 (1H,d, CHarom, J = 9.2 Hz), 7.22-7.15 (1H, m, CHarom), 6.63-6.57 (1H, m,CHarom), 6.23 (1H, d, CHarom, J = 8.8 Hz), 6.13 (1H, s, CHarom),3.83-3.75 (2H, m), 3.70-3.64 (1H, m), 3.46 (2H, t), 3.27 (4H, s), 2.44(4H, s), 2.23 (3H, s), 1.95-1.88 (2H, m), 1.39-1.26 (2H, m). 30-43:12.84 (1H, s, NH), 10.13 (1H, s, NH), 9.05 (1H, sl, NH), 8.81-8.74 (1H,m, CHarom), 8.05 (1H, d, NH, J = 7.2 Hz ), 7.89-7.84 (2H, m, CHarom),7.30 (1H, d, CHarom, J = 8.8 Hz), 7.23-7.15 (1H, m, CHarom), 6.67 (1H,s, CHarom), 6.64-6.58 (1H, m, CHarom), 6.51 (1H, d, CHarom, J = 8.4 Hz),3.83-3.76 (2H, m), 3.68-3.64 (1H, m), 3.47 (2H, t), 2.89 ( 2H, d, J =10.8 Hz), 2.45-2.40 (1H, m), 2.21 (3H, s), 2.01-1.91 (4H, m), 1.74-1.66(4H, m), 1.38-1.27 (2H, m). 30-44: 12.80 (1H, s, NH), 10.16 (1H, s, NH),8.89 (1H, s, CHarom), 8.52 (1H, s, NH), 8.34 (1H, d, NH, J = 7.6 Hz),7.89 (1H, d, CHarom, J = 9.2 Hz), 7.81 (1H, d, CHarom, J = 9.2 Hz), 7.41(1H, d, CHarom, J = 8.8 Hz), 7.35 (1H, d, CHarom, J = 9.2 Hz), 6.89 (1H,dd, CHarom, J = 8.4 Hz), 6.21 (1H, d, CHarom, J = 9.2 Hz), 6.11 (1H, s,CHarom), 3.83-3.75 (2H, m), 3.66-3.60 (1H, m), 3.46 (2H, t), 3.25 (4H,s), 2.44 (4H, s), 2.23 (3H, s), 1.95-1.87 (2H, m), 1.37-1.26 (2H, m).30-45: 12.86 (1H, s, NH), 10.10 (1H, s, NH), 8.91 (1H, s, CHarom), 8.54(1H, s, NH), 8.00 (1H, d, NH, J = 7.6 Hz), 7.90 (1H, d, CHarom, J = 9.2Hz), 7.85 (1H, d, CHarom, J = 8.0 Hz), 7.41 (1H, d, CHarom, J = 8.4 Hz),7.37 (1H, d, CHarom, J = 9.2 Hz), 6.88 (1H, dd, CHarom, J = 8.4 Hz),6.64 (1H, s, CHarom), 6.48 (1H, d, CHarom, J = 8.4 Hz), 3.83- 3.77 (2H,m), 3.67-3.60 (1H, m), 3.47 (2H, t), 2.88 (2H, d, J = 11.2 Hz),2.45-2.38 (1H, m), 2.21 (3H, s), 2.00-1.87 (4H, m), 1.75-1.65 (4H, m),1.37-1.26 (2H, m). 30-46: 13.74 (1H, sl, NH), 10.14 (1H, s, NH), 8.62(1H, s, CHarom), 8.33 (1H, d, NH), 7.81 (1H, d, CHarom, J = 8.7 Hz),7.12-7.03 (3H, m, CHarom), 6.26 (1H, d, CHarom, J = 8.8 Hz), 6.13 (1H,s, CHarom), 4.31 (2H, s), 4.14-4.07 (4H, m), 3.68 (1H, sl), 3.28 (4H,s), 2.43 (4H, s), 2.23 (3H, s), 1.92 (2H, d, J = 12.4 Hz), 1.38-1.26(2H, m). 30-47: 13.80 (1H, sl, NH), 10.41 (1H, s, NH), 8.64 (1H, s,CHarom), 8.02 (1H, d, NH), 7.85 (1H, d, CHarom, J = 8.1 Hz), 7.12-7.03(3H, m, CHarom), 6.69 (1H, s, CHarom), 6.52 (1H, d, CHarom, J = 8.1 Hz),4.30 (2H, s), 3.81 (2H, d, J = 11.1 Hz), 3.68 (1H, sl), 3.48 (2H, t),2.87 (2H, d, J = 10.5 Hz), 2.47-2.39 (1H, sl), 2.19 (3H, s), 2-1.88 (4H,m), 1.76-1.66 (4H, m), 1.39-1.27 (2H, m). 30-48: 13.99 (1H, sl, NH),10.17 (1H, s, NH), 8.34 (1H, s, CHarom), 8.29 (1H, dl, NH), 7.78 (1H, d,CHarom, J = 8.9Hz), 7.54-7.41 (3H, m, CHarom), 6.07 (1H, d, CHarom, J =8.9 Hz), 5.87 (1H, s, CHarom), 3.82 (2H, dl), 3.62 (1H, sl), 3.51-3.37(4H, m), 2.97 (3H, s), 2.28-2.19 (2H, m), 2.15 (6H, s), 2-1.90 (2H, m),1.71-1.61 (2H, m), 1.42-1.28 (2H, m). 30-49: 14.06 (1H, sl, NH), 10.56(1H, s, NH), 8.85 (1H, s, CHarom), 7.97 (1H, sl, NH), 7.85 (1H, d,CHarom, J = 8.1 Hz), 7.50-7.40 (3H, m, CHarom), 6.71 (1H, s, CHarom),6.54 (1H, d, CHarom, J+328.lHz), 3.83-3.76 (2H, m), 3.70 (1H, sl), 3.48(2H, t), 2.88 (2H, d, J+3210.6Hz), 2.48-2.40 (1H, m), 2.20 (3H, s),2.01-1.89 (4H, m), 1.76-1.66 (4H, m), 1.40-1.28 (2H, m). 30-50: 13.94(1H, sl, NH), 10.11 (1H, sl, NH), 8.59 (1H, s, CHarom), 8.30 (1H, sl,NH), 7.76 (1H, d, CHarom, J = 9.2 Hz), 7.27-7.13 (3H, m, CHarom), 6.04(1H, dd, CHarom, J = 9.2 Hz), 5.85 (1H, s, CHarom), 3.87-3.76 (2H, m),3.66-3.55 (1H, m), 3.49-3.26 (4H, m), 2.96 (3H, s), 2.22 (2H, t), 2.14(6H, s), 1.97-1.89 (2H, m), 1.69-1.60 (2H, q), 1.40-1.28 (2H, m). 30-51:13.95 (1H, sl, NH), 10.17 (1H, sl, NH), 8.54 (1H, s, CHarom), 8.28 (1H,sl, NH), 7.78 (1H, d, CHarom, J = 8.8 Hz), 7.59 (1H, d, CHarom, J = 9.2Hz), 7.42-7.38 (2H, m, CHarom), 6.23 (1H, d, CHarom, J = 8.0 Hz), 6.11(1H, s, CHarom), 3.82-3.77 (2H, m), 3.66 (1H, sl), 3.46 (2H, t), 3.26(4H, s), 2.43 (4H, s), 2.22 (3H, s), 1.92-1.88 (2H, m), 1.34-1.24 (2H,m). 30-52: 13.97 (1H, sl, NH), 10.20 (1H, s, NH), 8.38 (1H, s, CHarom),8.27 (1H, d, NH), 7.88 (1H, d, CHarom, J = 7.2 Hz), 7.78 (1H, d, CHarom,J = 9.2 Hz), 7.66-7.55 (3H, m, CHarom), 6.26 (1H, dd, CHarom, J = 9.2Hz), 6.13 (1H, s, CHarom), 3.85-3.76 (2H, m), 3.75-3.63 (1H, m), 3.48(2H, t), 3.37-3.26 (4H, m), 2.61-2.52 (4H, m), 2.32 (3H, sl), 1.96-1.88(2H, m), 1.39-1.26 (2H, m). 30-53: 13.64 (1H, s, NH), 10.20 (1H, s, NH),8.30 (1H, d, CHarom, J = 8.8 Hz), 8.23 (1H, d, CHarom, J = 8.0 Hz), 8.19(1H, d, CHarom, J = 8.8 Hz), 7.81 (1H, d, CHarom, J = 9.2 Hz), 7.75-7.65(3H, m, CHarom), 6.28 (1H, dd, CHarom, J = 8.8 Hz), 6.14 (1H, s,CHarom), 3.83-3.77 (2H, m), 3.70-3.64 (1H, m), 3.48 (2H, t), 3.29 (4H,s), 2.44 (4H, s), 2.23 (3H, s), 1.95-1.89 (2H, m), 1.38-1.26 (2H, m).30-54: 13.64 (1H, sl, NH), 10.48 (1H, sl, NH), 8.32 (1H, d, CHarom, J =8.8 Hz), 8.19 (1H, d, CHarom, J = 8.8 Hz), 7.91 (1H, sl, NH), 7.85 (1H,d, CHarom, J = 8.4 Hz), 7.77- 7.65 (3H, m, CHarom), 6.71 (1H, s,CHarom), 6.54 (1H, d, CHarom, J = 8.4 Hz), 3.86- 3.80 (2H, m), 3.71-3.64(1H, m), 3.48 (2H, t), 2.89 (2H, d, J = 11.2 Hz), 2.45-2.40 (1H, m),2.21 (3H, s), 2.00-1.90 (4H, m), 1.75-1.65 (4H, m), 1.38-1.27 (2H, m).30-55: 13.64 (1H, s, NH), 10.16 (1H, s, NH), 8.29 (1H, d, CHarom, J =8.8 Hz), 8.24 (1H, d, NH, J = 7.6 Hz), 8.17 (1H, d, CHarom, J = 8.8 Hz),8.09 (1H, t, CHarom), 7.88-7.85 (1H, m, CHarom), 7.81 (1H, d, CHarom, J= 9.2 Hz), 7.67 (1H, q, CHarom), 6.28 (1H, d, CHarom, J = 8.8 Hz), 6.14(1H, s, CHarom), 3.83-3.75 (2H, m), 3.72-3.67 (1H, m), 3.48 (2H, t),3.29 (4H, s), 2.44 (4H, s), 2.23 (3H, s), 1.96-1.89 (2H, m), 1.35-1.28(2H, m). 30-56: 13.67 (1H, s, NH), 10.43 (1H, s, NH), 8.31 (1H, d,CHarom, J = 8.8 Hz), 8.18 (1H, d, CHarom, J = 8.8 Hz), 8.13-8.05 (1H, m,CHarom), 7.92 (1H, d, NH, J = 7.6 Hz), 7.90- 7.82 (2H, m, CHarom), 7.66(1H, q, CHarom), 6.71 (1H, s, CHarom), 6.54 (1H, d, CHarom, J = 8.4 Hz),3.85-3.80 (2H, m), 3.73-3.65 (1H, m), 3.49 (2H, t), 2.89 (2H, d, J =11.2 Hz), 2.48-2.42 (1H, m), 2.21 (3H, s), 1.99-1.90 (4H, m), 1.76-1.68(4H, m), 1.37- 1.27 (2H, m). 30-57: 13.66 (1H, s, NH), 10.17 (1H, s,NH), 8.30 (1H, d, CHarom, J = 8.8 Hz), 8.24-8.16 (2H, m, CHarom et NH),8.03-7.97 (3H, m, CHarom), 7.81 (1H, d, CHarom, J = 9.2 Hz), 6.28 (1H,d, CHarom, J = 7.2 Hz), 6.14 (1H, s, CHarom), 3.83-3.77 (2H, m),3.71-3.67 (1H, m), 3.48 (2H, t), 3.29 (4H, s), 2.44 (4H, s), 2.23 (3H,s), 1.96- 1.89 (2H, m), 1.34-1.28 (2H, m). 30-58: 13.71 (1H, s, NH),10.45 (1H, s, NH), 8.32 (1H, d, CHarom, J = 9.2 Hz), 8.22 (1H, d,CHarom, J = 8.8 Hz), 8.02-7.96 (3H, m, CHarom), 7.86-7.81 (1H, m, NH),7.83 (1H, d, Charom), 6.71 (1H, s, CHarom), 6.54 (1H, d, CHarom, J = 7.6Hz), 3.85-3.78 (2H, m), 3.72-3.65 (1H, m), 3.48 (2H, t), 2.88 (2H, d, J= 11.2 Hz), 2.48-2.44 (1H, m), 2.21 (3H, s), 1.97-1.87 (4H, m),1.76-1.70 (4H, m), 1.36-1.28 (2H, m). 30-59: 13.69 (1H, s, NH), 10.04(1H, s, NH), 8.34 (1H, d, NH, J = 8.8 Hz), 8.26-8.16 (3H, m, CHarom),7.81 (1H, dd, CHarom, J = 8.4 Hz), 7.74 (1H, d, CHarom, J = 9.2 Hz),7.66 (1H, d, CHarom, J = 8.4 Hz), 6.24 (1H, dd, CHarom, J = 9.2 Hz),6.10 (1H, s, CHarom), 3.82-3.76 (2H, m), 3.68-3.62 (1H, m), 3.48 (2H,t), 3.27 (4H, s), 2.43 (4H, s), 2.22 (3H, s), 1.93-1.86 (2H, m),1.31-1.21 (2H, m). 30-60: 13.74 (1H, s, NH), 10.31 (1H, s, NH), 8.35(1H, d, CHarom, J = 8.8 Hz), 8.25 (1H, d, CHarom, J = 8.8 Hz), 8.21 (1H,s, CHarom), 7.85 (1H, d, NH, J = 7.2 Hz), 7.81 (1H, dd, CHarom, J = 8.8Hz), 7.76 (1H, d, CHarom, J = 8.0 Hz), 7.66 (1H, d, CHarom, J = 8.8 Hz),6.67 (1H, s, CHarom), 6.50 (1H, d, CHarom, J = 8.0 Hz), 3.85-3.78 (2H,m), 3.68-3.62 (1H, m), 3.48 (2H, t), 2.87 (2H, d, J = 11.2 Hz),2.46-2.40 (1H, m), 2.20 (3H, s), 1.97-1.87 (4H, m), 1.75-1.67 (4H, m),1.32-1.24 (2H, m). 30-61: 13.61 (1H, s, NH), 10.32 (1H, s, NH), 8.71(1H, d, NH, J = 8.0 Hz), 8.21 (1H, d, CHarom, J = 8.8 Hz), 7.87 (1H, d,CHarom, J = 9.2 Hz), 7.80 (1H, d, CHarom, J = 8.8 Hz), 7.17 (1H, t,CHarom), 7.05-7.02 (2H, m, CHarom), 6.29 (1H, d, CHarom, J = 9.2 Hz),6.14 (1H, s, CHarom), 4.93 (2H, s), 3.74- 3.68 (3H, m), 3.43 (2H, t),3.29 (4H, s), 2.44 ( 4H, s), 2.28 (3H, s), 1.90-1.84 (2H, m), 1.28-1.20(2H, m). 30-62: 13.67 (1H, sl, NH), 10.59 (1H, s, NH), 8.23 (1H, d,CHarom, J = 8.8 Hz), 8.10 (1H, d, NH, J = 7.6 Hz), 7.92 (1H, d, CHarom,J = 8.0 Hz), 7.82 (1H, d, CHarom, J = 8.8 Hz), 7.17 (1H, t, CHarom),7.05-7.02 (2H, m, CHarom), 6.71 (1H, s, CHarom), 6.56 (1H, d, CHarom, J= 8.0 Hz), 4.94 (2H, s), 3.77-3.70 (3H, m), 3.43 (2H, t), 2.87 (2H, d, J= 11.2 Hz), 2.45-2.40 (1H, m), 2.20 (3H, s), 1.98-1.91 (2H, m),1.89-1.95 (2H, m), 1.75-1.67 (4H, m), 1.30-1.20 (2H, m). 30-63: 13.63(1H, sl, NH), 10.28 (1H, s, NH), 8.37 (1H, d, NH, J = 8.0 Hz), 8.24 (1H,d, CHarom, J = 8.8 Hz), 7.88-7.82 (2H, m, CHarom), 7.24-7.17 (3H, m,CHarom), 6.29 (1H, d, CHarom, J = 9.2 Hz), 6.14 (1H, s, CHarom), 4.87(2H, s), 3.75-3.70 (3H, m), 3.43 (2H, t), 3.28 ( 4H, s), 2.45 ( 4H, s),2.23 (3H, s), 1.90-1.85 (2H, m), 1.32-1.20 (2H, m). 30-64: 13.69 (1H,sl, NH), 10.55 (1H, s, NH), 8.26 (1H, d, CHarom, J = 8.8 Hz), 8.05 (1H,d, NH, J = 7.6 Hz), 7.90 (1H, d, CHarom, J = 8.4 Hz), 7.86 (1H, d,CHarom, J = 8.8 Hz), 7.24-7.15 (3H, m, CHarom), 6.70 (1H, s, CHarom),6.56 (1H, d, CHarom, J = 8.0 Hz), 4.88 (2H, s), 3.80-3.65 (3H, m), 3.43(2H, t), 2.87 (2H, d, J = 11.2 Hz), 2.46-2.40 (1H, m), 2.20 (3H, s),2.00-1.86 (4H, m), 1.75-1.67 (4H, m), 1.29-1.23 (2H, m). 30-65: 13.49(1H, sl, NH), 10.45 (1H, s, NH), 9.31 (1H, sl, COOH), 8.21 (1H, d,CHarom, J = 8.8 Hz), 8.06 (1H, sl, NH), 7.92 (1H, d, CHarom, J = 8.4Hz), 7.57 (1H, d, CHarom, J = 8.8 Hz), 7.17-7.11 ( 2H, m, CHarom),6.96-6.91 (1H, m, CHarom), 6.67 (1H, s, CHarom), 6.53 (1H, d, CHarom, J= 8.0 Hz), 4.51 (1H, d, J = 13.2 Hz), 4.20 (1H, d, J = 13.2 Hz),3.81-3.76 (2H, m), 3.71-3.62 (1H, m), 3.56-3.41 (4H, m), 3.08 (2H, t),2.83 (3H, s), 2.45-2.40 (1H, m), 2.07-2.00 (2H, m), 1.95-1.86 (4H, m),1.41-1.29 (2H, m). 30-66: 13.62 (1H, sl, NH), 10.22 (1H, sl, NH), 8.36(1H, d, NH, J = 7.6 Hz), 8.23 (1H, d, CHarom, J = 8.8 Hz), 7.85 (1H, d,CHarom, J = 9.2 Hz), 7.80 (1H, d, CHarom, J = 8.8 Hz), 7.48 (1H, s,CHarom), 7.45-7.37 ( 2H, m, CHarom), 6.29 (1H, d, CHarom, J = 7.2 Hz),6.14 (1H, s, CHarom), 4.97 (2H, s), 3.76-3.70 (3H, m), 3.44 (2H, t),3.28 (4H, s), 2.44 (4H, s), 2.23 (3H, s), 1.91-1.86 (2H, m), 1.30-1.24(2H, m). 30-67: 13.67 (1H, sl, NH), 10.49 (1H, s, NH), 8.25 (1H, d,CHarom, J = 8.8 Hz), 8.02 (1H, d, NH, J = 7.2 Hz), 7.89 (1H, d, CHarom,J = 8.0 Hz), 7.82 (1H, d, CHarom, J = 8.8 Hz), 7.49 (1H, t, CHarom),7.45-7.35 (2H, m, CHarom), 6.70 (1H, s, CHarom), 6.56 (1H, d, CHarom, J= 8.0 Hz), 4.97 (2H, s), 3.78-3.64 (3H, m), 3.44 (2H, t), 2.88 (2H, d, J= 11.2 Hz), 2.45-2.40 (1H, m), 2.20 (3H, s), 1.98-1.86 (4H, m),1.76-1.66 (4H, m), 1.32- 1.22 (2H, m). 30-68: 13.46 (1H, s, NH), 10.36(1H, s, NH), 8.21 (1H, d, CHarom, J = 8.8 Hz), 8.00 (1H, d, NH, J = 7.6Hz), 7.86 (1H, d, CHarom, J = 8.4 Hz), 7.59 (1H, d, CHarom, J = 8.8 Hz),7.43-7.33 (2H, m, CHarom), 7.28 (1H, s, CHarom), 6.69 (1H, s, CHarom),6.54 (1H, d, CHarom, J = 7.6 Hz), 4.58 (1H, d, J = 12.8 Hz), 4.30 (1H,d, J = 12.8 Hz), 3.78-3.75 (2H, m), 3.70-3.65 (1H, m), 3.46 (2H, t),2.92-2.88 (2H, m), 2.45- 2.40 (1H, m), 2.24 (3H, s), 2.05-1.95 (2H, m),1.93-1.89 (2H, m), 1.77-1.70 (4H, m), 1.34-1.24 (2H, m). (ND:notdetermined).

Example 30-bis(S)-4-(3-aminopyrrolidin-1-yl)-N-(5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide

876 μl (20 eq) of triethylamine is added to a solution of 238 mg (0.314mmol) of(S)—N-(5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)-4-(3-(2,2,2-trifluoroacetamido)pyrrolidin-1-yl)benzamidein 6 ml of methanol. The reaction medium is stirred at 65° C. for 4hours. After returning to room temperature, 8 ml of n-butanol and 260 mg(6 eq) of potassium carbonate are added. The reaction medium is stirredat 80° C. for 24 hours. After returning to room temperature, thesolvents are evaporated, water is added and the product is extractedwith dichloromethane. The organic phase is washed with saturated sodiumchloride solution, dried on magnesium sulfate, filtered and evaporated.The residue is purified by silica gel chromatography (8:2dichloromethane/methanol as eluent) to yield 87 mg (yield=49%) of(S)-4-(3-aminopyrrolidin-1-yl)-N-(5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyrazine-3-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamidein the form of a brown powder.

LCMS (EI, m/z): (M+1) 566.24.

¹H NMR: δH ppm (400 MHz, DMSO): 10.46 (1H, bs, NH), 8.60 (1H, s,CH_(arom)), 8.50 (1H, s, CH_(arom)), 8.26 (1H, d, NH), 7.78 (1H, d,CH_(arom)), 7.08 (1H, t, CH_(arom)), 6.86 (2H, d, CH_(arom)), 5.86 (1H,dd, CH_(arom)), 5.71 (1H, d, CH_(arom)), 3.80-3.88 (2H, m, CH),3.63-3.70 (2H, m, CH), 3.40-3.55 (5H, m, CH), 3.01-3.08 (1H, m, CH),2.08-2.13 (1H, m, CH), 1.92-1.99 (2H, m, CH₃), 1.76-1.82 (1H, m, CH),1.30-1.41 (2H, m, CH_(pyranone)).

Examples of Method F2 Reduction Example 31N-(5-(3,5-difluorophenethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide

10 mg of 10% Pd/C is added to 100 mg (0.175 mmol) ofN-(5-((3,5-difluorophenyl)ethynyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamidein solution in a mixture of 10 ml of tetrahydrofuran and 5 ml ofmethanol before placing the reaction medium under an atmosphere ofhydrogen. The reaction mixture is stirred for 12 hours at roomtemperature and then filtered on Celite and concentrated. 62 mg(yield=60%) ofN-(5-(3,5-difluorophenethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamideare isolated in the form of a white solid.

LCMS (EI, m/z): (M+1) 576.23.

¹H NMR: δH ppm (400 MHz, DMSO): 13.14 (1H, bs, NH), 10.32 (1H, bs, NH),8.40 (1H, d, CH_(arom)), 8.22 (1H, d, NH), 7.96 (1H, d, CH_(arom)), 7.80(1H, d, CH_(arom)), 7.03-6.98 (3H, m, CH_(arom)), 6.23 (1H, d,CH_(arom)), 6.16 (1H, bs, CH_(arom)), 3.84-3.81 (2H, dt, CH), 3.70 (1H,m, CH), 3.52-3.46 (2H, m, CH), 3.04-2.93 (4H, m, CH), 2.59-2.69 (4H, m,CH), 2.42-2.46 (4H, m, CH), 2.38 (3H, s, CH₃), 1.96-1.93 (2H, m, CH),1.40-1.33 (2H, m, CH).

The following derivative was obtained according to the same method:

Ex.** ArX R₁ R₂ Y₁ n W R_(j) Compound names Yield Mass 31-1

N 0 H H N-(5-(3,5-difluorophenethyl)- 1H-pyrazolo[3,4-b]pyrazin-3-yl)-4-(4-methylpiperazin-1-yl)- 2-(tetrahydro-2H-pyran-4-ylamino)benzamide 47% 577.07 (M + H) **¹H NMR, dmso-d₆, Ex.: 31-1: 13.68(1H, sl, NH), 10.11 (1H, s, NH), 8.52 (1H, s, CHarom), 8.35 (1H, dl,NH), 7.82 (1H, d, CHarom, J = 9 Hz), 7.05-6.97 (3H, m, CHarom), 6.27(1H, dd, CHarom), 6.14 (1H, s, CHarom), 3.83-3.76 (2H, m), 3.74-3.64(1H, m), 3.47 (2H, t), 3.32-3.20 (6H, m), 3.07 (2H, dd), 2.44 (4H, dd),2.23 (3H, s), 1.91 (2H, d), 1.38-1.27 (2H, m).

Example 325-(3,5-difluorophenylthio)-N-(4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzyl)-1H-pyrazolo[3,4-b]pyridin-3-amine

100 mg (0.173 mmol) ofN-(5-(3,5-difluorophenylthio)-1-H-pyrazolo[3,4-b]pyridine-3-yl)-4-(4-methylpiperazine-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamideis added, in small fractions, to a solution of 19.64 mg (0.518 mmol) ofLiAlH₄ in 3 ml of anhydrous tetrahydrofuran under argon at 0° C. Thereaction mixture is heated at 90° C. for 15 hours. An additional portionof 20 mg of LiAlH₄ is then added and the reaction medium stirred at 90°C. for 5 hours. 45 μl of water at 0° C. is then added to the reactionmixture, followed by 45 μl of sodium hydroxide (15% wt) and finally 120μl of water. The reaction mixture is stirred at 25° C. for 1 hour andthen filtered on Dicalite. After evaporation of the solvents, the crudeproduct is purified by chromatography. 16.80 mg (17%) of5-(3,5-difluorophenylthio)-N-(4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzyl)-1H-pyrazolo[3,4-b]pyridin-3-aminein the form of a yellow solid is obtained.

LCMS (EI, m/z): (M+1) 566.68.

¹H NMR: δH ppm (400 MHz, DMSO): 12.57 (1H, bs, NH), 8.45 (2H, d,CH_(arom)), 6.97-7.06 (2H, m, CH_(arom)), 6.73-6.75 (2H, m, CH_(arom)),6.65 (1H, t, NH), 6.13-6.19 (2H, m, CH_(arom)), 4.98 (1H, d, NH), 4.30(2H, m, CH₂), 3.73-3.77 (2H, m, CH), 3.60 (1H, m, CH), 3.45-3.50 (2H, m,CH), 3.04 (4H, m, CH), 2.42 (4H, m, CH), 2.18 (3H, s, CH₃), 1.80-1.83(2H, m, CH), 1.27-1.32 (2H, m, CH).

The following derivatives were obtained according to the same method:

Ex.** ArX R₁ R₂ (U)_(n) V Y₁, Y₂, Y₃, Y₄ R₃ Compound name Yield Mass32-1

n = 0 CH₂ N, ArXC, CH, N H 5-(3,5-difluorophenylthio)-N-(4-(4-methylpiperazin-1-yl)- 2-(tetrahydro-2H-pyran-4-ylamino)benzyl)-1H- pyrazolo[4,3-b]pyrazin-3- amine 1% 567.3

Example 332-(4-aminophenyl)-N-(5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-yl)acetamide

A solution of 152 mg (2.72 mmol) of iron and 70 mg (1.3 mmol) ofammonium chloride in 100 μl of water is added to a solution of 0.24 g(0.544 mmol) ofN-(5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-(4-nitrophenyl)acetamidein 10 ml of a 2:1 ethanol/water mixture. Several drops of acetic acidare added to this mixture and it is heated at 60° C. for 4 hours. Aftercooling and concentration of the solvents, the crude reaction product isextracted with ethyl acetate and is washed with saturated sodiumbicarbonate solution. The organic phases are combined, dried onmagnesium sulfate and then concentrated. The crude product is purifiedby silica gel chromatography (DCM/MeOH) to yield 11 mg (4%) of2-(4-aminophenyl)-N-(5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-yl)acetamide in the form of a brown solid.

LCMS (EI, m/z): (M+1) 412.09.

¹H NMR: δH ppm (400 MHz, DMSO): 13.60 (1H, bs, NH), 10.96 (1H, bs, NH),8.68 (1H, d, CH_(arom)), 8.55 (1H, d, CH_(arom)), 7.06 (1H, m,CH_(arom)), 6.98 (2H, d, CH_(arom)), 6.79 (2H, m, CH_(arom)), 6.50 (2H,m, CH_(arom)), 4.92 (2H, s, NH), 3.51 (2H, m, CH₂).

Examples of Method F3 Sulfide Oxidation Example 345-(3,5-difluorophenylsulfonyl)-1H-pyrazolo[3,4-b]pyridin-3-amine

A solution of 663 mg (1.078 mmol) of oxone in 1.1 ml of water is addedto a solution of 300 mg (1.078 mmol) of5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyridin-3-amine in 10 ml ofa 1:1 mixture of tetrahydrofuran and methanol at 0° C. The reactionmixture is stirred at room temperature for 16 hours. An additionalportion of 663 mg of oxone at 0° C. is then added and the reactionmedium stirred at room temperature for 24 hours. The solvents areevaporated and the reaction medium is diluted with sodium bicarbonatesolution, extracted with ethyl acetate, dried on MgSO₄ and thenconcentrated to yield 340 mg (81%) of5-(3,5-difluorophenylsulfonyl)-1H-pyrazolo[3,4-b]pyridin-3-amine in theform of a yellow solid.

LCMS (EI, m/z): (M+1) 311.03.

¹H NMR: δH ppm (400 MHz, DMSO): 12.72 (1H, bs, NH), 8.92 (1H, d,CH_(arom)), 8.84 (1H, d, CH_(arom)), 7.89-8.01 (1H, d, CH_(arom)),7.62-7.80 (2H, m, CH_(arom)), 6.06 (2H, bs, NH).

The following compounds were also obtained by this method:

Ex.** ArX Q Y₁, Y₄ W Compound name Yield Mass MH⁺ 34-2

H CH, N H 5-(3,5- difluorobenzylsulfonyl)- 1H-pyrazolo[3,4-b]pyridin-3-amine ND (M + 1) 325.07 34-3

N, CH H tert-butyl 5-(3,5- dichlorophenylsulfonyl)- 1H-pyrazolo[4,3-b]pyridin-3-ylcarbamate ND ND **¹H NMR, DMSO-d₆, Ex.: 33-2: 12.64 (1H, bs,NH), 8.56 (1H, d, CH_(arom)), 8.49 (1H, d, CH_(arom)), 7.24 (1H, ddd,CH_(arom)), 6.94 (2H, bd, CH_(arom)), 6.03 (2H, bs, NH), 4.80 (2H, s,CH). (ND: not determined).

Alternatively, a protection step can be carried out before the oxidationreaction, followed by a deprotection step which can lead to thepreparation of the corresponding sulfones or sulfoxides.

Example 34-bis5-(3,5-difluorophenylsulfinyl)-1H-pyrazolo[4,3-b]pyrazin-3-amine

0.55 mL of triethylamine and 22 mg of 4-dimethylaminopyridine are addedunder argon to a solution of 500 mg (1.790 mmol) of5-(3,5-difluorophenylthio)-1H-pyrazolo[3,4-b]pyrazin-3-amine in 10 mL oftetrahydrofurane. The solution is stirred at 0° C. and 0.915 mL ofdi-tert-butyl dicarbonate is added and the reaction medium is stirredovernight. An aqueous fraction is added to the reaction medium which isthen extracted with ethyl acetate. The organic phases are dried on MgSO₄and concentrated in vacuum to give a crude product which is used in theoxidation step without further purification. The crude product obtainedis dissolved in 10 mL of a 1:1 mixture of tetrahydrofurane and methanolat 0° C. and then a solution of 1.103 g (1.794 mmol) of oxone in 2 mL ofwater is added. The reaction medium is stirred at room temperature for16 hours. An additional portion of 550 mg of oxone is then added and thereaction medium is stirred at room temperature for 5 hours. The solventsare evaporated and the reaction medium is diluted with a sodiumbicarbonate solution, extracted with ethyl acetate, dried on magnesiumsulfate and concentrated to lead to a mixture of the correspondingsulfone and sulfoxide which are used without further purification in thedeprotection step. 0.373 mL of TFA in 4 mL of anhydrous THF is added at0° C. to a solution of 600 mg of the previously obtained mixture in 6 mLof dichloromethane. The mixture is stirred 1 hour at room temperatureand an additional portion of 4 equivalents of TFA in 4 mL of THF isadded. After 1 hour of stirring, this operation is repeated and thereaction medium is stirred for a total time of 3 h 45. The solvents areevaporated and the reaction medium is diluted with a potassium carbonatesolution, extracted with ethyl acetate, dried on magnesium sulfate andconcentrated to yield a 1:1 mixture of5-(3,5-difluorophenylsulfonyl)-1H-pyrazolo[3,4-b]pyrazin-3-amine and5-(3,5-difluorophenyl sulfinyl)-1H-pyrazolo[3,4-b]pyrazin-3-amine. Thismixture is used in the following steps without further purification.

The following compounds were also obtained by this method:

Ex.** ArX Y₁, Y₄ Compound names Yield Mass MH⁺ 34bis-1

CH, N 5-(2,5-difluorophenylsulfonyl)-1H- pyrazolo[4,3-b]pyridin-3-amine58% 3 steps (M + 1) 310.9 34bis-2

CH, N 5-(3,5-dichlorophenylsulfonyl)-1H- pyrazolo[4,3-b]pyridin-3-amine38% 3 steps (M + 1) 342.8 34bis-3

CH, N 5-(2,5-dichlorophenylsulfonyl)-1H- pyrazolo[4,3-b]pyridin-3-amine41% 3 steps (M + 1) 342.9 34bis-4

CH, N 5-(3,5-difluorobenzylsulfonyl)-1H- pyrazolo[4,3-b]pyridin-3-amine58% 3 steps (M + 1) 325.0 34bis-5

CH, N 5-(2,5-difluorobenzylsulfonyl)-1H- pyrazolo[4,3-b]pyridin-3-amine45% 3 steps (M + 1) 325.0 34bis-6

CH, N 5-(2,5-difluorobenzylsulfinyl)-1H- pyrazolo[4,3-b]pyridin-3-amine 5% 3 steps (M + 1) 308.9 34bis-7

CH, N 5-(2,5-dichlorobenzylsulfonyl)-1H- pyrazolo[4,3-b]pyridin-3-amine 3% 3 steps ND 34bis-8

CH, N 5-(2,5-dichlorobenzylsulfonyl)-1H- pyrazolo[4,3-b]pyridin-3-amine18% 3 steps ND **1H NMR, DMSO-d6, Ex.: 34bis-1: 12.31 (1H, sl, NH),8.08-8.18 (1H m, CHarom), 8.05 (1H, d, CHarom, J = 11.6 Hz), 7.97 (1H,d, CHarom, J = 11.6 Hz), 7.87-7.93 (1H, m, CHarom), 7.64-7.76 (1H, m,CHarom), 5.81 (2H, sl, NH₂). 34bis-2: 12.32 (1H, sl, NH), 7.94-8.11 (5H,m, CHarom), 5.85 (2H, sl, NH₂). 34bis-3: 12.34 (1H, sl, NH), 8.27 (1H,s, CHarom), 8.12 (1H, d, CHarom, J = 11.6 Hz), 8.01 (1H, d, CHarom, J =11.6 Hz), 7.82-7.89 (1H, m, CHarom), 7.67 (1H, d, CHarom, J = 11.2 Hz),5.70 (2H, sl, NH₂). 34bis-4: 12.28 (1H, sl, NH), 7.89 (1H, d, CHarom, J= 8.8 Hz), 7.68 (1H, d, CHarom, J = 8.8 Hz), 7.21 (1H, m, CHarom),6.91-6.97 (2H, m, CHarom), 5.87 (2H, s, NH₂), 4.94 (2H, s, CH). 34bis-5:12.28 (1H, sl, NH), 7.89 (1H, d, CHarom, J = 8.8 Hz), 7.68 (1H, d,CHarom, J = 8.8 Hz), 7.20-7.25 (2H, m, CHarom), 7.10-7.15 (1H, m,CHarom), 5.84 (2H, s, NH2), 4.87 (2H, s, CH). 34bis-6: 12.04 (1H, s,NH), 7.87 (1H, d, CHarom, J = 8.8 Hz), 7.40 (1H, d, CHarom, J = 8.8 Hz),7.10-7.25 (2H, m, CHarom), 6.90-6.97 (1H, m, CHarom), 5.61 (2H, s, NH2),4.47 (1H, d, CH, J = 13.2 Hz), 4.18 (1H, d, CH, J = 13.2 Hz). 34bis-7:12.28 (1H, s, NH), 7.89 (1H, d, CHarom, J = 8.8 Hz), 7.64 (1H, d,CHarom, J = 8.8 Hz), 7.40-7.50 (3H, m, CHarom), 5.81 (2H, s, NH2), 4.96(2H, s, CH).

Example of Method F4 Demethylation Example 35N-(5-(3,5-difluorophenylthio)-6-hydroxy-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide

443 μl (3 eq) of a solution of 1 M boron tribromide in dichloromethaneis added to a solution of 90 mg (0.148 mmol) ofN-(5-(3,5-difluorophenylthio)-6-methoxy-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide(example 18) in 4 ml of 1,2-dichloroethane at 0° C. The reaction mediumis stirred at 60° C. for 3 hours and then cooled in an ice bath beforeadding methanol. The solvents are evaporated and the residue isredissolved in a mixture of methanol and ethyl acetate. The solid formedis filtered, redissolved in 3 ml of tetrahydrofuran and is added to 1 Nsoda solution. The reaction medium is stirred for 18 hours at roomtemperature. The pH of the solution is adjusted to 8-9 and the aqueousphase is extracted with ethyl acetate. The organic phase is dried onmagnesium sulfate and the crude product is purified on a silica gelcolumn (dichloromethane/methanol as eluent) to yield 21 mg (24%) ofN-(5-(3,5-difluorophenylthio)-6-hydroxy-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamidein the form of a yellow powder.

LCMS (EI, m/z): (M+1) 596.13.

¹H NMR: δH ppm (400 MHz, DMSO): 12.96 (1H, broad flat singlet), 12.02(1H, broad flat singlet), 10.64 (1H, bs, NH), 8.46 (1H, bs), 8.09 (1H,bs), 7.72 (1H, d, CH_(arom)), 6.97-7.10 (1H, m, CH_(arom)), 6.60-6.74(2H, m, CH_(arom)), 6.28 (1H, dd, CH_(arom)), 6.13 (1H, d, CH_(arom)),3.80-3.90 (2H, m, CH_(pyranone)), 3.65-3.77 (1H, m, CH_(pyranone)), 3.50(2H, t, CH_(pyranone)), 3.25-3.32 (4H, m, 2*CH₂), 2.37-2.45 (4H, m,2*CH₂), 2.22 (3H, s, CH₃), 1.91-2.00 (2H, m, CH_(pyranone)), 1.28-1.43(2H, m, CH_(pyranone)).

II. Biological Tests of the Compounds According to the Invention Testfor Measuring Inhibition of TrkA, TrkB or TrkC Kinase

These kinases are produced by Millipore or Kinome Scan (DiscoverX) andare screened according to the manufacturer's protocols.

The results are presented in the table below:

Enzymatic inhibition at 10 nM (%) 30 30-9 27-1 14-11 30-8 TrkA 93.8 5597.8 97.4 99 TrkB 84 98 93 88 96.6 TrkC 64 96.8 93.4 97.3

Test for Measuring Antiproliferative Activity Against Human Colon CancerCells (KM-12)

The antiproliferative activities of the compounds according to theinvention were measured by the ATPlite technique (Perkin Elmer).

Adherent human colon cancer cells (KM-12 colon cancer cells areTrkA-dependent) are inoculated in 96-well plates (3500 cells/well) onday 0, at a concentration compatible with logarithmic growth for the 72hours required for the evaluation of the compounds. All of the cells aretreated on day 1 and then placed in an incubator at 37° C. under anatmosphere of 5% CO₂. Cell viability is evaluated on day 4 by assayingreleased ATP, which is characteristic of viable cells. IC₅₀s aredetermined by nonlinear regression on the basis of a sigmoidaldose/response relationship model, wherein the Hill coefficient is leftvariable, carried out on the GraphPad software package according to thealgorithm provided.

Cell proliferation inhibition (KM-12) Compound IC₅₀ (M) 30 3.6 · 10⁻⁸14-11 2.2 · 10⁻⁹

In Vivo Antitumor Activity:

The compounds of the present invention, such as compound 30, exhibit amarked in vivo antitumor activity against the KM-12 experimental tumormodel, when administered by the oral route according to the (q1d6)×2weeks schedule (i.e. one dose every days during 6 consecutive days, thistreatment being repeated twice during two consecutive weeks). Thisactivity is reflected by a tumor growth inhibition up to 96%, that lastsone week after the end of treatment and that was recorded at least attwo doses (120 and 240 mg/kg), without any adverse effects. Thisactivity is noticeable since colon cancer is overall poor responsive tochemotherapy.

Comparative Experiments

An in vitro kinase glo plus-based kinase assay (Promega) was developedin a 96 wells assay plate format to assess the inhibiting properties ofcompounds on tropomyosin related kinases (Trk) receptors, using thesoluble intracellular segment of theses receptors, containing the kinaseactivity (TrkA (or NTRK1; 400 ng/well; Millipore) and TrkB (or NTRK2;200 ng/well; Invitrogen)). The assay was performed in a final volume 50μl containing 8 mM MOPS (pH 7.0), 0.2 mM EDTA, 40 mM Mg Acetate, 25 mM2-glycerophosphate, 1 mM DTT, 2 mM Na Vanadate, 0.01% Triton X-100,either 1 (TrkA) or 2.5 (TrkB) mg/ml poly EY (poly Glu-Tyr 4:1;substrate) and 30 (Trk A) or 40 (Trk B) μM ATP. Test compounds weredissolved (10 mM), and diluted in 100% DMSO through serial dilution,with tested half log concentrations generally ranging from 1 to 30 000nM final concentration (5% DMSO final), but these concentrations couldbe adapted according to compound's potency. The reaction was started byaddition of ATP, and the plates were incubated for 2 hours at 30° C.Plates were removed from incubator, and 50 μl of kinase-glo plus wasadded to each well, followed by a 10 minute incubation at roomtemperature. The luciferase-induced luminescence, which is proportionalto the ATP remaining in the well, was measured on a luminometer.Controls on each plates included wells with the kinase alone (maximalATP consumption, or 0% inhibition), wells without the kinase (maximalATP signal or 100% inhibition), and wells with 20 μM staurosporine(positive control of inhibition). A full concentration-responseinhibition curve with K252a (half log concentrations from 1 to 10 000nM) was also included on each plate. pIC₅₀ values were derived fromfitting the inhibition curve of ATP consumption, using the 0-100%luminescence range defined by the controls, with a sigmoidaldose-response equation: % Inhibition=100−(100/(1+10^((X+pIC)50^()*nH))),where X is the logarithm of the tested compound concentrations. Underthese conditions, K252a had a pIC₅₀ of 7.46±0.07 on TrkA (mean±SD; N=42;IC₅₀=30 nM), and 7.16±0.18 on TrkB (N=36; IC₅₀=74 nM), these valuesbeing consistent with in vitro literature data (Tapley et al (1992)Oncogene 7: 371-381, Tan et al (2007) Mol Pharmacol 72: 1440-1446).

The results obtained are presented below:

IC₅₀ (μM) Structure Compound TrkA TrkB

  C₂₉H₃₁F₂N₇O₂S 30 0.045 0.031

  C₂₈H₃₁F₂N₉O₂ A about 10 >100

  C₂₈H₃₁F₂N₉O₂ B 3.3 18

  C₂₉H₃₂F₂N₈O₂ C 2.1 5.8

  C₁₂H₈F₂N₄S D 22 35

  C₂₄H₂₂F₂N₆OS E 0.04 0.048

  C₁₉H₁₂F₂N₄OS F 0.31 0.31

The invention claimed is:
 1. A method for treating a cancer associated with the overexpression of at least one Trk protein comprising the administration to a person in need thereof of an effective dose of a compound of following general formula (I):

or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, wherein: Y₁ and Y₄ each represent, independently of each other, a CH group or a nitrogen atom on the condition that at least one of Y₁ and Y₄ represent a nitrogen atom, Y₂ represents a C—X—Ar group, Y₃ represents a C—W group, Ar represents an aryl or heteroaryl group optionally substituted by one or more groups selected from a halogen atom, (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, (C₁-C₆)haloalkoxy, (C₁-C₆)halothioalkoxy, CN, NO₂, OR₁₁, SR₁₂, NR₁₃R₁₄, CO₂R₁₅, CONR₁₆R₁₇, SO₂R₁₈, SO₂NR₁₉R₂₀, COR₂₁, NR₂₂COR₂₃, NR₂₄SO₂R₂₅, and R₂₆NR₂₇R₂₈ and/or optionally fused to a heterocycle, X represents a divalent group selected from O, S, S(O), S(O)₂, NR₄, S(NR₄), S(O)(NR₄), S(O)₂(NR₄), NR₄S, NR₄S(O), NR₄S(O)₂, CH₂, CH₂S, CH₂S(O), CH₂S(O)₂, SCH₂, S(O)CH₂, S(O)₂CH₂, CH₂CH₂, CH═CH, CH₂O, OCH₂, NR₄CH₂, and CH₂NR₄, W represents an R₅, SR₅, OR₅ or NR₅R₆ group, U represents a CH₂ or NH group, one or more hydrogen atoms which may be replaced by a (C₁-C₆)alkyl group, V represents C(O), C(S) or CH₂, n represents 0 or 1, R₁ represents a hydrogen atom, or an OR₇ or NR₇R₈ group, R₂ represents a hydrogen atom, an optionally substituted heterocycle, NO₂, OR₉ or NR₉R₁₀, R₃, R₄, R₁₁ to R₂₅ and R₂₇ to R₂₈ each represent, independently of each other, a hydrogen atom or a (C₁-C₆)alkyl group, R₅ and R₆ each represent, independently of each other, a hydrogen atom or a (C₁-C₆)alkyl, optionally substituted aryl or optionally substituted benzyl group, R₇, R₈, R₉ and R₁₀ each represent, independently of each other, a hydrogen atom or an optionally substituted (C₁-C₆)alkyl or (C₃-C₁₂)cycloalkyl group or an optionally substituted heterocycle, and R₂₆ represents a (C₁-C₆)alkyl group.
 2. The method according to claim 1, wherein the mixture of stereoisomers is a racemic mixture.
 3. The method according to claim 1, wherein: Y₁═CH or N, and Y₄═N.
 4. The method according to claim 3, wherein Y₁ represents a CH group.
 5. The method according to claim 1, wherein X represents a divalent group selected from S, S(O), S(O)₂, NR₄, CH₂, CH₂S, CH₂S(O), CH₂S(O)₂, CH₂O, CH₂NR₄, NHS(O)₂, SCH₂, S(O)CH₂, S(O)₂CH₂, S(O)₂NH, OCH₂, NR₄CH₂, CH₂CH₂, CH═CH, and C≡C.
 6. The method according to claim 5, wherein X represents a divalent group selected from S, S(O), S(O)₂, NR₄, CH₂, SCH₂, S(O)CH₂, S(O)₂CH₂, S(O)₂NH, CH₂CH₂, OCH₂, and NR₄CH₂ wherein the first atom of these groups is bound to atom C of chain C—X—Ar.
 7. The method according to claim 6, wherein X represents a divalent group selected from S, S(O)₂, CH₂, SCH₂, S(O)₂CH₂, S(O)₂NH, CH₂CH₂, and wherein the first atom of these groups is bound to atom C of chain C—X—Ar.
 8. The method according to claim 1, wherein Ar represents an aryl group optionally substituted by one or more groups selected from a halogen atom, (C₁-C₆)alkyl, (C₁-C₆)haloalkyl, (C₁-C₆)haloalkoxy, (C₁-C₆)halothioalkoxy, CN, NO₂, OR₁₁, SR₁₂, NR₁₃R₁₄, CO₂R₁₅, CONR₁₆R₁₇, SO₂R₁₈, SO₂NR₁₉R₂₀, COR₂₁, NR₂₂COR₂₃ and NR₂₄SO₂R₂₅; or a pyridine group.
 9. The method according to claim 8, wherein Ar represents a group selected from the following groups:


10. The method according to claim 1, wherein W represents an R₅, SR₅, OR₅ or NR₅R₆ group, with R₅ and R₆ representing, independently of each other, a hydrogen atom or a (C₁-C₆)alkyl group.
 11. The method according to claim 1, wherein: R₃═H, U═CH₂ or NH, V═C(O) or C(S), and n=0 or
 1. 12. The method according to claim 11, wherein: V═C(O), and n=0.
 13. The method according to claim 1, wherein R₁ represents a hydrogen atom or an NR₇R₈ group, with R₇ representing a hydrogen atom and R₈ representing an optionally substituted (C₃-C₁₂)cycloalkyl group or an optionally substituted heterocycle.
 14. The method according to claim 13, wherein R₁ represents one of the following groups: H,


15. The method according to claim 1, wherein R₂ represents NO₂, NR₉R₁₀ or a heterocycle optionally substituted by (C₁-C₆)alkyl or NH₂.
 16. The method according to claim 15, wherein R₂ represents one of the following groups: NH₂, NH(CH₂)₃NMe₂, NMe(CH₂)₃NMe₂, NO₂,


17. The method according to claim 1, wherein the compound of formula (I) is selected from the following compounds:


18. The method according to claim 1, wherein the cancer associated with an overexpression of a Trk protein is a cancer overexpressing a Trk protein of the colon, prostate, pancreas, ovarian, lung, bladder, breast, melanoma, thyroid, head or neck, or a neuroblastoma overexpressing a Trk protein.
 19. A method for treating a cancer associated with the overexpression of at least one Trk protein comprising the administration to a person in need thereof of an effective dose of a pharmaceutical composition comprising at least one compound of formula (I) according to claim 1, and at least one pharmaceutically acceptable excipient.
 20. The method according to claim 19, wherein the pharmaceutical composition further comprises at least one other active ingredient.
 21. The method according to claim 20, wherein the at least one other active ingredient is an anticancer agent.
 22. The method according to claim 19, wherein the cancer associated with an overexpression of a Trk protein is a cancer overexpressing a Trk protein of the colon, prostate, pancreas, ovarian, lung, bladder, breast, melanoma, thyroid, head or neck, or a neuroblastoma overexpressing a Trk protein.
 23. A method for treating a cancer associated with the overexpression of at least one Trk protein comprising the simultaneous, separate or sequential administration to a person in need thereof of an effective dose of a combination product comprising: (i) at least one compound of formula (I) according to claim 1, and (ii) at least one other active ingredient.
 24. The method according to claim 23, wherein the at least one other active ingredient is an anticancer agent.
 25. The method according to claim 23, wherein the cancer associated with an overexpression of a Trk protein is a cancer overexpressing a Trk protein of the colon, prostate, pancreas, ovarian, lung, bladder, breast, melanoma, thyroid, head or neck, or a neuroblastoma overexpressing a Trk protein. 